COMPREHENSIVE INVITED REVIEW
ANTIOXIDANTS & REDOX SIGNALING
Volume 15, Number 12, 2011
ª Mary Ann Liebert, Inc.
DOI: 10.1089/ars.2010.3765
The Role of Oxidative Stress in the Pathophysiology
of Gestational Diabetes Mellitus
Martha Lappas,1,2 Ursula Hiden,3 Gernot Desoye,3 Julia Froehlich,3
Sylvie Hauguel-de Mouzon,4 and Alicia Jawerbaum 5
Abstract
Normal human pregnancy is considered a state of enhanced oxidative stress. In pregnancy, it plays important roles
in embryo development, implantation, placental development and function, fetal development, and labor. However, pathologic pregnancies, including gestational diabetes mellitus (GDM), are associated with a heightened level
of oxidative stress, owing to both overproduction of free radicals and/or a defect in the antioxidant defenses. This
has important implications on the mother, placental function, and fetal well-being. Animal models of diabetes have
confirmed the important role of oxidative stress in the etiology of congenital malformations; the relative immaturity of the antioxidant system facilitates the exposure of embryos and fetuses to the damaging effects of oxidative
stress. Of note, there are only a few clinical studies evaluating the potential beneficial effects of antioxidants in
GDM. Thus, whether or not increased antioxidant intake can reduce the complications of GDM in both mother and
fetus needs to be explored. This review provides an overview and updated data on our current understanding of
the complications associated with oxidative changes in GDM. Antioxid. Redox Signal. 15, 3061–3100.
I. Introduction to Gestational Diabetes Mellitus
A. Incidence
B. Etiology and risk factors
C. Short- and long-term risks of GDM
1. GDM increases the risk of metabolic complications in the mothers
2. GDM increases the risk of metabolic programming for the offspring
3. GDM modifies fetal growth pattern
II. Brief Overview of Oxidative Stress
A. Reactive oxygen species
B. Antioxidants
III. Brief Overview of Nitrative Stress
IV. Oxidative Stress in the GDM Mother
A. Oxidant species
1. Lipid peroxidation
2. Protein oxidation
3. Transitional metals
B. Antioxidants
1. Nonenzymatic antioxidants
2. Enzymatic antioxidants
3. Transitional metals
C. Concluding comments
3062
3063
3063
3063
3063
3063
3063
3064
3064
3064
3065
3066
3066
3066
3066
3067
3067
3067
3067
3069
3069
Reviewing Editors: Ulf Eriksson, Sushil Jain, Emile Levy, Masao Kaneki, Mary R. Prater, Christopher Rogers, Luis Sobrevia, and
Deirdre K. Tobias
1
Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia.
Mercy Perinatal Research Centre, Mercy Hospital for Women, Victoria, Australia.
3
Department of Obstetrics and Gynaecology, Medical University of Graz, Graz, Austria.
4
Department of Reproductive Biology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio.
5
Laboratory of Reproduction and Metabolism, CEFYBO-CONICET School of Medicine University of Buenos Aires, Buenos Aires, Argentina.
2
3061
3062
LAPPAS ET AL.
V. Oxidative Stress in the GDM Placenta and Fetus
A. Oxidative stress in the placenta
1. ROS in the GDM placenta
2. Antioxidants in the GDM placenta
3. Reactive nitrogen species in the GDM placenta
B. Oxidative stress and the fetus
1. Oxidative stress and fetal malformations
2. Nitrative stress and fetal malformations
3. Oxidative stress in the fetal organs
4. Oxidative stress in the umbilical cord of GDM women
C. Concluding comments
VI. Pathways Contributing to the Generation of Oxidative Stress in GDM
A. Advanced glycation endproducts
B. Hexosamine pathway
C. Polyol pathway
D. NADPH oxidase
E. Protein kinase C
F. Xanthine oxidase
G. ROS production via mitochondria
H. Concluding comments
VII. The Biological Role of Oxidative Stress on Placental Function in GDM Pregnancies
A. Inflammatory cytokines
B. Metalloproteinases
C. Apoptosis
D. Vascular molecules
E. Nuclear factor-kappa B
F. Concluding comments
VIII. The Role of Oxidative and Nitrative Stress in the Pathogenesis of GDM
A. Decidualization and implantation
B. Trophoblast invasion
C. Organogenesis
D. Endothelial and vascular dysfunction
E. Placental nutrient transport mechanisms
1. Glucose transport
a. Glucose metabolism in pregnancy
b. Insulin signaling in GDM
2. Fatty acid transport
3. Amino acid transport
4. Placental ion transport mechanisms
F. Cervical ripening and labor
G. Intrauterine programming
H. Concluding comments
IX. Effects of Therapeutic Approaches on GDM
A. Can antioxidant treatment reduce oxidative stress in GDM?
B. Flavonoids as potential antioxidant supplements to reduce oxidative stress in GDM
C. PPARs as targets to reduce oxidative and nitrative stress in GDM
X. Future Directions
XI. Conclusions
I. Introduction to Gestational Diabetes Mellitus
Key points:
Gestational diabetes mellitus (GDM) is commonly defined as any degree of glucose intolerance with first
recognition during pregnancy.
GDM is the most common type of diabetes found
in pregnancy; its prevalence ranges between 1% and
14% of all pregnancies depending on the population
studied and the diagnostic tests used.
3069
3069
3069
3070
3070
3071
3071
3071
3072
3072
3072
3072
3072
3074
3075
3075
3075
3075
3076
3076
3076
3076
3076
3077
3077
3077
3077
3077
3077
3078
3078
3078
3079
3079
3079
3080
3082
3083
3084
3084
3084
3085
3085
3085
3086
3086
3087
3087
The prevalence of GDM is increasing worldwide, intensified with advancing maternal age, racial/ethnic
disparities, and obesity.
GDM is associated with markedly increased risk of
adverse outcome for mother and infant, in both shortand long-term.
The impact that GDM and its consequences has on
community health, health economics, and human capital is substantial.
GESTATIONAL DIABETES AND OXIDATIVE STRESS
A. Incidence
The increasing prevalence of GDM parallels the temporal
rise of type 2 diabetes in the nonpregnant population with lowand middle-income countries facing the greatest burden. There
is a disparity by race and ethnicity with Asians having the
highest rate, followed by Hispanics, African Americans, and
Caucasians (49, 115). The International Diabetes Federation
estimated that in 2010, India, China, the United States, Russia,
and Brazil were the five countries with the largest numbers
of people affected by diabetes (www.diabetesatlas.org). The
estimated incidence of GDM will also largely depend on the
screening strategies that are applied by each country because
an international consensus has not yet been accepted. The relevance and consequences of applying the hyperglycemia and
adverse pregnancy outcome (HAPO) detection criteria are
currently debated because reaching the safest goals would
move the total incidence of GDM from 3%–5% to *17% (72).
The incidence of GDM also increases in obesity with odds ratios
of 1.9, 3.0, and 5.5, respectively, for overweight, obese, and
severe obese compared with women with normal body mass
index (350).
B. Etiology and risk factors
GDM is a heterogeneous disorder involving a combination
of factors responsible for decreased insulin sensitivity and inadequate insulin secretion. The underlying pathophysiology of
GDM is in most instances similar to that of type 2 diabetes. The
inability of the pancreatic beta cells to match increased insulin
resistance to normalize systemic glucose translates into maternal hyperglycemia. Like type 2 diabetes, GDM is a multifactorial disease associated with both genetic and nongenetic/
environmental risk factors (Table 1). Once the genetic predisposition of an individual is being challenged by increasing insulin resistance during pregnancy, there is an additional
burden on the pancreatic b-cell, resulting in dysfunction, that is,
inadequate insulin response to glucose challenges (33).
Genetic predisposition to GDM has been suggested since
GDM tends to cluster in families. Several specific gene mutations identified in type 2 diabetes also increase the susceptibility to GDM although the underlying pathogenesis of the
disease is still largely unknown (317). A growing number of
common variants have been identified in candidate as well as
noncandidate genes. The type 2 diabetes risk variants are located both in biological candidate and noncandidate genes.
Table 1. Summary of Risk Factors Associated
with Gestational Diabetes Mellitus
Nonmodifiable factors
Genetic background
Age
Parity
Ethnicity
Modifiable factors
Overweight/obesity
High fat diet
High blood pressure
Excess weight gain in pregnancy
Endocrine dysfunction (such as polycystic ovary syndrome)
Physical activity (sedentary life style)
3063
The pathophysiologic role of some of the risk alleles involves
the impairment of b-cell function (KCNJ11, WFS1, CDKAL1,
SLC30A8, HHEX/IDE, CDKN2A/B, and IGF2BP2), insulin resistance (PPARG), and obesity (FTO), which are major pathophysiological traits associated with type 2 diabetes loci. The
strongest known type 2 diabetes association is found with
variants in TCF7L2 (394). The number of molecular defects
common to type 2 diabetes and GDM is now fueling the hypothesis that both are manifestations of the same disease.
However, different environmental challenges may shadow
the global figure as they occur with specific timing in the life
cycle (198, 215). Although the expression of a gene variant
significantly increases the risk of developing GDM, only a
small proportion ( < 10%) of GDM can be accounted by genetic
predisposition clearly pointing to other etiologic factors.
Obesity, defined on the pre-gravid body mass index > 30,
high-fat diet, and advancing age represent the most important
nongenetic factors that modulate the incidence of GDM (58).
C. Short- and long-term risks of GDM
1. GDM increases the risk of metabolic complications in
the mothers. The link between GDM and postpartum diabetes in the mother has long been recognized. Approximately
5%–10% of cases of GDM are assumed to be previously undetected cases of diabetes, based upon background prevalence of diabetes in the population (131). The remaining
majority of GDM cases is attributable to the metabolic challenge of pregnancy and impaired insulin secretory response
(34). The reduced beta-cell reserve in GDM women can
manifest as overt diabetes as late as one decade after pregnancy with a sevenfold higher risk than in women without
history of GDM (19). It is associated with a higher risk of
future maternal cardiovascular disease (42). The role of maternal micronutrients particularly low vitamin B12 and high
folate associated with GDM may also increase the risk of
gestational diabesity and later diabetes (191).
2. GDM increases the risk of metabolic programming for
the offspring. GDM has long been managed with the primary goal of minimizing if not preventing the adverse outcomes for both the mother and her offspring. At the onset of
the 21st century, serious perinatal complications associated
with GDM or perinatal deaths have become uncommon.
Macrosomia is the main factor linked to reported cases of
peripartum complications in infants of women with GDM
(248). However, establishing optimal regulation of maternal
glucose levels continues to be a challenge in controlling
perinatal morbidity. Failure in achieving early glycemic control and associated derangement in maternal metabolism
contributes to impaired embryogenesis (322). Maternal hyperglycemia is considered as the primary teratogenic factor
(6) although hyperketonemia, hypoglycemia, and excess free
oxygen radicals have also been suggested to induce congenital anomalies (89).
3. GDM modifies fetal growth pattern. The macrosomia
of fetuses of women with GDM has been defined using various criteria, including birth weight greater than the 90th
centile, birth weight greater than 4000 g, and/or estimates of
neonatal adiposity based on body composition measures.
However, more than just affecting lean mass, GDM modifies
3064
body composition resulting in higher adiposity (45). What
causes excess fetal growth in diabetic pregnancy? Since glucose is an easily measurable marker, most studies evaluating
the effect of diabetes on fetal growth have used measures of
glucose as a reference for satisfactory management. Results
from the HAPO cohort have confirmed the relationship between glucose, birth weight, and adiposity while highlighting
the role of insulin. Based on the early work of Pedersen, fetal
insulin has long been considered as a primary anabolic factor
for in utero fetal growth (311). Multiple studies have since
confirmed the association between increased cord insulin
concentrations and fetal macrosomia in both early and late
gestation (246). When obesity is associated with GDM, additional mechanisms contributing to facilitate fetal adiposity
relate to other maternal circulating nutrients for, for example,
free fatty acids, and amino acids available in greater amount
because of the plethoric environment of the mother (155).
In addition to the perinatal association with excessive fetal
growth, there are significant long-term risks for the infants of
women with GDM. There is an increase in the risk of obesity
in children and adolescents in offspring of GDM women (46).
The increased risk of obesity further extends to later life
characterized by a higher incidence of type 2 diabetes, illustrating the impact of metabolic intrauterine programming
(166). Clinical recognition of GDM is important because efficient therapy can reduce long-term sequelae in the offspring
but also complications for the pregnant women. Besides insulin therapy, the interventions proposed for women with
GDM are relatively noninvasive (diet, physical activity, lifestyle, and glucose monitoring alone) and have effects on
maternal weight gain and energy metabolism limiting complications peri- and postpartum (137). Indeed, diet is critical
for prevention and control of GDM and also in the prevention of
induction of type 2 diabetes after GDM (98, 124). Animal studies
have shown that maternal malnutrition predisposes offspring to
develop insulin resistance and diabetes in the later life (98, 124).
Although increased oxidative stress may be a mechanism of
relevance in intrauterine programming of metabolic diseases
further research in needed to clarify this point (225).
II. Brief Overview of Oxidative Stress
Key points:
Oxidative stress is defined as a disturbance in the
equilibrium status of pro-oxidants and antioxidants
system in intact cells.
Excessive oxidative stress can lead to massive cellular
damage by acting on proteins, lipids, and DNA.
Reactive oxygen species (ROS) is a term used to describe
both free radical and nonradical derivatives of oxygen.
ROS include superoxide anion (O2 - ), hydrogen peroxide (H2O2) and hydroxyl radical (OH), and organic
hydroperoxide (ROOH), peroxy radicals (RO, alkoxy
and ROO), and hypochlorous acid (HOCl).
In the following section, a brief overview of ROS and antioxidants will be presented. More comprehensive reviews on free
radicals and antioxidants can be found elsewhere (128, 354).
A. Reactive oxygen species
Lipid peroxidation results in the formation of a number of
secondary products such as conjugated dienes and lipid hy-
LAPPAS ET AL.
droperoxides (LOOHs), and degradation products such as
alkanes, aldehydes, and isoprostanes. Lipid oxidation intermediates are toxic for cells, mainly as a result of damage of the
cell membranes. It has been etiologically involved in a variety
of physiological, pathological, and clinical conditions. Lipid
peroxidation leads to the production of the end products,
including malondialdehyde (MDA) and 4-hydroxynonenal or
trans-4-hydroxy-2-nonenal (4-HNE). MDA is a stable, toxic,
and reactive aldehyde that is commonly used as a biomarker
to measure the level of oxidative stress. It forms covalent
protein adducts that are referred to as advanced lipoxidation
end products, in analogy to advanced glycation endproducts
(AGE). MDA forms a 1:2 adduct with thiobarbituric acid and
produces thiobarbituric acid reactive substances (TBARS).
The measurement of TBARS is a well-established method for
screening and monitoring lipid peroxidation; however, this
test is not specific for lipid peroxidation because MDA can
also be formed by cyclooxygenase. LOOH, a marker of oxidative stress, is formed from unsaturated phospholipids,
glycolipids, and cholesterol by peroxidative reactions under
oxidative stress. 8-isoprostane (8-epi prostaglandin F2a or 15F2t-IsoP) is an F2 isoprostane: one of a unique series of prostaglandin-like products derived from free radical-catalyzed,
nonenzymatic oxidation of arachidonic acid independent of
the cyclooxygenase enzyme. 8-isoprostane is considered to be
an accurate, stable, and sensitive indicator of oxidative stress
and endogenous lipid peroxidation.
ROS are able to oxidize proteins or convert lipid and carbohydrate derivatives to compounds that react with functional groups on proteins. Proteins can undergo different
types of oxidation, including carbonylation, nitration of tyrosine, and oxidation of methionine to methionine sulphoxide. Carbonylation is an irreversible process that gives rise
to protein carbonyl derivatives, which serve as more general
and universal biomarker of oxidative stress.
B. Antioxidants
Antioxidants can be either soluble in water (hydrophilic) or
in lipids (hydrophobic). Water-soluble antioxidants, which react with oxidants in the cell cytosol and the blood plasma,
include vitamin C, glutathione, lipoic acid, and uric acid. Lipidsoluble antioxidants, which protect cell membranes from lipid
peroxidation, include carotenes, vitamin E, and ubiquinol (coenzyme Q). Antioxidants may be derived from exogenous
sources such as the diet or they may be endogenous antioxidants that are produced within the cell. The distribution and
level of antioxidants in tissues and fluids varies greatly (354).
Enzymatic antioxidants are capable of detoxifying superoxide; superoxide is first converted to H2O2 and then further
reduced to give water. Superoxide dismutase (SOD) enzymes
catalyze the first step and then catalases and various peroxidases remove the H2O2. In mammals, there are 3 forms of
SOD: copper/zinc SOD (CuZnSOD), manganese SOD
(MnSOD), and extracellular SOD (ECSOD). MnSOD and
ECSOD are localized in the mitochondrial matrix and on the
outer surface of cell membranes, respectively, whereas
CuZnSOD is found in the cytosol. The glutathione system,
which includes glutathione, glutathione reductase (GSR),
glutathione peroxidase (GPx), and glutathione S-transferases
(GST), also controls superoxide formation. GPx, an inducible
enzyme, contains four selenium-cofactors that catalyze the
GESTATIONAL DIABETES AND OXIDATIVE STRESS
breakdown of H2O2 and organic hydroperoxides. Human
have at least four different GPx isozymes; GPx1 is the most
abundant and is most active against H2O2, whereas GPx4 is a
very efficient scavenger of LOOHs.
III. Brief Overview of Nitrative Stress
Key points:
Nitric oxide (NO) is a signaling molecule with a wide
range of biological effects such as vasodilatation,
formed by NO synthases (NOS).
Diabetes leads to changes in NO production and bioavailability.
Oxidation of NO leads to NO-derived molecules such as
peroxynitrite, a powerful oxidant.
Peroxynitrites induce damage to proteins, lipids, and
DNA. Peroxynitrite-induced damage can lead to cellular
dysfunction and apoptotic and necrotic signals.
NO is generated from the metabolism of L-arginine by the
enzyme NOS, of which there are three isoforms: neuronal
(nNOS), inducible (iNOS), and endothelial (eNOS). All the
isoforms use L-arginine and molecular oxygen as substrates
and require the cofactors nicotinamide adenine dinucleotide phosphate (NADPH), 6(R)-5,6,7,8 tetrahydrobiopterin
3065
(BH4), flavin adenine dinucleotide (FADH + ), and flavin
mononucleotide (FMNH + ), as schematized in Figure 1.
Uncoupling of the three NOS isoforms, which leads to the
formation of O2 - instead of NO, can occur (270, 347, 380).
Both low arginine and low BH4 are related to NOS uncoupling (193).
NO is a free radical, a simple diatomic gas, and a signaling
molecule with a wide range of biological effects (Fig. 2). It
classically exerts its action by binding iron-containing enzymes as soluble guanylate cyclase. By this classical pathway, NO transmits highly relevant biological effects such
as muscle relaxation, blood pressure regulation, platelet
aggregation, and neurotransmition (104, 146, 252, 255). In
several pathological situations, including GDM, the NOinduced cGMPsignaling pathway is impaired due to further
oxidation of NO, reduced NO bioavailability, and increased
NO-derived S-nitrosylation and nitration pathways. Peroxynitrite is a powerful oxidant and nitrating molecule formed
from O2 - and NO. Peroxynitrite can diffuse and cross cell
membranes, but its half-life is very short and reacts very
rapidly to nitrate or nitrosylate DNA, proteins, and lipids.
DNA nitration leads to apoptosis of damaged cells, whereas
protein nitration influences enzyme activities, and both
protein and lipid nitration exerts influences on many signaling pathways (276).
FIG. 1. (A) NOS structure
and (B) biochemistry of the
synthesis of NO. (A) NOS is
a homodimeric oxidoreductase. The monomer of all
three isoforms of NOS contain NADPH, FADH + , and
FMNH + binding sites at the
carboxy-terminal reductase
domain (RD) and the binding
sites for the heme iron, BH4,
and L-arginine at the aminoterminal oxygenase domain
(OD). Both domains are connected by a regulatory calmodulin-binding
region
(CAM). The dimer interface
occurs at a large portion of
the oxygenase domain of the
monomers and involves BH4,
calmodulin and heme as active stabilizing molecules.
Stabilization of homodimer
also depends on the integrity
of a zinc thiolate cluster coordinated by critical cysteine
residues in the oxygenase
domain. NOS catalytic function. Electrons flow from
NADPH through flavine nucleotides,
FADH +
and
+
FMNH , at the reductase
domains. The binding of calmodulin allows electrons
generated in the reductase domains to flow to the oxygenase domains, where the electrons interact with the heme iron and
BH4 at the active site to catalyze the incorporation of molecular oxygen into the guanidine group of L-arginine, generating
NO and L-citrulline as products, through an intermediate product, named N-hydroxyl-L-arginine. NOS, NO synthase.
3066
LAPPAS ET AL.
FIG. 2. Schematic representation of main physiological and pathological effects of NO.
The peroxynitrite-induced changes in DNA are the result of
the capacity of peroxynitrite to induce DNA single-strand
breaks, a damage that triggers the activation of the nuclear
enzyme poly(ADP-ribose) polymerase (PARP). PARP uses
NAD + as a substrate to form poly(ADP-ribose), which plays a
role in numerous physiological mechanisms, including DNA
repair, regulation of genomic stability, and gene expression.
However, pathological alterations are induced when PARP is
overactivated and lead to cellular dysfunction, induction of
apoptotic signals, and necrotic cell death (277).
The high amounts of NO produced by iNOS can have
beneficial microbicidal, antiviral, antiparasital, and antitumoral activity (25, 229). On the other hand, aberrant iNOS
induction is involved in the pathophysiology of human diseases such as asthma, arthritis, multiple sclerosis, colitis,
psoriasis, neurodegenerative diseases, tumor development,
transplant rejection, and septic shock (25, 150, 192). Hyperglycemia induces iNOS gene expression and is involved in the
consequent generation of nitrosative/nitrative stress (190, 384).
IV. Oxidative Stress in the GDM Mother
Key points:
A hyperglycemic environment is associated with oxidative stress. Likewise, in women with GDM, there is an
overproduction of free radicals, and the radical scavenger function mechanisms are impaired.
Oxidative stress in the GDM mother is presented below,
and summarized in Table 2.
A. Oxidant species
1. Lipid peroxidation. Measures of lipid peroxidation include MDA, 4-hydroxynonenal, TBARS, and LOOH. Maternal MDA levels in serum and plasma are increased in GDM
women compared to normal glucose tolerant (NGT) pregnant
women (56, 174, 230, 282, 336). Likewise, enhanced levels of
TBARS (239, 296) and LOOH (38, 239) have been reported in
diabetic women. Further, there is a significant positive correlation relationship between maternal HbA1c and MDA (20,
167, 282), suggesting that higher levels of lipid peroxidation
are evident in patients with poor glycemic control. No differences in TBARS and LOOH between GDM and control
have also been reported (82, 273, 348).
2. Protein oxidation. Human serum albumin (HSA), the
most abundant protein in amniotic fluid, can undergo modifications in response to oxidative stress (269). There is some
evidence to suggest that amniotic fluid is oxic in the first trimester of pregnancy (227). In a very recent study, it was
shown that there is increased protein oxidation in amniotic
fluid of GDM women obtained before 15 weeks of gestation
(27). Specifically, amniotic fluid HSA isoforms were compared between GDM and NGT women collected at 15 weeks
of gestation and analyzed by mass spectrometry (27). The
relative contribution of permanently oxidized HSA was
greater and reversibly oxidized cysteinylated HSA was lower
for GDM compared to NGT samples. These results show that
amniotic fluid HSA is highly oxidized and that the increased
GESTATIONAL DIABETES AND OXIDATIVE STRESS
oxidative stress associated with GDM alters amniotic fluid
albumin toward the irreversibly oxidized isoforms, thus
suggesting that the path toward GDM has been set in the first
trimester of gestation. Currently, the accepted method of diagnosing GDM is via glucose blood testing between 24 and 28
weeks of gestation. Although a direct clinical benefit of the
early diagnosis of GDM remains to be established conclusively, identification of women at greatest risk would allow
triage of the patients to an appropriate model of care and
identify a group who are at particular need of glucose tolerance assessment. Early diagnosis may also minimize exposure
of the developing fetus to suboptimal conditions and prevent
perinatal complications and their sequelae.
When proteins undergo oxidative damage, they become increasingly susceptible to proteolytic degradation. Erythrocytes
contain proteolytic enzymes that can degrade oxidatively damaged proteins such as hemoglobin, thus preventing the accumulation of nonfunctional proteins and protein fragments. GDM
is associated with higher levels of maternal erythrocyte proteolytic activity than NGT controls (167).
3. Transitional metals. The formation of the extremely
reactive OH from O2 - and H2O2 is catalyzed by iron; this is
referred to as the Haber-Weiss reaction. There is now increasing evidence that increases in transitional metal, such as
iron, may play a role in the generation of oxidative stress
(287). Administration of an iron supplement during the third
trimester of pregnancy is associated with significantly increased TBARS in the 27 supplemented women compared
with controls (196). The positive association between body
iron stores and the development of glucose intolerance and
thus type 2 diabetes has long been recognized (241). However,
data now also exist demonstrating a similar relationship between hemoglobin, serum ferritin, transferrin saturation,
and/or iron concentrations and GDM (1, 24, 200–202, 331).
Free copper or low-molecular-weight copper complexes
catalyze the reaction between O2 - and H2O2 producing the
OH. In addition, copper binds to free thiols of cysteines, resulting in oxidation and subsequent crosslinks between proteins leading to impaired activity. GDM is associated with
increased copper contents in serum when compared to NGT
women (361).
B. Antioxidants
As presented above, in much of the literature, increased
levels of ROS are consistently observed in the maternal circulation of women with GDM. However, there are discrepancies on the expression and activity of antioxidants in
GDM, which may be due to differences in the criteria for diagnosis of GDM and gestation at which sample was collected.
In the following section, all the literature pertaining to antioxidants in GDM will be reviewed. A complete summary of
all the available data is presented in Table 2.
1. Nonenzymatic antioxidants. Maternal circulating levels of a-tocopherol are unchanged (82, 174, 282, 311, 327) or
lower (121, 336) in GDM women. Lower (175, 336) and higher
(82, 121) maternal plasma vitamin C levels have also been
reported.
Glutathione is present in high concentrations and as such is
considered of the most important cellular antioxidants. It can
3067
exist in either a reduced (GSH) or oxidized (GSSG) state. Both
lower (296, 336) and higher (82) GSH levels in GDM women
have been reported.
High levels of uric acid have casually been associated with
insulin resistance for a while (134). However, it is only recently, in prospective follow-up studies (the Rotterdam
Study), that high serum uric acid has been identified as a
novel strong and independent risk factor for type 2 diabetes
(76). Significantly elevated levels of serum uric acid are observed in GDM as compared to those in controls (175).
In addition to the above-mentioned antioxidants, several
other natural antioxidants have been implicated in GDM.
They include, but are not limited to, b-carotene, selenium,
flavonoids, and vitamins B1 (thiamine), B9 (folic acid), and B6
(pyridoxine, pyridoxal, and pyridoxamine). When compared
to NGT women, levels of serum selenium (177, 341) and folic
acid (75) are significantly lower in pregnant woman with GDM.
2. Enzymatic antioxidants. Enzymatic antioxidants are
capable of detoxifying superoxide; superoxide is first converted
to H2O2 and then further reduced to give water. SOD enzymes
catalyze the first step and then catalases and various peroxidases remove the H2O2. SOD activity significant increases (223,
336), decreases (56, 82, 121), or does not change (20, 282) in
women with GDM when compared to NGT controls. On the
other hand, catalase activity is GDM women (20, 336).
The glutathione system includes GSR, GPx, and GST. GPx
activity is unchanged (273), higher (336), or lower (282) in
GDM women. Likewise, there are higher maternal serum
GST levels in patients with GDM when compared to NGT
controls (82).
Paraoxonase and arylesterase are endogenous free-radical
scavenges that act together to bind to high-density lipoprotein
(HDL) and low-density lipoprotein (LDL), protecting them
from oxidation by hydrolyzing activated phospholipids and
lipid peroxide products. Basal and salt-stimulated paraoxonase and arylesterase activities are significantly lower in
patients with GDM, and their activities in GDM patients inversely correlate with lipid LOOH levels (38). The authors
suggested that the decreased serum paraoxonase and arylesterase activities might play a role in the potential early
pathogenesis for atherosclerotic heart disease in GDM beyond
their antioxidant properties. Oxidative stress plays a crucial
role in the development of atherosclerosis through the oxidation of LDL that subsequently leads to the formation of
foam cells (41), and HDL is a well-known anti-oxidant molecule that prevents atherosclerosis (14). Thus, the independent association between serum paraoxonase activity with
serum HDL and LDL levels, but not with oxidative parameters, is in keeping with and GDM being associated with subclinical atherosclerosis (342).
Haptoglobin (Hp), an Hb-binding plasma protein, exists in
two major allelic variants. Hp is an acute-phase protein that,
in response to interleukin (IL)-6, is synthesized primarily in
the liver and to some extent in fat tissue. Hp forms a complex
with free Hb that can be rapidly cleared by the liver and
macrophages. As such, Hp is thought to act as an antioxidant
as free Hb catalyzes the generation ROS (in particular, OH)
by the Fenton reaction. Hp1 has higher Hb binding and antioxidant capacity compared with Hp2. Women missing Hp2
have an increased risk to develop impaired glucose tolerance
during pregnancy (256).
3068
LAPPAS ET AL.
Table 2. Reactive Oxygen Species and Antioxidants in Maternal and Fetal Circulation
Biomarker
Reference
Source of sample (gestation)
Maternal
XO
MDA
(20)
(327)
(174)
Plasma (term Caesarean section, not in labor)
Plasma (delivery)
Plasma and Erythrocytes (term delivery)
(311)
(20)
(56)
(230)
(282)
Serum (31 weeks till delivery)
Plasma (term Caesarean section, not in labor)
Serum (during pregnancy, *32 weeks)
Plasma (term delivery)
Plasma and Erythrocytes (during pregnancy,
26–32 weeks)
Erythrocytes (not stated)
Plasma and Erythrocytes
[ GDM
=
= plasma;[GDM
erythrocytes
=
[ GDM
[ GDM
[ GDM
[ GDM plasma and
erythrocytes
[ GDM
(336)
(167)
TBARS
LOOH
a-tocopherol
c-tocopherol
Vitamin C
GSH
Protein thiols
Uric Acid
SOD
Catalase
GPx
GST
(180)
(273)
(82)
(296)
(121)
(239)
(38)
(239)
(348)
(327)
(311)
(282)
(82)
(336)
(174)
(121)
(327)
(336)
(82)
(121)
(174)
(296)
(336)
(82)
(180)
(82)
(175)
(223, 336)
(56)
(121)
(82)
(20)
(282)
(180)
(20)
(336)
(56)
(273)
(20)
(82)
(296)
(336)
(273)
(282)
(82)
(273)
Plasma
Plasma (3rd trimester and after delivery)
Erythrocytes (delivery, 34–39 weeks)
Plasma (pre- and postdelivery)
Serum
Platelets (during pregnancy, 28–32 weeks)
Serum (during pregnancy, 28–32 weeks)
Platelets (during pregnancy, 28–32 weeks)
Plasma and serum (2nd and 3rd trimester)
Plasma (at delivery)
Serum (31 weeks till delivery)
Plasma and Erythrocytes (during pregnancy,
26–32 weeks)
Plasma (delivery, 34–39 weeks)
Erythrocytes (not stated)
Plasma and Erythrocytes (term delivery)
Serum (3rd trimester)
Plasma (at delivery)
Erythrocytes (not stated)
Plasma (delivery, 34–39 weeks)
Serum (3rd trimester)
Erythrocytes (32–39 weeks)
Erythrocytes (pre- and postdelivery)
Erythrocytes (not stated)
Erythrocyte (delivery, 34–39 weeks)
Plasma
Serum (delivery, 34–39 weeks)
Serum (32–39 weeks)
Erythrocytes (not stated)
Serum (during pregnancy, *32 weeks)
Erythrocytes (3rd trimester)
Erythrocyte (delivery, 34–39 weeks)
Plasma (term Caesarean section, not in labor)
Plasma and Erythrocytes (during pregnancy,
26–32 weeks)
Plasma
Plasma (term Caesarean section, not in labor)
Erythrocytes (not stated)
Serum (during pregnancy, *32 weeks)
Plasma (3rd trimester and after delivery)
Plasma (term Caesarean section, not in labor)
Erythrocyte (delivery, 34–39 weeks)
Erythrocytes (pre- and postdelivery)
Erythrocytes (not stated)
Plasma (3rd trimester and after delivery)
Plasma and Erythrocytes (during pregnancy,
26–32 weeks)
Serum (delivery, 34–39 weeks)
Plasma (3rd trimester and after delivery)
=
=
[ GDM
[ GDM
[ GDM
[ GDM
[ GDM
=
=
[ GDM
=
=
YGDM
=
YGDM
[ GDM
YGDM
=
[ GDM
YGDM
YGDM
YGDM
[ GDM
[ GDM
[ GDM
[ GDM
YGDM
YGDM
YGDM
=
=
YGDM
YGDM
=
=
=
Cord
[ GDM
NS
[ GDM
[ GDM
[ GDM
erythrocytes
[ GDM
=
=
[ GDM
YGDM
YGDM
=
=
=
YGDM
[ GDM
[ GDM
YGDM
[ GDM
YGDM
YGDM
=
YGDM
[ GDM
[ GDM
[ GDM
=
YGDM erythrocytes
=
[ GDM
=
=
=
(continued)
GESTATIONAL DIABETES AND OXIDATIVE STRESS
3069
Table 2. Continued
Biomarker
Reference
ApoB
TAC
(296)
(121)
(20)
(348)
(296)
Source of sample (gestation)
Erythrocytes (pre- and postdelivery)
Serum (3rd trimester)
Plasma (term Caesarean section, not in labor)
Plasma and serum (2nd and 3rd trimester)
Erythrocytes (pre- and postdelivery)
Maternal
YGDM
=
=
YGDM
Cord
[ GDM
YGDM
YGDM
GDM, gestational diabetes mellitus; GPx, glutathione peroxidase; GST, glutathione S-transferases; GSH, reduced glutathione; MDA,
malondialdehyde; LOOH, lipid hydroperoxide; TAC, total antioxidant capacity; TBARS, thiobarbituric acid reactive substances.
Total antioxidant capacity (TAC) is considered a measure
of the oxygen radical absorbance capacity or the capacity of
the sample to inhibit an oxidant reaction; however, this is not
always reflective of all major antioxidants. No difference in
maternal plasma TAC between GDM and NGT has been reported (20, 348). However, when TAC was corrected for uric
acid (uric acid is considered to be the major determinant of
TAC), it significantly decreased in GDM compared to NGT in
both the second and third trimesters (348). This is in keeping
with other reports of lower TAC in GDM women (121, 296).
3. Transitional metals. Selenium, zinc, and copper are
commonly referred to as antioxidant nutrients, but they do
not themselves possess any antioxidant properties, instead
they are required for the activity of some antioxidant enzymes. There is some evidence that the levels of zinc (23, 361)
and selenium (23, 177) are lower in women with GDM.
The activity CuZnSOD is sensitive to tissue copper as these
enzymes require copper as a catalytic cofactor. Thus, the increase in CuZnSOD activity observed in GDM may be due to
zinc and copper levels in GDM. Consistent with this hypothesis, compared with normal pregnant women, the copper
contents in serum of pregnant women with GDM are increased (361). This is also consistent with the ability of copper
to produce excessive amounts of ROS (as detailed above).
C. Concluding comments
The maternal circulating levels of free radicals and antioxidants are altered in GDM pregnancies. Given that the
placenta provides the interface of the maternal and fetal circulations, it may play a crucial role in protecting the fetus
from adverse effects of the maternal diabetic milieu, whereas
disturbances in placental function may exacerbate this state.
In the following section, the effect of diabetes in pregnancy,
from both human and animal studies, on oxidative stress,
nitrative stress, and antioxidants in the placenta and fetus is
discussed.
V. Oxidative Stress in the GDM Placenta and Fetus
Key points:
In GDM pregnancies, there is an overproduction of free
radicals, placental oxidation reactions are accelerated,
and the radical scavenger function mechanisms are
impaired.
The relative immaturity of the antioxidant system facilitates the exposure of embryos and fetuses to the
damaging effects of oxidative stress.
Animal models of diabetes and pregnancy have been
very useful to address the presence of increased oxidative stress in the intrauterine compartment throughout
diabetic gestations.
A. Oxidative stress in the placenta
The placenta is a rich source of oxidants and antioxidants.
There is increased metabolic activity in the mitochondria of
the placenta that generates ROS and superoxide generation
from NADPH oxidase. The placenta is also capable of inducing protective enzymatic and nonenzymatic scavengers
against these free radicals. The placenta provides the interface
of the maternal and fetal circulations, and it may play a crucial
role in protecting the fetus from adverse effects of the maternal diabetic milieu, whereas disturbances in placental
function may exacerbate this state.
1. ROS in the GDM placenta. The GDM placenta is associated with increased expression of xanthine oxidase (XO)
(20), MDA (20, 181), 4-HNE (261), and protein carbonyl (71).
Likewise, the placental release of 8-isoprostane is greater from
women with GDM compared to NGT pregnant women (71,
206). Quite interestingly, there was a significant positive correlation between plasma glucose (2 h after a glucose challenge
at the time of diagnosis) and placental release of 8-isoprostane, suggesting that lipid peroxidation may be, at least in
part, associated with glycemic control.
Several studies have found that diabetes leads to an aberrant ROS generation during intrauterine development in genetic and chemical-induced experimental models of type 1
and type 2 diabetes (162). In diabetic rat models, together with
higher lipoperoxidation in maternal and fetal blood, lipoperoxidation is increased in the placenta at different developmental stages and is greater at term gestation (74, 114, 275,
374). Indeed, in the mild diabetic model obtained by streptozotocin administration to rat neonates, studies performed in
the postplacentation period have shown that TBARS concentrations are increased in the decidua, the placenta, and the
fetuses, but that lipoperoxidation is elevated in the decidua
than in the placenta, and higher in the placenta than in the
fetuses, thus suggesting a protective role of the placenta from
oxidative stress (291).
Data from our laboratory have demonstrated that GDM
placenta have a reduced capacity to respond to oxidative
stress. Specifically, we have shown that when placental tissue
was subjected to oxidative stress (hypoxanthine plus xanthine
oxidase [HX/XO]), 8-isoprostane release increased by twofold in normal pregnant women, but was unchanged in GDM
(70). This was associated with a decrease in catalase and GPx
3070
gene expression. In contrast, in GDM placentas, there was no
effect of HX/XO on antioxidant gene expression (204). This
response to HX/XO was specific to placenta; adipose tissue
(both subcutaneous and omental) from women with and
without GDM responded similarly to an oxidative challenge.
That is, oxidative challenge stimulated 8-isoprostane release
equally in normal and GDM omental and subcutaneous adipose tissue with no effect of HX/XO on antioxidant gene
expression (204). Taken together, these data suggest that in
both normal placenta, and normal and GDM adipose tissue,
induction of oxidative stress displaces the prooxidant-antioxidant balance of this defense system, by increasing the
prooxidants and depleting the antioxidant capacities. However, in the GDM placenta, we hypothesize that it may be
preconditioned by transient intracellular oxidative stress,
which attenuates its responsiveness to further oxidative insult. That is, it has been exposed to oxidative stress during the
course of pregnancy and to counteract this, it has increased
placental antioxidants. Thus, when it is further challenged
with further oxidative challenges, it may be better able to
respond as it has increased antioxidants. Certainly, there are
data to suggest that the ability of cells to accommodate oxidative stress may be enhanced by preexposure or preconditioning to a mild oxidative challenge, thus inducing
resistance to subsequent oxidative stress. In support, our data
show that the GDM placenta does not alter its antioxidant
capacity in response to HX/XO (204). Similarly, some tissues,
in response to diabetes, overexpress the genes for the antioxidant enzymes, whereas other tissues are more susceptible
to oxidative damage (237). It has also been proposed that in
the early stages of diabetes there may be an initial elevation in
antioxidant enzymes to counteract oxidative stress, whereas
chronic diabetes continually depletes the sources of antioxidant enzymes.
2. Antioxidants in the GDM placenta. There is certainly
much evidence to suggest that in GDM pregnancies, to
maintain redox homeostasis, the placental production and the
activities of antioxidant enzymes increase. Although it has
been reported that catalase activity is decreased in placenta
from women with GDM (20), we have found increased catalase and GSR mRNA expression in GDM placentas when
compared to NGT placenta (204). There is no effect of GDM on
GPx activity (20, 71) and GPx mRNA expression (204) in human placenta.
Discrepancies in the levels of SOD in GDM placenta have
also been reported. The level of total SOD in placental tissues
of GDM (both diet- and insulin-controlled) patients is lower
(181) or did not significantly change (20, 204). However, our
studies report that CuZnSOD activity is significantly higher in
GDM placenta (71). This is particularly interesting as it is
mainly compartmentalized in trophoblast cells within the
placenta and may thus serve as an important antioxidant at
the maternal-fetal interface (362). It is suggested that increased SOD activity may be a compensatory mechanism
against increased XO activity and superoxide production.
However, the relative ratio of CuZnSOD to 8-isoprostane or
protein carbonyl was lower in GDM placentas, suggesting
that the increase in SOD is not sufficient to compensate for the
increased oxidative stress (71).
The lectin-like oxidized LDL receptor-1 (OLR1) is the
principal scavenger receptor responsible for the uptake for
LAPPAS ET AL.
oxidatively modified LDL in placental cells (278). Interestingly, the protein expression (but not mRNA expression) of
OLR1 is increased in GDM placenta (92).
Apolipoprotein D (ApoD) is a lipocalin antioxidant that is a
component of HDL. ApoD is higher in GDM placenta (261).
As the trophoblastic cells and villous macrophages were
positive for ApoD, the authors hypothesized that these cells
may play a scavenger role protecting the diffusion of lipoperoxidation products from the mother to the embryo. This is
in keeping with enhanced levels of arachidonic acid and
docosahexaenoic acids observed in the placenta of the GDM
women (21).
Similar to the studies in humans, in the placenta from experimental models of diabetes and pregnancy, antioxidant
enzymes can be found either up-regulated, to compensate the
oxidative dysbalance, or down-regulated, overwhelmed by
the increased ROS. These changes are dependent on the developmental stage and are generated in response to the
gradual increase in ROS, which is more pronounced at term
gestation (291, 374). Besides, compensatory increases in the
gene Txnip, which codifies the thioredoxin interacting protein
(a protein involved in oxidative stress responses), have been
reported in placentas from diabetic mice (389).
There is some evidence to show a beneficial effect of antioxidants in placenta. Specifically, studies in mitochondria
of human placentas revealed a beneficial effect of ascorbate
on lipid peroxidation, which is mediated by recycling of
a-tocopherol. With the limitation of the nonspecific nature of
TBARS, these data indicate that release of lipid peroxides
from mitochondria can be prevented by ascorbate and
a-tocopherol in human placental tissue (245).
3. Reactive nitrogen species in the GDM placenta. Oxidative stress plays a significant role in both NO overproduction and loss of NO bioavailability (116, 259, 346, 380).
Oxidative stress leads to iNOS-dependent increases in NO
production in different tissues. Although reductions in eNOS
are related to diabetes-induced endothelial dysfunction,
eNOS increases can also be induced by diabetes, and this is the
change mostly found when eNOS is evaluated in gestational
tissues in GDM. In addition, excess of NO production leads to
changes in NOS function, yielding O2 - instead of NO.
Moreover, increases in ROS lead to a reduction in NO bioactivity and increase the formation of peroxynitrites.
NO can also exert antioxidant effects (377). NO induces the
expression of antioxidant enzymes MnSOD, CuZnSOD, and
heme oxygenase-1 and increases intracellular glutathione
concentration (250). Although NO stimulates O2 - -induced
lipoperoxidation in membranes, it can also mediate protective
reactions to inhibit O2 - and ONOO - induced lipoperoxidation (305).
As a main regulator of vasodilatation, vascular remodeling,
and angiogenesis, NO has been a focus of research in GDM.
NO production has been found increased in the placenta, placental veins and arteries, and in umbilical vein endothelial cells
from GDM patients (99, 288, 329, 359), although some studies
have shown no significant increases in circulating nitrates/
nitrites and no changes in placental NOS activity in placental
tissues from GDM patients (83, 222). Accordingly, NOS expression is also altered, as iNOS has been found overexpressed
in the placenta and eNOS increased in umbilical vein endothelial cells from GDM patients (308, 314). However, other
GESTATIONAL DIABETES AND OXIDATIVE STRESS
studies have shown no changes in the expression of NOS isoenzymes in the placenta from GDM patients (83).
In GDM, increases in ROS and NO production, evident
in the placenta and umbilical vessels, lead to peroxynitrite
formation. Indeed, there is evidence of protein nitrosylation
in placentas, umbilical arteries, and umbilical veins in insulin-treated GDM patients, although not in diet-treated
GDM patients (144). This indicates that in those cases in
which insulin is required to prevent aglycemia there is risk
of peroxynitrite-induced damage. In platelets from GDM
patients, elevated NOS activity and peroxynitrite production have been reported, possibly associated with platelet
dysfunction and membrane damage due to increased lipid
peroxidation (144, 239).
It is interesting that NO production, evaluated through the
concentrations of nitrates/nitrites, is highly elevated in the
placenta from mild diabetic rats at midpregnancy (40, 290). As
strong protein nitration is found in term placentas from diabetic rats (40), increases in ROS, characteristic of term gestations and aggravated by the diabetic disease, may lead to the
rapid conversion to peroxynitrites with the consequent loss of
bioactive NO.
Collectively, these data provide evidence of reactive nitrogen species (RNS)-induced damage in GDM in the placenta
and the vasculature of the mother, the placenta, and the
umbilical cord, produced as a resulting consequence of exacerbated NO and ROS production.
B. Oxidative stress and the fetus
The above data demonstrate that the placenta is endowed
with many antioxidants, some of which are increased in
GDM. However, there is much data to indicate that maternal
diabetes during pregnancy may induce oxidative stress in the
newborn that may entail biochemical disturbances of the fetus
(77, 259, 307). By using both chemical and genetic diabetes
and pregnancy animal models, the studies carried out have
confirmed the important role of ROS in the etiology of congenital malformations. Indeed, the relative immaturity of the
antioxidant system facilitates the exposure of embryos and
fetuses to the damaging effects of oxidative stress.
1. Oxidative stress and fetal malformations. Before the
formation of the placenta, and despite the hypoxic state during embryo early organogenesis, there are increases in ROS, as
determined by higher levels of isoprostanes and protein carbonyls in embryos from diabetic rats (51, 357). The increases in
ROS, together with the impaired antioxidant activity and elevated RNS, as detailed below, are clearly related to the induction of malformations (88, 158). During early organogenesis,
apoptosis is highly needed in an appropriate location and
temporal pattern, and increased ROS are related to the increase
in apoptosis induced in diabetic experimental models (55).
Congenital malformations are mostly induced in pregestational diabetic pregnancies, although they can also arise
in GDM, possibly caused by a pre-existing diabetes first recognized during pregnancy (67). Congenital malformations,
mainly cardiac and neural tube defects, are induced in both
chemical-induced and genetic experimental models of diabetes (162). Interestingly, alterations in embryonic and fetoplacental development in experimental models of diabetes
have been associated with the increase in ROS in intrauterine
3071
tissues. Evidence of increased ROS has been found in embryos, fetuses, and placentas in streptozotocin- and alloxaninduced diabetes experimental models (89, 159, 274).
Maternal diabetes-induced damage, clearly associated with
the degree of ROS formed, is more marked in severe diabetic
models (glycemia higher than 250 mg/dL) than in mild diabetic models (glycemia lower than 250 mg/dL) (158).
Interestingly, the susceptibility to the induction of malformations in chemical models of diabetes and pregnancy is
clearly dependent on the rat strain and related to the embryonic concentrations of the antioxidant enzyme SOD, which
are decreased in embryos from susceptible strains but not
from malformation-resistant strains (53). Similarly, susceptibility to the induction of malformations in maternal diabetes
is also clearly dependent on the embryonic levels/activity of
antioxidant enzymes in genetic models of diabetes (364, 393).
Of note, there is a decreased expression of GPx in malformed
embryos from diabetic rats when compared to nonmalformed
ones, an alteration localized in the developing heart (367).
There is evidence that several teratogens affect the developing embryo by increasing its oxidative stress. Human and
animal studies show that the main mechanism of fetal damage induced by high levels of ionizing irradiation, cocaine and
alcohol abuse, hypoxia, and cigarette smoking is also by increased embryonic oxidative stress.
Collectively, these data clearly indicate the relevance of
ROS as teratogenic agents. Fetal malformations are mostly
induced in the first trimester of pregnancy. As detailed in
Section I, GDM is defined as glucose intolerance first detected
at any time during gestation. Since GDM is mostly induced in
the second trimester of pregnancy, its diagnosis is performed
on weeks 24–28 of pregnancy, but, as detailed in Section IV,
increased ROS have been detected in amniotic fluid in GDM
before the 15th week of gestation. Therefore, the risk for fetal
malformations is increased in pre-gestational diabetes and
may affect GDM only in those cases in which the pathology is
present in the first trimester of pregnancy, possibly as a result
of the increased intrauterine ROS generated.
2. Nitrative stress and fetal malformations. As reviewed
elsewhere, both NO production and NOS activity are enhanced in embryos from diabetic rats during organogenesis,
alterations related to the induction of embryo malformations
(88, 158). Moreover, peroxynitrite-induced damage has been
found in the neural tube and developing heart in embryos
obtained from diabetic rats during early organogenesis, being
both neural tube defects and cardiac malformations the most
common congenital defects induced by maternal diabetes
both in patients and in experimental diabetic models (89, 160).
It is interesting that there are many endogenous regulators of
NO production in the embryo during organogenesis, suggesting that NO concentrations should be tightly regulated
during organ formation. Indeed, leptin, Prostaglandin E2
(PGE2), 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2), and endothelin-1 can negatively regulate embryonic NO production
(160, 161, 373). These bioactive molecules show changes in
their concentrations and impaired capacity to regulate NO in
diabetes and pregnancy models in which hyperglycemia is
> 250 mg/dL (160). The involvement of iNOS as the NOS
isoenzyme responsible for NO overproduction in diabetic
embryopathy has been addressed by the use of iNOS inhibitors and the evaluation of iNOS knockout mice, in which
3072
diabetes-induced congenital malformations have been found
highly reduced (335). ROS-induced teratogenesis is also reduced in iNOS knockout mice (168).
The available data suggest that NO overproduction and
NO-derived oxidant species, mainly peroxynitrites, are involved in the induction of congenital malformations. Therefore, RNS are likely to be related to the induction of fetal
malformations in pre-gestational diabetes, and also in GDM if
the metabolic impairments that lead to NO overproduction in
intrauterine tissues are increased in the first trimester of
pregnancy when most congenital malformations are induced.
3. Oxidative stress in the fetal organs. Studies performed in a genetic rat model of type 2 diabetes have shown
that lipoperoxidation is enhanced in different fetal organs
such as the heart and brain (275). Likewise, in the rat neonate,
chemical-induced maternal diabetes induces increases in ROS
and lipoperoxidation in different organs such as the liver,
kidney, and brain (182, 298). In the offspring from diabetic
rats, the plasma levels of lipoperoxides are elevated (385).
No changes, increases or reductions in the activity of SOD,
catalase, and GPx, have been found in fetuses in different
diabetes and pregnancy animal models, differences that are
dependent on both the genetic background and the degree of
metabolic impairment (162, 182, 275, 291). Studies performed
in the offspring have shown that there are reduced concentrations of glutathione and SOD in different organs such as the
liver, kidney, and brain in neonates born to chemical-induced
diabetic rats (182, 298). Studies performed in chemicalinduced pregestational diabetic rats have shown a decreased
expression of CuZnSOD, MnSOD, and GPx in embryos from
diabetic rats when compared to controls (324, 392). Similar
decreases in SOD activity in the macrosomic offspring of diabetic rats have been demonstrated (385).
In animal models, under diabetic condition there was a
significant decrease in the activity of endogenous antioxidant
enzymes and of vitamins C and E in the embryos and their
yolk sacs (274). Reduced concentrations of vitamin E have also
been found in both embryos and livers from fetuses from
diabetic animals (321).
The maternal surface of the trophoblastic microvilli of the
human placenta is very rich in transferrin receptors (221). Iron
from maternal transferrin is transferred from the syncytiotrophoblasts of the placenta into the fetus—a process that
increases as pregnancy progresses (44). Although the oxidative stress and in vivo consequences caused by iron excess
have been studied in detail, the effect of excess iron on the
fetus is not known.
Relevant alterations in NO and peroxynitrite formation
have been found throughout pregnancy in experimental
models of diabetes (158). At the fetal stage, and even in mild
diabetes and pregnancy animal models, NO production is
increased (290).
A higher transfer of metabolic substrates from the maternal compartment, higher fetal insulin concentrations,
and fetal macrosomia are characteristic in GDM patients.
Interestingly, postmortem examinations in human fetuses
with islet cell hyperplasia, an indicator of fetal hyperglycemia, have shown that only those fetuses that have increased insulin immunoreactivity in pancreatic islets show
increased nitrotyrosine immunoreactivity in the central
nervous system (141).
LAPPAS ET AL.
In summary, the available data indicate that maternal diabetes leads to oxidative and nitrative stress in many fetal
organs, alterations associated with either impaired or compensatory responses in antioxidant enzymes. Although fetal
organs can be evaluated mainly in experimental models of
diabetes, the alterations in umbilical cord blood obtained at
term gestations suggest that GDM exposes the fetus to both
ROS and RNS, as detailed below.
4. Oxidative stress in the umbilical cord of GDM women. Certainly, evidence suggests that the fetus at term is
exposed to oxidative stress, as higher ROS and lower antioxidants are evident in the umbilical cord blood of GDM
women. The evidence is discussed below and summarized
in Table 2.
Markers of reactive oxidative species are increased in diabetic pregnancies. MDA activity (20, 181, 230), GSH levels
(181), and serum protein thiol levels (82) are increased in cord
plasma from GDM women when compared to NGT women
(20, 181, 230). The macrosomic offspring of women with GDM
have enhanced TBARS levels (121). Others have reported no
differences (273).
On the other hand, antioxidants are unchanged, higher, or
lower in cord blood from diabetic women. Cord plasma vitamin E levels (20, 327), catalase activity (20, 336), GPx activity
(20), SOD activity (20, 181), and TAC activity (20) are significantly decreased in GDM. Correlation analysis demonstrated
a significant inverse relationship between maternal HbA1c
(higher levels) and cord plasma TAC (lower levels), suggesting that oxidant stress and peroxidation reactions are in parallel with diabetic deterioration (20). These data suggest that
maternal diabetes during pregnancy may induce oxidative
stress in the newborn. On the other hand, SOD activity (20),
erythrocyte GPx activity (82, 296), and apolipoprotein B (296)
are elevated in cord blood from GDM women.
C. Concluding comments
In placenta and fetuses of GDM pregnancies, oxidative
stress reactions are increased. In concert with this, there are
alterations in the antioxidant defense mechanisms. The
pathways that contribute to the increased oxidative stress
observed in the GDM placenta are discussed below.
VI. Pathways Contributing to the Generation
of Oxidative Stress in GDM
Key points:
Hyperglycemia induces oxidative stress and cell and
tissue damage through several metabolic mechanisms.
These include the polyol pathway, formation of AGE,
activation of protein kinase C (PKC), the hexosamine
pathway, and increased oxidative stress generation by
enhanced ROS production in the mitochondria.
Pathological pathways involved in the generation of
these metabolites are discussed below and illustrated in
Figure 3.
A. Advanced glycation endproducts
An important source of free radicals in diabetes is the interaction of glucose with proteins leading to the formation
GESTATIONAL DIABETES AND OXIDATIVE STRESS
3073
FIG. 3. Mechanisms by which hyperglycemia induces cellular dysfunction and damage. Advanced glycation endproducts (AGE), protein kinase C (PKC), oxidized (NAD + ) and reduced form (NADH) of nicotinamide adenine dinucleotide,
reactive oxygen species (ROS). The pathways, enzymes, and outcomes marked in gray have been reported to be increased or
activated in GDM. Please refer to the text for the details.
of an Amadori product and then AGEs. AGEs, such as Necarboxymethyl-lysine (CML), are late-stage glycoxidation and
glycation adducts of the Maillard reaction that form by nonenzymatic glycation through covalent attachment of highly
reactive aldehyde or ketone groups of reducing sugars and
the free amino groups on proteins, lipids, and nucleic acids.
This can occur at intracellular and extracellular sites. In particular, elevated concentration of glucose metabolism products from glycolysis and the tricarboxylic acid (TCA) cycle
initiate glycation of intracellular proteins. The interaction of
aldehyde groups of glucose with free amino groups on proteins generates a Schiff’s base. It spontaneously rearranges
into a much more stable ketoamine, the Amadori product
(16, 122). Amadori products are degraded into other reactive dicarbonyl compounds such as 3-deoxyglucosone and
methylglyoxal, which can react directly with amino groups
of intra- and extracellular proteins to generate AGE. This
covalent modification of proteins has severe consequences
and leads to altered protein function. Indeed, tissue and
plasma of diabetic patients contain higher amounts of AGE
(26, 117).
Extracellular AGE can bind to the AGE receptor (RAGE), a
multi-ligand member of the immunoglobulin superfamily.
Besides its capability to activate transcription factors such as
nuclear factor-kappa B (NF-jB), it stimulates ROS formation
by NADPH oxidase. In this way, AGE lead to cellular dys-
function and injury and to formation of ROS (303). There is
also a soluble form of RAGE (sRAGE), which is a truncated
form of the receptor produced by alternative splicing of RAGE
mRNA (endogenous secretory RAGE, esRAGE) and proteolytic cleavage of membrane-bound RAGE by metalloproteinase action (proteolytically cleaved RAGE, c-RAGE).
Circulating sRAGE is composed of only the extracellular
ligand-binding domain lacking the cytosolic and transmembrane domains. It has the same ligand binding specificity of
RAGE, and thus it competes with cell-bound RAGE for ligand
binding, neutralizing AGE-mediated damage by acting as a
decoy. Engagement of RAGE by AGE results in activation of
intracellular signaling molecules resulting in oxidative stress
and inflammation. Since oxidative stress generation and inflammation are closely associated with GDM (68, 206, 301), it
is plausible that the AGE-RAGE system could play a role in
the pathogenesis of this metabolic disease.
Although AGE and RAGE have recently been identified in
human placenta (35, 57, 105) and increase in association with
pregnancy and pregnancy complications (35, 57, 66, 96, 105,
279), to date, there are limited data available on the circulating
levels of AGE in relation to GDM. In recent studies, we have
profiled the maternal circulating levels of CML, sRAGE, and
esRAGE during pregnancy from pregnant women with NGT
and GDM. The maternal plasma concentrations of CML,
sRAGE, and esRAGE were measured from 46 NGT women
3074
LAPPAS ET AL.
FIG. 4. CML and soluble-form RAGE levels in maternal plasma from NGT and GDM women. The box represents the
mean and interquartile range; the whiskers represent the 5th and 95th centiles. xp < 0.05 versus NGT. GDM, gestational
diabetes mellitus; CML, Ne-carboxymethyl-lysine; NGT, normal glucose tolerant.
and 40 women with GDM at the time of term Caesarean delivery. Maternal circulating CML levels were significantly
higher in GDM women than in NGT women. On the other
hand, statistically lower sRAGE and esRAGE levels at the
time of term delivery were also observed in GDM women
compared to NGT women (Fig. 4).
During pregnancy, the AGE-RAGE axis may be involved
in oxidative and inflammatory responses. By increasing intracellular oxidative stress, AGE activates NF-jB, thus promoting up-regulation of various NF-jB controlled target
genes. For example, AGE-RAGE signaling plays a pivotal
role in regulating the production and/or expression of proinflammatory mediators such as cytokines and oxidative
stress, as well as endothelial dysfunction in type 2 diabetes via
NF-jB (107). In previous studies, we used in vitro human
tissue explant system to examine the potential inflammatory
effects of AGE-BSA in human intrauterine tissues. Our data
show that AGE-BSA, but not nonglycated BSA, has proinflammatory actions in human gestational tissues. Specifically, AGE-BSA stimulated the release of the pro-inflammatory cytokines IL-1b, IL-6, IL-8, and tumor necrosis factor
(TNF)-a and prostaglandins PGE2 and PGF2a. These proinflammatory actions of AGE-BSA were elicited through a
number of intracellular signaling pathways, namely, extracellular-signal-regulated kinase 1/2 and NF-jB (210). NF-jB
and MAPK activate several pro-inflammatory genes, including pro-inflammatory cytokines, the adhesion molecules
vascular cell adhesion molecule (VCAM)-1, and intercellular
cell adhesion molecule (ICAM)-1, and RAGE causing cellular
inflammation. This is consistent with GDM being closely associated with low-grade inflammation (68, 184) and atherosclerosis (7, 129). Additionally, the activation of cytokines
by AGE in human placenta may also be involved in insulin
resistance associated with GDM (63). We also reported increased release of 8-isoprostane, a marker of oxidative stress,
from human placenta in the presence of AGE (210). Thus,
elevated circulating AGE observed in this study may contribute to elevated oxidative stress concentrations observed in
GDM (71, 113). In isolated human first-trimester trophoblasts,
AGE stimulate secretion of chemokines such as macrophage
inflammatory protein (MIP)-1a and MIP-1b, induces apoptosis, and suppresses the secretion of human chorionic
gonadotropin, an effect that could be suppressed by inhibitors
of NOS or the NF-jB pathway (187), thus suggesting that RNS
as well as ROS contribute to AGE-mediated actions in the
human placenta. There is also much evidence to show that
AGE activates the expression of adhesion molecules such as
VACM-1, ICAM-1, and E-selectin (15).
B. Hexosamine pathway
Hyperglycemia elevates oxidative stress and increases the
activation of the hexosamine biosynthetic pathway (295). This
pathway of glucose metabolism uses fructose-6-phosphate derived from glycolysis to metabolize glucosamine-6-phosphate by
glucosamine-6-phosphate amidotransferase. Glucosamine-6phosphate is a competitive inhibitor of glucose-6-phosphate
dehydrogenase (G6PD), the rate-limiting enzyme of the pentose
phosphate pathway. The pentose phosphate pathway is an alternative pathway for glycolysis and produces the major portion
of NADPH in cells. The activation of G6PD converts glucose-6phosphate into 6-phosphogluconate, and, subsequently under
formation of NADPH, to cellular ribose-5-phosphate (30). The
NADPH generated is used to maintain the redox state
through the reduction of GSSG to its reduced form GSH.
G6PD is the rate-limiting enzyme of the pentose phosphate
pathway and its inhibition, for instance, by glucosamine-6
phosphate produced in the hexosamine pathway, leads to
decreased NAPDH concentrations, diminished cellular GSH
levels, and elevated oxidative stress (395). The activity of
G6PD also rapidly increases in response to intracellular ROS
production (148). Therefore, G6PD seems to constitute a
critical cytosolic antioxidant enzyme essential for the maintenance of the cytosolic redox status. In an animal studies, it
prevents embryopathies (2), demonstrating the protective
role of G6PD against oxidative stress. G6PD is present in
human placental trophoblasts (238); however, the effects of
GDM on the G6PD levels in placenta are not known.
GESTATIONAL DIABETES AND OXIDATIVE STRESS
3075
UDP-N-acetylglucosamine is generated as a product of the
hexosamine pathway, which is a substrate for glycosylation of
several transcription factors, leading to activation of gene
expression (303). In addition, nuclear and cytoplasmic proteins are modified by N-acetylglucosamine via phosphorylation. Thus, activation of the hexosamine pathway by
hyperglycemia may cause changes in gene expression as well
as in protein function (31). Again, there is a paucity of data
with respect to placenta and GDM.
C. Polyol pathway
The polyol pathway leads to the generation of ROS via a
number of mechanisms. Under normal conditions, the enzyme aldose reductase has a low affinity for glucose; however, hyperglycemia promotes the conversion of glucose to
polyalcohol sorbitol. Since sorbitol does not cross cell membranes, it subsequently accumulates within the cells and
causes cell and tissue damage (93). Sorbitol can be further
oxidized by sorbitol dehydrogenase to fructose with concomitant reduction of NAD + to NADH. Enhanced cytosolic
NADH to NAD + ratio inhibits the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) activity and, therefore, provides
increased substrate availability to complex I of the mitochondrial respiratory chain. Inhibition of GAPDH also elevates the concentration of AGEs (31, 100, 303). The polyol
pathway also results in decreased levels of NADPH, glutathione, and antioxidant equivalents, thus leading to an overproduction of intracellular ROS. The effect of GDM on
placental polyol levels in GDM pregnancies is not known.
D. NADPH oxidase
NADPH oxidase is a cytosolic enzyme complex accounting
for ROS generation by electron transport and especially
important in redox signaling. It first was discovered in
neutrophils, where it plays a crucial role in nonspecific hostpathogen defense. It is composed of membrane-bound subunits gp91 phox (Nox2)/Nox1/Nox4, p22 phox, the catalytic
site of the oxidase, and the cytoplasmic regulatory components p47 phox and p67 phox. Under diabetic conditions it can
be stimulated by AGE, insulin, and angiotensin II. Hypoxia
possibly induces all these stimuli, which can activate NADPH
oxidase (Fig. 5). Once activated in response to high glucose
NADPH oxidase catalyzes the transfer of electrons from
NADPH to molecular oxygen to produce O2 - and H2O2 (106,
125). High glucose levels lead to generation of ROS by stimulation of NADPH oxidase (379).
Under physiological conditions ROS is eliminated by cellular defense mechanisms, including diverse enzymes and
vitamins. However, imbalance of ROS production and antioxidant systems of a cell can lead to an upregulation of antioxidant gene expression through activation of nuclear
antioxidant response elements (ARE) by the redox-sensitive
transcription factor nrf2 (106). Hyperglycemia causes excessive ROS formation, thus activating the Nrf2/ARE pathway
(382). It appears that basal activity of NADPH oxidase provides ROS production to trigger Nrf2/ARE-mediated antioxidant gene expression to sustain redox homeostasis (236).
NADPH oxidase was shown to be higher expressed and activated in endothelial cells of pregnant women with GDM
(310). Expression of Nox1 was observed in the syncytiotrophoblast, in villous endothelium and in some stromal cell
FIG. 5. Cytosolic ROS formation and degradation.[indicates increased levels in the maternal or the fetal circulation
(glucose, AGE, and insulin) or increased expression or activity
in the placenta in GDM.
of the human placenta (73). This is paralleled by superoxide
production via NADPH. On this basis, NADPH oxidase
was suggested to represent the major enzymatic source of
superoxide in the placenta (286).
E. Protein kinase C
PKC represents a family of highly homologous kinases,
including several isoforms, which differ in their activation requirements and substrate specificities. Some isoenzymes (primarily b and d) are activated by 1,2-diacylglycerol, a glycolysis
intermediate compound, in the presence of phosphatidylserine.
Activated PKC isoforms are capable to induce a variety of
biological processes, that is, cell proliferation and differentiation, transmembrane ion transport, glucose and lipid metabolism, smooth muscle contraction, and gene expression (10, 31).
Recently, a study has shown an activation of the PKC b2 isoform by hyperglycemia in heart and superior mesenteric
artery as well as in cardiomyocytes of diabetic mice (260).
PKC promotes the activation of mitochondrial NADPH oxidase, thereby leading to increased oxidative stress events.
Once stimulated, NADPH oxidase reduces glutathione levels
and impairs the cellular antioxidant defense systems (183).
F. Xanthine oxidase
Xanthine oxidoreductase (XOR) belongs to a group of enzymes known as molybdenum iron-sulfur flavin hydroxylases.
It exists as two inter-convertible forms: XO and xanthine dehydrogenase (XDH). XOR is the rate-limiting enzyme in the
conversion of hypoxanthine to xanthine and of xanthine to
urate. XOR is present in vivo as XDH but it can be easily oxidized to XO. XDH does not lead to raised ROS production
because of its greater affinity for NAD + compared to oxygen
molecules. During XO re-oxidation the enzyme transfers its
six free electrons onto molecular oxygen causing the production of H2O2 and O2 - (Fig. 5). Observations in diabetic mice
showed increased activity of XO in tissue and serum. Treatment with the XO inhibitor allopurinol reduced the activity
of XO back to normal levels (297). Immunohistochemistry
3076
LAPPAS ET AL.
demonstrated XO expression in the human placenta (286).
Higher levels of active XO were also detected in umbilical cord
blood from fetuses of GDM pregnancies, suggesting fetal ROS
formation in this condition (20).
G. ROS production via mitochondria
In most mammalian cells mitochondria are the major
source of ROS. ROS are produced as a result of incorrectly
coupled electron transport in the mitochondrial respiratory
chain by oxidative phosphorylation. Once generated, ROS can
either mediate mitochondrial damage or it can play a crucial
role in redox signaling from the mitochondrion to the rest of
the cell. Superoxide cannot move across the mitochondrial
membrane. Therefore, it is converted to H2O2 by MnSOD.
Subsequently, the hydrogen radical is formed that diffuses
across the mitochondrial membrane. H2O2 itself can be further degraded to water by GPx. This represents the primary
elimination process of ROS in mitochondria (395).
Normal human pregnancy is considered a state of enhanced
oxidative stress. This is because there is increased metabolic
activity in the mitochondria of the placenta, which generates
ROS, superoxide generation from NADPH oxidase, as well as
altered antioxidant scavenging capacity. The role of the mitochondria in the generation of oxidative stress in normal pregnancy has previously been reviewed (259). In general, in vitro
hyperglycemia-induced ROS production is reduced in extraplacental tissues by an inhibitor of electron transport chain
complex II, by an uncoupler of oxidative phosphorylation, by
MnSOD, and by uncoupling protein-1 (UCP1), which is exclusively expressed in brown adipose tissue. These data suggest
that the TCA cycle is the major source of high glucose-induced
ROS production (263). Further, it was shown that elevated ROS
levels caused by hyperglycemia are involved in morphological
changes of mitochondria (388). However, the effect of hyperglycemia on mitochondrial ROS generation and its contribution
to increased oxidative stress in GDM is not known.
H. Concluding comments
There are a number of pathways that may contribute to
oxidative stress observed in the GDM placenta. In the placenta, ROS and RNS are an important source of growth and
signaling factors, and are susceptible to ROS-mediated apoptosis. In the following section, the effect of oxidative stress on
placental function is discussed.
VII. The Biological Role of Oxidative Stress on Placental
Function in GDM Pregnancies
FIG. 6. Schematic representation of the main targets of
oxidative and nitrative stress in GDM.
centration of adipokines and inflammatory cytokines is increased by the accumulation of functional macrophages in the
interstitial stroma of both the placenta and maternal adipose
tissue of women with GDM (17, 78, 185, 293). Although the
initial stimulus triggering inflammation in pregnancy with
GDM is not currently known, potential candidates include
dietary and environmental factors such as caloric overload or
changes in microbiota in the pregnant women (39, 214). Thus,
the combined condition of inflammation and metabolic dysfunction of women with GDM may be regarded as a state of
metabolic inflammation as proposed for other metabolic diseases associated with insulin resistance (145).
Data from our laboratories demonstrate that GDM placentas are less responsive to an oxidative challenge than
placental tissue from normal women (70, 204). In normal
placenta, oxidative stress induced a significant increase cytokine expression and release, an effect that was blunted in the
GDM placenta (204). In marked contrast, adipose tissue obtained from women with and without GDM both respond to
oxidative stress by increasing cytokine release. This may
represent adaptive mechanism to protect the fetus from any
further damage.
GDM is associated with elevated levels of activin A (281)
and lower follistatin-like-3 levels, an inhibitor of activin A
(344). The release of activin A, together with TNF-a, is considered to be one of the very first responses to inflammation
(165). Oxidative stress induced by HX/XO increases placental
and endothelial cell activin A secretion (234). Collectively, this
suggests that oxidative stress associated with GDM may be a
mechanism underlying the increased levels of activin A
present in women with GDM.
Key points:
Oxidative stress has a number of important roles, including regulation of pro-inflammatory cytokines, matrix
metalloproteinases (MMPs), adhesion molecules, apoptosis, and the redox-sensitive transcription factor NF-jB.
The biological functions of oxidative stress in pregnancy
are summarized in Figure 6 and discussed below.
A. Inflammatory cytokines
Low-grade chronic inflammation is a central feature of
GDM. Maternal systemic inflammation with increased con-
B. Metalloproteinases
Placental development requires proper trophoblast invasion and tissue remodeling, processes involving MMPs—
proteases that degrade various components of the extracellular matrix (ECM). Members of the MMP family include
collagenases, gelatinases, stromelysins, matrilysins, and
membrane-type MMPs (MT-MMPs). Oxidative stress is a
potent activator of MMPs. Both ROS and NO can disrupt the
cysteine switch that maintains the latency of proMMPs,
leading to the activation of several different MMPs, including
the gelatinases MMP-2 and MMP-9 (207, 231, 291, 292). H2O2
GESTATIONAL DIABETES AND OXIDATIVE STRESS
enhances MMP activity in the maternal side of the placenta
and in the fetuses from control and diabetic rats (291). On the
other hand, SOD reduces MMP activity in the maternal side of
the placenta and in the fetuses from control and diabetic rats
(291), and the antioxidant N-acetyl-cysteine (NAC) reduces
MMP-9 activity in human placenta (207). Of note, placental
MMPs are increased in the placenta from pre-gestational diabetic patients, in which both NO overproduction and peroxynitrite-induce damage has been found (188, 228, 288).
MT1-MMP expression in first-trimester placental tissue is
upregulated in type 1 diabetes and by TNF-a (138).
C. Apoptosis
Oxidative stress may trigger apoptotic cascades in the human placenta. For example, hypoxia-reoxygenation in vitro is
a potent stimulus of apoptosis in the syncytiotrophoblast and
that apoptosis can be modulated by the addition of antioxidants (59).
The available data demonstrate that GDM is associated
with apoptosis. Specifically, a higher incidence of TUNELpositive nuclei and lower expression of the anti-apoptotic
protein Bcl-2 was reported in placental villous trophoblasts in
GDM groups compared to the NGT pregnant women (316).
Further, in GDM pregnancies, the leukocyte activity of the
pro-apoptotic protein PARP is elevated as early as the middle
of pregnancy (144); a positive linear correlation was observed
between the severity of carbohydrate intolerance (the 2 h oral
glucose tolerance test value) and PARP activity of circulating
leukocytes. Additionally, hyperglycemia upregulates p53,
triggering the mitochondrial death cascade pathway in the
mouse placenta (251), and increases the rate of apoptosis in
cultured trophoblast cell lines (363). Although alterations in
RNS-induced S-nitrosylation have not been addressed in
GDM, they might be related to the pathogenesis of GDM.
Indeed, NO-induced S-nitrosylation affects key enzymes involved in the apoptosis cascade-like caspases and PARP (179,
320). Apoptosis effects of NO are highly dependent on the
context and the levels of NO.
D. Vascular molecules
E-selectin, VCAM-1, and ICAM-1 are cell adhesion molecules expressed only on endothelial cells and as such play a
role in the pathogenesis of vascular disease, which eventually
leads to the development of atherosclerosis. Circulating
E-selectin and VCAM-1 are increased in GDM (171). There is
some evidence to show that oxidative stress activates the expression of E-selectin (294). However, there is limited data
with respect to placenta and GDM.
Among the growth factors produced by trophoblasts, it is
believed that vascular endothelial growth factor (VEGF) and
its receptor family (including fms-like tyrosine kinase receptor
[Flt-1]) play an important role in regulating trophoblast survival and angiogenesis in the placenta. Peroxynitrite have been
shown to alter VEGF angiogenic signaling pathways (86).
Hypoxia-induced increases in VEGF production and soluble
Flt-1 (sFlt-1) expression have also been found in trophoblast cell
lines (173, 219). The increased sFlt-1 production was positively
correlated with increased lipid peroxide production (219). Increased sFlt-1 and VEGF release into maternal circulation
could contribute to vascular endothelial dysfunction.
3077
E. Nuclear factor-kappa B
NF-jB is an ubiquitous and inducible transcription factor
that is a central regulator of immune and inflammatory responses, cell adhesion, differentiation, redox metabolism, and
apoptosis. More comprehensive reviews on the role and regulation of NF-jB in human pregnancy can be read at (212,
300).
Oxidative stress stimulates NF-jB translocation into the
nucleus, thus inducing up-regulation of genes associated with
inflammatory response. Our previous studies have shown
that in human placenta, NF-jB is activated in response to
oxidative stress (70, 207) and this is associated with increased
expression of pro-inflammatory cytokines, prostaglandins,
and MMPs (70, 207, 213, 300). Likewise, antioxidants such as
NAC can attenuate oxidative stress NF-jB activation. This
positive regulatory loop may amplify and perpetuate local
inflammatory reactions. However, GDM is associated with
decreased placental NF-jB DNA-binding activity (70),
suggesting that a regulatory mechanism may exist in GDM
placenta.
Low concentrations of NO control NF-jB by activation of
IjB kinases, whereas high concentrations inhibit NF-jB by
increasing the stability of the NF-jB inhibitor IjB (169).
However, it is of note that iNOS can both up- and downregulate NF-jB independent of IjB as well.
F. Concluding comments
Growth factors, cytokines, MMPs, and apoptosis play important roles in placental structure and function. ROS leads to
chronic inflammation, dysregulation of MMPs, and apoptosis. The sequelae of elevated ROS on trophoblast health,
which may influence development of conceptus, are discussed below.
VIII. The Role of Oxidative and Nitrative Stress
in the Pathogenesis of GDM
Key Points:
Reactive oxygen and nitrogen species play a number
of important roles throughout pregnancy, including
embryo development, implantation, angiogenesis, placental development and function, and thus fetal development and subsequent adult diseases.
The involvement of oxidative and nitrative stress in
impairing developmental processes in diabetic pregnancies is discussed below.
The involvement of oxidative and nitrative stress in altering placental function and transport in diabetic
pregnancies is also discussed below.
A. Decidualization and implantation
Diabetes in pregnancy is associated with suboptimal decidualization (110). Implantation involves the interaction
between several vasoactive agents, including cytokines,
prostaglandins, and NO, which lead to increases in MMPs
(158, 268, 345). Indeed, NO plays a key role in decidualization
and embryo implantation (265). It increases vascular permeability, vasodilation, and blood flow in the uterus, and is a
component of the decidual cell reaction (345, 353). In rat decidua, when NO is inhibited, apoptosis is increased,
3078
suggesting that NO plays a role in survival of decidual cells
(338). In the rat uterus, NO increases during the peri-implantation days in rats, and diminishes after the implantation
period (158). Accordingly, eNOS and iNOS expression, and
NOS activity are enhanced during the peri-implantation days
of pregnancy (266, 315). Implantation, however, occurs at
normal rates in the diabetic rats; it is thought that implantation under these pro-inflammatory conditions may be involved in the increased resorption and malformation rate
evident in experimental diabetes and pregnancy models (158,
267).
The early steps of decidualization and implantation should
not be affected when GDM is induced in the second trimester
of pregnancy, but, as stated in other sections, if glucose intolerance and its related changes in NO and ROS production
are present in the first trimester of pregnancy, this may affect
these early processes, impairing the initial steps of embryonic
and placental development.
B. Trophoblast invasion
Normal placentation requires trophoblast invasion of maternal spiral arteries, and development of a high-flow, lowresistance uteroplacental circulation. Trophoblast invasion is
influenced by a number of factors such as cytokines and
growth factors, adhesion molecules, MMPs, and oxygen tension (224, 375). As detailed in Section VII, oxidative and nitrative stress can regulate these factors, which may then play
an important role in abnormal trophoblast invasion. Certainly, the ability of the trophoblast to invade the uterus is
related to NO production during implantation and during the
remodeling of uteroplacental arteries (170, 345). Trophoblastderived NO seems to serve to dilate the vessels and turn the
uterus receptive to trophoblast penetration. The role of eNOS
in the trophoblast is highlighted by the presence of this NOS
isotype in villous and labyrinthine cytotrophoblasts and the
syncytiotrophoblast, feto-placental endothelium, cell columns
of anchoring villi, and invasive cytotrophoblasts (353). On the
other hand, NO overproduction can also induce trophoblast
apoptosis, although this may rely on iNOS-derived NO (390).
Indeed, iNOS, the NOS isotype mostly related to NO overproduction, is also expressed in the placental microvascular
endothelium, syncytiotrophoblast, and cytotrophoblast cells,
and has been found to be involved in alterations in fetoplacental circulation in pathological situations (91).
Interestingly, nitrosylation of MMPs at the edge of migrating trophoblasts has been found associated with an increase in iNOS expression and related to the process of
trophoblast invasion (130). All this suggests that trophoblast
invasion and remodeling of uteroplacental arteries are processes highly related to the mature placental function that can
be highly affected by hyperglycemia-induced oxidative and
nitrative stress.
C. Organogenesis
As detailed in Section IV, diabetes during pregnancy is
associated with embryonic dysmorphogenesis. Due to its capacity to regulate cell survival, apoptosis, differentiation, and
ECM remodeling, oxidative and nitrative stress play a significant role in embryo organogenesis. Indeed, low and high
levels of NO can leads to embryonic maldevelopment, pos-
LAPPAS ET AL.
sibly due to an improper regulation of apoptotic events,
which should occur in appropriate space and temporal location to allow the formation of the organs (216, 285). Further, a
particular pattern of expression of NOS during organogenesis
supports its role as a morphogen (22, 349, 387).
During embryo and fetal development, NO has been found
to be relevant in regulating differentiation of cell types (e.g.,
cardiomyocytes and neuronal cells) and organ formation (e.g.,
lung branching morphogenesis, cephalic morphogenesis,
heart development, and nephrogenesis) (22, 97, 283, 340).
Fetal growth is also regulated by NO, and fetal growth is
restricted in the presence of NOS inhibitors (262).
The higher 8-isoprostane levels observed in the offspring of
diabetic animals (368) have its own teratogenic potency (366),
thus supporting a link between oxidative stress and increased
malformation rate in embryos exposed to a diabetes-like environment. Diabetic embryopathy is also associated with inhibition of GAPDH activity and GAPDH gene expression
resulting from an excess of ROS in the embryo (365), an effect
that can be restored by treatment with the antioxidant NAC.
Impaired induction of transcription factors, such as paired
box (PAX)-3 and peroxisome proliferator-activated receptor
(PPAR) d, has been found to be involved in the induction of
both neural tube and heart malformations, the most common
malformations induced by maternal diabetes in both humans
and experimental models of diabetes (139, 194, 220). The impaired induction of PAX-3, which leads to an increase in apoptosis of neural crest cells and an impairment of the process
of neural tube closure and neural crest cell migration, is
clearly related to increases in oxidative stress. Indeed, different antioxidants such as a-tocopherol and gluthatione ethyl
ester increase expression of PAX-3 and prevent apoptosis and
the induction of hyperglycemia-induced neural tube and
heart defects (54, 254).
In summary, there is clear evidence of the capacity of oxidative and nitrative stress to impair embryo organogenesis.
Thus, if glucose intolerance and its related changes in NO and
ROS production are present in the first trimester of pregnancy, organogenesis can be profoundly affected.
D. Endothelial and vascular dysfunction
Placental development is associated with significant increases in both angiogenesis and vasodilatation, giving rise to
a dramatic elevation of placental blood flow during pregnancy. This increased blood flow is directly correlated with
fetal growth and survival as well as neonatal birth weights
and survivability. ROS and RNS can modulate angiogenesis,
vasculogenesis, and vessel reactivity in the feto-placental
circulation. Studies performed in ewes have been helpful to
understand the role of NO in controlling vasodilation during
pregnancy. NO production is increased in ewes carrying
multiple fetuses compared to singletons, possibly due to the
increased demand of uterine blood flow to sustain multiparity
and to potentially aid in the remodeling of the vascular bed
(360). The reduction of NO production through the inhibition
of NOS leads to a reduction in uterine blood flow in pregnant
ewes (304). Similarly, NO production is increased in pregnant
rats, as evidenced by the increased plasma and urinary levels
of nitrates/nitrites, and the increased urinary levels of cGMP
(65). Interestingly, pregnant rat inhibition of NO leads to preeclampsia-like effects (383). Formation of peroxynitrites,
GESTATIONAL DIABETES AND OXIDATIVE STRESS
3079
(207, 231, 291, 292), oxidative stress may also induce a fibrotic
response and disrupt the structural integrity of placental
endothelial cells, and influence angiogenesis by degrading
matrix molecules, loosening the cellular network, and releasing growth factors sequestered in the ECM. Further, the
oxidative stress-mediated increases in adhesion molecules
may cause the endothelial cell dysfunction and atherosclerosis
observed in GDM (7, 129).
Collectively, the changes described show profound alterations in the placental and umbilical vasculature and dysfunction of endothelial cells derived from excessive oxidative
and nitrative stress. These changes, together with changes in
maternal metabolites and impairments in placental transport
function (described in Section F), will lead to complex alterations in the quality and quantity of nutrients and in the oxygen available to the fetus in GDM.
E. Placental nutrient transport mechanisms
FIG. 7. Schematic representation of the main targets and
consequences of reactive nitrogen species in GDM.
generated from NO and ROS, reduces NO bioavailability.
Indeed, in perfusion studies, feto-placental vasoreactivity has
been shown to be clearly altered by the addition of peroxynitrites (188). These alterations are relevant when addressing
the effects of RNS in GDM, as summarized in Figure 7 and
described below.
Several alterations in both maternal and fetal endothelial
dysfunction have been observed in GDM patients (43, 257,
308). Considerable evidence exists that oxidative stress plays
an important role in endothelial dysfunction. As maternal
hyperglycemia leads to fetal hyperglycemia and exposure to
hyperglycemia leads to AGE formation, oxidative stress will
be induced in the feto-placental endothelium. In support, 8isoprostane is capable of inducing vasoconstriction in the
placenta (217). Thus, placental secretion of 8-isoprostane into
the maternal circulation could contribute to vasoconstriction
observed in GDM. Nitrative stress is also likely to increase
nitration of proteins in GDM, leading to endothelial and
vascular dysfunction. NO produced by eNOS in the endothelial cells may interact and form peroxynitrite, which covalently modifies proteins and DNA. In a pregnancy
complicated by diabetes, eNOS expression is increased in
placental arteries, veins, and HUVECs (11, 95, 356). Moreover,
expression of transporters for L-arginine (the precursor of NO
synthesis) is increased in microvascular placental endothelial
cells and HUVEC from GDM pregnancies (328), further promoting NO synthesis. Excess generation of NO and ROS may
therefore stimulate peroxynitrite formation. Elevated levels of
placental nitrotyrosine residues have been shown in type I
diabetes, insulin-treated GDM patients, and experimental
models of diabetes (144, 228, 371). The resulting nitration of
proteins will alter protein function, resulting in vascular
damage and dysfunction.
Fibrosis is characterized by excessive ECM deposition in
various organs and the vasculature and often by a change in
the quality of the ECM, as well as angiogenesis. There is certainly evidence to show that diabetes is associated with fibrosis in a number of tissues (12), and that GDM is associated
with placental angiogenesis (163). Thus, by activating MMPs
Pregnancy requires specific adaptations of maternal nutrient metabolism (i.e., carbohydrate, lipid, and protein) to meet
the increase energy needs of the mother and growing fetus.
These adaptations are exacerbated in women with GDM
(306). As the primary target of maternal environment, the
placenta is naturally exposed to all modifications of maternal
homeostasis. The maternal metabolic changes have been long
documented to affect placental transport function and metabolism of energy nutrients in women with GDM (80, 151).
The potential impact of oxidative stress on glucose, lipid, and
amino acid metabolism in the placenta is discussed below.
1. Glucose transport.
a. Glucose metabolism in pregnancy. To sustain continuous
growth and development of the fetus, the maternal metabolism changes with and adapts to pregnancy. The first trimester of pregnancy is characterized by higher insulin
sensitivity, which augments the anabolic effects of insulin,
ultimately allowing the mother to build up energy and nutrient stores for the second and third trimester (48, 186). When
gestation advances, rapid growth of the fetal tissue increases
its nutrient demand and the anabolic glucose metabolism
shifts to a catabolic state. Glucose is the main energy source
for both the fetus and the placenta and, hence, has to be easily
available. Therefore, in sharp contrast to the first trimester, in
the second half of pregnancy maternal metabolism shifts into
an insulin resistant state resulting in decreased glucose uptake
by insulin target tissues of the mother. This facilitates transplacental glucose transport to the fetus and enables adequate
glucose supply of 30–50 g glucose per day (133).
In normal pregnancy, the increase in insulin resistance is
compensated by a concomitant increase in insulin production,
which is the result of hypertrophy and hyperplasia of b-cells
(355). In patients with GDM, insulin resistance is either
comparable or greater than that in nondiabetic pregnancy,
whereas insulin secretion appears to be compromised. Failure
to adequately compensate insulin resistance (32) ultimately
leads to maternal hyperglycemia. Although b-cell dysfunction
seems to be the principal cause of GDM, higher levels of leptin
(172), and higher villous secretion of TNF-a in response to
glucose (68) have been reported. Both are inhibitors of insulin
signaling at the receptor level and may be responsible for the
maternal peripheral insulin resistance.
3080
Along its transport-route through the placental barrier into
the fetal blood, glucose has to pass the syncytiotrophoblast
layer, which covers the placental villi. In segments of the
syncytiotrophoblast characterized by exchange activity, fetal
capillaries are located underneath the syncytiotrophoblast.
Glucose transport through plasma membranes is accomplished by a family of glucose transport proteins designated
as glucose transporters (GLUTs), which facilitate glucose
uptake. They enable glucose transport along a concentration
gradient by facilitated, carrier-mediated sodium-independent
diffusion (9). Different GLUT isoforms are expressed in a
tissue-specific manner and vary in their regulation and substrate specificity. GLUT-1 is the ubiquitous transporter involved in the trans-placental movement of glucose and is
expressed in the apical and basal membrane of the syncytiotrophoblast as well as in all other cell types of the villi. Various
other GLUTs, such as GLUT-3 (132), GLUT-4 (381), GLUT-8
(120), and GLUT-12 (123), have also been identified within the
placenta. However, the localization of GLUT-3, -4, and -12 in
cells of the placental endothelium or the villous stroma makes
their involvement in trans-placental glucose transport unlikely (87). Once having traversed, the syncytiotrophoblast
glucose will pass through the paracellular clefts between
the endothelial cells that line the feto-placental vessels. Hence,
the two membranes of the syncytiotrophoblast represent the
placental barrier for glucose (Fig. 8). GLUTs expressed on the
endothelial cells will serve to cover the energy requirements of
the endothelial cells. Presence of high-affinity GLUT-3 on the
endothelial cells ensures energy supply even in situations of
low glucose levels.
FIG. 8. Placental glucose transport. The placental barrier is
formed by the syncytiotrophoblast (ST) cells that face the
maternal side and the placental endothelial cells (ECs) that
line the fetal vascular system. GLUT-1 glucoses transporters
(closed circles) are expressed on the microvillous membrane
(MVM) and the basal membrane (BM) of the ST and on the
ECs. GLUT-3 (open circles) is expressed mainly in the ECs,
suggesting a role in constant delivery of glucose to the fetus,
even in situations of low nutrient availability. Maternal-tofetal glucose transport requires glucose passage through the
syncytiotrophoblast and between the paracellular clefts in
the placental endothelium (black arrow). Increased ROS seen
in GDM pregnancies may play an important role in regulating the expression of GLUTs localized at the maternal and
fetal interface of the placenta. Any alterations in glucose
availability may results in deregulation of fetal growth and
development. GLUT, glucose transporter.
LAPPAS ET AL.
The placenta is a metabolically highly active organ and uses
a considerable part of the glucose derived from the mother for
itself. Only 40%–50% of the glucose taken up is released to the
fetus, whereas the rest is metabolized by the placenta. Oxidative glucose metabolism is low and about 80% of the glucose used by the placenta is converted to lactate, which is
released to the maternal and fetal circulation, or stored as
glycogen mostly in placental endothelial cells and pericytes
(79, 81, 164). The placental processing of glucose and its
downstream metabolites uses involves and affects a variety of
metabolic pathways. Therefore, an increase in glucose availability may induce multiple cellular changes. Maternal and
fetal hyperglycemia may result in the activation of glycolysis,
one of the key metabolic pathways of glucose metabolism and
will lead to production of adverse side products or to an accumulation of metabolic intermediates in the placenta. The
glucose gradient as a key determinant of flux has an important clinical consequence. Adequate glycemic control of the
mother alone does not avoid hyperglycemia of the fetus. Fetal
hyperinsulinemia stimulates fetal glucose metabolism,
steepens the gradient, and results in glucose stealing from the
mother (264).
The effect of oxidative stress on placental glucose metabolism is not known. However, in nongestational tissues, there is
certainly plenty of evidence demonstrating oxidative stress
regulates GLUT-1 and/or GLUT-3 dependent glucose uptake
and transport. Thus, we suggest that oxidative stress may also
positively or negatively regulate glucose metabolism in human placenta, and this would have implications for the
amount of glucose that is being delivered to the fetus (Fig. 9).
On the other hand, we suggest that the GDM placenta will be
less sensitive to oxidative stress due to the heightened level
of antioxidants. In keeping with this, preliminary data from
the Lappas group supports this hypothesis. Specifically, we
have shown that the NGT placenta decreases glucose uptake
in response to HX/XO, an effect that can be restored by the
co-incubation with antioxidants. On the other hand, in
the GDM placenta, there is no effect of HX/XO on glucose
uptake (Fig. 9). Although it is not known what effect HX/
XO has glucose transport to the fetus, our preliminary data
show that HX/XO increases glucose transport in placental
BeWo cells (Lappas, personal communications). Overexpression of thioredoxin-1 reduces oxidative stress in the
placenta of mice and promotes fetal growth by increasing
placental glucose availability through up-regulation of
GLUT-1 expression (351). Collectively, these data suggest
that the placental antioxidant systems play a role in influencing fetal growth.
b. Insulin signaling in GDM. Several studies investigated
GDM-associated changes in insulin signaling components in
maternal muscle and adipose tissue samples, classical target
tissues of insulin-stimulated glucose uptake (Table 3). Basically, the changes observed were similar between adipose
tissue and skeletal muscle. In tissues, decreased expression of
insulin receptor substrate (IRS)-1 and GLUT-4 as well as increased phosphatidylinositol 3-kinase (PI3K) p85 expression
was shown. Binding of only the p85 subunit of PI3K to IRS-1
prevents binding of the PI3K signaling complex composed of
p85/p110 heterodimers. Hence, upregulation of p85 PI3K will
decrease the PI3K-mediated IRS-1 signaling. A study investigating long-term changes in skeletal muscle insulin
GESTATIONAL DIABETES AND OXIDATIVE STRESS
3081
FIG. 9. Effect of oxidative
stress on placental glucose
uptake. In the NGT placenta,
HX/XO decreases antioxidants while increasing ROS
production (204). Further, our
preliminary data demonstrate
that in the NGT placenta, HX/
XO decreases placental glucose uptake (Lappas, unpublished), suggesting less glucose
available for the fetus. On
the other hand, there is no
effect of HX/XO on ROS and
antioxidants (204) and glucose uptake (Lappas, unpublished) in the GDM placenta,
an effect attributable to the
increased antioxidant expression. This suggests that glucose uptake and transfer to
the fetus is unaltered in GDM
placenta in the presence of
HX/XO. In keeping with an
important role for antioxidants in the regulation of
placental glucose metabolism, SOD and catalase can
restore the decrease in placental glucose uptake elicited by HX/XO in the NGT placenta (Lappas, unpublished). = no
change;Ydecreased;[increased. SOD, superoxide dismutase; HX/XO, hypoxanthine plus xanthine oxidase.
signaling after a GDM pregnancy (102) found elevated TNF-a
expression, reduced insulin receptor auto-phosphorylation,
and serine phosphorylation of IRS-1 one year postpartum.
This indicates that insulin resistance once commenced in
pregnancy is a long lasting condition.
Maternal GDM, but not obesity, is associated with reduced
levels of IRS-1 and GLUT-4 also in the placenta. In contrast to
maternal adipose tissue and muscle, protein expression of
placental p85 PI3K was decreased (63). Oxidative stress has
also been shown to reduce IRS-1 and GLUT-4 expression by
protein degradation (IRS-1) and reduction of gene expression (GLUT-4). This suggests that the GDM-associated
changes in maternal tissue and placenta are a result of oxidative stress.
Recent data showing the physiological and pathological
function of oxidative stress in insulin signaling and glucose
metabolism indicate an even tighter interplay of hyperglycemia and insulin resistance than thought for long (Fig. 10).
Under normal conditions, physiological levels of ROS promote and stimulate adequate insulin signaling. This is also
reflected by the finding that addition of antioxidants inhibits
insulin signaling (313). Most likely, this is because the insulin
signaling pathway leads to low levels of ROS production itself
and ROS act as second messengers of which disposal impairs
insulin signaling. Insulin-induced ROS production is accounted for by activation of the NADPH oxidase NOX4
through PI3K. The ROS pathway subsequently activates kinases or induces gene expression by redox-sensitive transcription factors.
Chronic hyperinsulinemia as present in obesity and prediabetes may cause increased ROS generation and result in
impaired insulin signaling, insulin resistance, and oxidative
stress (112). Additionally, in the hyperglycemic environment
of diabetes, excessive, pathological ROS levels overwhelm the
ROS levels generated by and required for insulin signaling.
This leads to attenuated insulin signaling. The stress responsive c-Jun N-terminal kinase ( JNK) as well as the inhibitor
kappa b kinase complex (IKKb) become activated by ROS and
phosphorylate IRS-1 at serine and threonine residues, thus
inhibiting its function and insulin receptor signal transduction
(3, 108). Inhibition of IRS-1 leads to reduced GLUT-4 translocation and glycogen synthesis in response to insulin. This is
further reinforced by decreased GLUT-4 transcription in response to ROS (280). Impaired GLUT-4 translocation lowers
insulin-stimulated glucose uptake by muscle and adipose
tissue, and glucose storage as glycogen, hence increasing extracellular glucose levels. Virtually, all cells express insulinindependent GLUTs for their own energy supply. This basal
glucose uptake is accomplished mainly by GLUT-1 and -3.
Thus, resulting from facilitated diffusion of glucose through
these transporters, extracellular hyperglycemia increases also
intracellular glucose. High glucose, however, contributes to
ROS formation, which in turn will impair insulin signaling
(Fig. 10). The levels of TNF-a are higher GDM, which may also
contribute to the accelerated ROS production by increasing
NOX4 expression (235) and activation (18). Hence, not only
hyperglycemia, but also the inflammatory conditions of diabetes, can induce insulin resistance, thereby creating a vicious
circle, that is, promoting hyperglycemia and failure of glucose
lowering insulin action.
As detailed above, GDM is associated with increased placental oxidative stress. GDM is also associated with higher
levels of glycogen deposited around the feto-placental vessels
(164), demonstrating higher levels of intracellular glucose in
GDM. The effects of oxidative stress on placental glucose
metabolism itself, however, remain elusive. In recent studies,
LAPPAS ET AL.
= no change.
Ydecreased in GDM.
[increased in GDM.
GLUT, glucose transporter; PI3K, phosphatidylinositol 3-kinase; IRS, insulin receptor substrate.
[ mRNA and Y mRNA and
protein (63)
protein (63)
Y Protein (63)
[ Protein (62)
= mRNA and Y Protein
protein (13)
(101, 319)
Y mRNA and
protein (13, 62)
Y Protein (13, 62)
Y Protein (13)
we have demonstrated that pro-inflammatory cytokines,
which we have previously shown to exhibit pro-inflammatory and pro-oxidative effects in placenta and adipose tissue
and are increased in GDM pregnancies (208), increase GLUT-4
mediated insulin signaling and thus glucose uptake in placenta, whereas in adipose tissue they cause insulin resistance
(Lappas M, personal communications). Adipose tissue insulin
resistance makes glucose available for uptake by the placenta
and thus potentially more glucose available for transport to
the fetal circulation, resulting in larger babies.
Placenta
Skeletal muscle
Adipose tissue
Y mRNA and membrane
protein (62, 271)
Y mRNA and membrane
Y (101)
protein (62) = mRNA (111)
[ Protein (63) Y mRNA and membrane
protein (63)
[ Protein (13, 62)
Tissue
Insulin-induced
glucose uptake
GLUT-4
Total p110
PI3K
Total p85 PI3K
Total IRS-2
Total IRS-1
Phosphorylated
IRb
Total IRb
Table 3. Changes in Expression or Protein Phosphorylation of Insulin Signaling Components in the Mother and the Placenta
Resulting from Gestational Diabetes Mellitus Compared to Normal Pregnancy
mother
3082
2. Fatty acid transport. The highest growth rate in a human life span occurs during the fetal period. Deposition of fat
stores in the fetus is high, where body fat growth occurs essentially during the last trimester of intra-uterine life. During
this rapid growth, the fetus requires significant amounts of
fatty acids. The fetus has an absolute requirement for the n-3/
n-6 fatty acids, and docosahexaenoic acid (22:6 n-3; DHA), in
particular, is essential for proper development (127, 135).
Fatty acids are needed as structural components of membrane
phospholipids, precursors of important bioactive compounds
(such as the prostacyclins, prostaglandins, thromboxanes,
and leukotrienes), a source of energy, precursors to signaling
molecules, and are critical for organogenesis.
Pregnancy is characterized by changes in maternal adiposity and thus changes in lipid metabolism. There is an
accumulation of maternal fat stores in early and mid pregnancy (anabolic phase), and enhanced fat mobilization in late
pregnancy (catabolic phase). In late pregnancy, the overall
proportion of maternal fat oxidized is reduced, and plasma
maternal circulating concentrations of triacylglycerols (TAGs),
phospholipids, nonesterified fatty acid, and glycerol are increased. This implies that the mobilization is to increase the
availability of fatty acids for the fetus. The cellular mechanisms that trigger the transition from lipid storage to increased lipolysis during pregnancy are unknown; however,
current dogma suggests an important role for insulin (84) and
placentally derived hormones (218). In early pregnancy, increased estrogen and progesterone, and increased insulin
sensitivity favor lipid deposition and inhibit lipolysis. On the
other hand, late pregnancy hyperinsulinemia and insulin resistance promote the mobilization of fat stores, which is responsible for the hypertriglyceridemia of pregnancy (323). In
obese pregnant women and women with GDM, peripheral
insulin resistance is even more pronounced (62), and changes
in hepatic and adipose metabolism alter circulating concentrations of TAGs, fatty acids, cholesterol, and phospholipids
(243). GDM is accompanied by a threefold increase in plasma
TAG concentrations during the third trimester of pregnancy,
elevation of plasma postprandial fatty acids, delayed postprandial clearance of fatty acids, and elevation of the branched-chain amino acids (136, 147).
The effect of GDM on placental lipid metabolism is poorly
understood. The insulin resistance of GDM and obese mothers
may be a potential factor to enhance substrate availability to the
fetus, which may either result in immediate (i.e., large baby) or
long-term consequences (i.e., obesity and/or diabetes in later in
life). The availability of fetal energy substrates is regulated in
the first place by their maternal circulating concentrations and
to the extent that they are transported across the placenta (Fig.
11). Whether an excess of placental lipids are mobilized from
maternal adipose tissue and exported into the fetal circulation
GESTATIONAL DIABETES AND OXIDATIVE STRESS
3083
FIG. 10. Oxidative stress as
a promoter and inhibitor of
insulin signaling in GDM.
GDM is associated with elevated fetal and maternal insulin levels. By NOX4
activation, insulin signaling
induces
ROS
generation
(233), which acts as a second
messenger. ROS activate JNK
and IKKb that further phosphorylate IRS at serine and
threonine residues, thus inactivating it. Inhibition of
IRS-1 leads to reduced
GLUT-4 translocation as well
as reduced glycogen synthesis in muscle and liver.
Moreover, ROS down-regulates GLUT-4 transcription,
further impairing insulindependent glucose uptake.
Consequently, extracellular
hyperglycemia remains high.
Glucose can enter virtually all
cells through insulin-independent GLUTs such as
GLUT-1 and GLUT-3. This
raises intracellular glucose
concentration and enhances
ROS generation, which, again, impairs insulin signaling. Also, TNF-a, a cytokine with elevated levels in GDM, desensitises
insulin signaling and activates ROS production by increasing NOX4 transcription and activation. IRS, insulin receptor
substrate; TNF, tumor necrosis factor.
is critical information. Further, in placenta, there are three coordinated pathways that control the amount of fatty acids that
are available for the fetus in response to GDM: (i) rate of fatty
acid uptake from maternal circulation; (ii) esterification/
storage capacity; (iii) mobilizing activity for export. In wellcontrolled GDM pregnancies, maternal lipids are strong predictors for fetal lipids and fetal growth. Infants with abnormal
growth seem to be exposed to a distinct intrauterine environment compared than those with appropriate growth (312).
The effect of oxidative stress on placental lipid metabolism
is not known. However, recent data highlight important roles
for pro-inflammatory cytokines in the regulation of lipid
metabolism in placenta, which may be expected to facilitate
the transfer of lipids through the placental barrier to the fetus.
Leptin induces a reduction in triglyceride levels through
mechanisms that do not involve a reduction in de novo lipid
synthesis (372), and in cultured primary human trophoblast
cells, IL-6 stimulates fatty acid accumulation (197). We hypothesize that oxidative stress-induced pro-inflammatory
cytokines may regulate placental lipid metabolism (Fig. 12).
3. Amino acid transport. Alterations in placental amino
acid transport may contribute to accelerated fetal growth in
pregnancies complicated by diabetes (152). This results in
increased uptake of neutral amino acids across the microvillous membrane, which may be used in placental metabolism,
or be delivered to the fetus to contribute to accelerated fetal
growth in these patients.
Together with the increased NO production, L-arginine,
substrate from NO synthesis, is increased in plasma from
GDM patients, and L-arginine transport is increased in umbilical vein endothelial cells from GDM patients (37, 329, 330).
In addition, in umbilical vein endothelial cell cultures from
GDM patients the concentration of adenosine, a purine nucleoside that regulates vascular tone in the placenta, is increased (299, 356). Further to this, a very recent study has also
shown that umbilical vein blood adenosine concentrations are
higher in GDM (370). As profoundly addressed and reviewed
elsewhere (91, 308, 369), a complex interaction between
adenosine, its receptors from the equilibrative nucleoside
transporters family, and the NO substrate L-arginine, is involved in the regulation of NO synthesis in the umbilical
circulation and the placental endothelial microvasculature.
Adenosine-induced NO/endothelium-dependent umbilical
vein relaxation was lower in GDM (370). Changes in this
delicate system, together with those related to NO reactivity
with ROS, lead to an impaired NO synthesis and bioavailability in GDM (259, 308). Adenosine acts as an antioxidant
(232); thus, the increase in adenosine in umbilical veins of
GDN patients suggests an important protective role.
GDM is a state of insulin resistance by the fetus. Recent
studies have shown that there are defects in its biological actions in the placenta from GDM and normal pregnancies. For
example, in HUVECs, insulin restores the decrease in adenosine transport induced by GDM, an effect that could be
blocked by the NOS inhibitor L-NAME (370). Similarly,
insulin induces HUVEC relaxation by increasing HUVEC
L-arginine transport (119). Collectively, this suggests that
insulin acts to protect against endothelial dysfunction, a characteristic of GDM.
3084
LAPPAS ET AL.
FIG. 11. Schematic diagram showing molecules
that are related to placental
lipid transport. The arrows
refer to genes that are upregulated or down-regulated
in GDM placentas. Fatty acid
binding proteins (FABPs) are
located on both the MVM
and BMs of the syncytiotrophoblast cells bind fatty
acids for import from the
maternal circulation and export from the placenta to the
fetal circulation. The fatty
acyl-CoA ligases (FACLs)
process the first step of fatty
acid elongation toward esterification of NEFA into
TAGs. The lipases endothelial
lipase (LIPG) and lipoprotein
lipase (LPL) break down
TAG and complex lipids before uptake by trophoblast
cells or export to the fetal
circulation. NEFA, nonesterified fatty acid; TAG, triacylglycerol.
It is well known that after pregnancy, GDM predisposes to
type 2 diabetes. As endothelial dysfunction has been considered a putative causal role in insulin resistance (284), endothelial dysfunction has been studied in women with previous
GDM. Studies have revealed endothelial dysfunction in
forearm conduit arteries and skin microvasculature of women
with previous GDM (7, 129). Besides, formation of asymmetrical dimethyl-L-arginine, a product of the methylation of
L-arginine that competitively inhibits cellular L-arginine uptake and NOS activity in endothelial cells (61), is also increased in sera from patients with previous GDM (249).
In addition to L-arginine, there are a number of other amino
acid transport systems that are altered in GDM (154). Neutral
amino acid transport capacity by System A is increased in
both GDM and type I DM with large for gestational age babies
(152). In addition to this, leucine is also increased in GDM
placentas (152). It is therefore interesting that ROS reduces
amino acid activity (176), perhaps representing an adaptive
response where substrate availability may be increased. Collectively, the above data suggest that amino acid transport is a
key regulator of fetal growth.
4. Placental ion transport mechanisms. Oxidative stress
in human pregnancy may be linked to dysregulation of ion
transport mechanisms, which allow the transport of ions into
the placenta. It is well established that ROS has deleterious
actions on a number of ion transport mechanisms, including
ion channels (including Ca2 + , K + , and Na + and Cl - channels),
transport enzymes, ion exchangers, and other transporters
(189). However, ROS and a peroxidised lipid environment inhibit the activity of the transient receptor potential (TRP)-type
Ca2 + -permeable nonselective cation channel polycystin-2
(PC2) in term human syncytiotrophoblast (253). It is hypothesized that the inhibitory function of ROS on PC2 activity may
play an important regulatory role by preventing a Ca2 + over-
load in stressed cells in the placenta. In support of this hypothesis, hypoxic placental villous fragments have increased
TBARS and reduced plasma membrane Ca2 + -ATPase activity,
as compared to normoxic villous fragments (28). Collectively,
the above data are consistent with neonates of women with
GDM being associated with hypocalcinemia.
F. Cervical ripening and labor
At term, animal and human studies have shown that NO has
the ability to induce cervical ripening, which occur as a result of
the close relationship between prostaglandins and NO production (352). Indeed, cervical release of NO is increased during labor, and NO induces relaxation of cervical smooth muscle
and stimulates prostaglandin production (118). NO overproduction has been found related to the mechanisms of induction
of septic abortion (4). Likewise, ROS has also been implicated in
the mechanisms of human labor. Oxidative stress is increased
in placental tissues after labor (60), which may be related to its
ability to induce NF-jB activation (207). Thus, it is tempting to
speculate that the increase in oxidative stress observed in women with diabetes may explain why they have higher rates of
spontaneous preterm labor (242). In keeping with this, as detailed in Section III, iron concentrations are higher in women
with GDM (1, 24, 200–202, 331), and iron-dependent oxidative
stress has been linked to the pathophysiology of preterm labor.
G. Intrauterine programming
The in utero environment in which a fetus grows and develops may have long-term effects on subsequent health and
survival. Intrauterine programming of metabolic, cardiovascular, and renal disease has been addressed in experimental
models of diabetes and pregnancy (98, 162). Cardiac, vascular,
and renal dysfunction in adult offspring from diabetic pregnant rats reflects impairments in NO synthesis and decreased
GESTATIONAL DIABETES AND OXIDATIVE STRESS
3085
FIG. 12. Proposed effect of
oxidative stress on placental
fatty acid metabolism. Oxidative stress state of GDM women induces j inflammation.
These cytokines may act in an
endocrine manner to increase
placental k fatty acid uptake at
the MVM, l extracellular lipolysis of triglycerides, and/or
m fatty acid storage. These
may all result in n greater fatty
acid transfer to the fetal circulation. Additionally, these cytokines may o increase fatty
acid oxidation which may play
an important role as a fuel
source for steps k–n. Adipokines may also p activate placental NF-jB activity, which
may directly or indirectly further increase steps k–o. Enhanced lipid availability to the
fetus may result in immediate
(large baby) or long-term
(obesity/diabetes in later life)
consequences. NF-jB, nuclear
factor-kappa B.
endothelium-dependent vasodilatation, although preserved
vascular response to exogenous NO (143, 302). Maternal
diabetes-induced hypertension in rat offspring is prevented
by supplementation with L-arginine, a treatment that also
improves glomerular hypertrophy (50).
GDM also has long-term implications for the mother. Interestingly, in a recent study performed in a mouse model of
GDM, impaired endothelial vascular reactivity has been
found in the mothers after GDM, an alteration related to increases in superoxide production and peroxynitrite formation
in the vessels (333). These data suggest that GDM affects endothelial function and may contribute to an increased risk of
cardiovascular disease later in life.
H. Concluding comments
Oxidative stress disturbs placental function, leading to
perpetrations in fetal growth and development. Thus, of vital
important is the management of oxidative stress in women
with GDM. In the following section, we will discuss the
therapeutic approaches that may be of benefit in these pregnancies.
IX. Effects of Therapeutic Approaches on GDM
Key points:
Evidence suggests that by decreasing oxidative stress,
we may be able to reduce or even ameliorate oxidative
stress-induced impacts on the fetus of GDM women.
In diabetic animal models, antioxidant treatment has
been shown to be effective in reducing the deleterious
effects of GDM on the offspring.
There are only a couple of clinical studies evaluating the
potential benefits antioxidants in GDM women. These
studies have not evaluated the effects on the fetus.
Alternative approaches (including flavonoids or PPAR
agonists) may be of potential benefit, as their efficacy in
the treatment of a variety of diseases has been demonstrated in numerous clinical studies.
A. Can antioxidant treatment reduce oxidative
stress in GDM?
There is a higher incidence of congenital malformations in
the offspring of diabetic women, and there is some evidence to
suggest that higher lipid peroxidation levels and lower antioxidants may be a causative factor (88, 324).
Together with the characterization of several impairments
in antioxidants in intrauterine tissues from diabetic animals
throughout pregnancy, animal models of diabetes and pregnancy have been highly relevant in the understanding of the
relevance of antioxidants that counteract these insults in the
prevention of maternal diabetes-induced embryopathy. Both
vitamin E and C have been shown to reduce diabetic embryopathy (324, 325, 358). These vitamins reduce lipoperoxidation and change the activity of SOD and catalase in
different fetal organs (275). Lipoic acid reduces resorption and
malformation rates and prevents damage in the placental
vasculature in animals rendered diabetic through streptozotocin administration during pregnancy (5, 378). Likewise,
pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in
offspring (90). Administration of vitamins E and C reduces
fetal dysmorphogenesis and TBARS concentrations in fetal
livers from diabetic rats, although the doses needed to normalize development in offspring of diabetic animals are above
physiological levels, probably due to the difficulties to reach
the embryonic tissues to exert their protective functions (52).
Indeed, transgenic mice that overexpress SOD are protected
from chemical diabetes-induced embryo malformations (126).
3086
Folate treatments are capable of reducing malformation rate
in chemical models of diabetes and pregnancy, and are also
able to increase the expression of antioxidant enzymes in the
embryonic yolk sacs, and to reduce the concentrations of apoptotic proteins in the embryos from diabetic animals (109,
391). Antioxidant treatments also reduce lipoperoxidation
and correct the altered ratio between vasodilator and vasoconstrictor prostanoids in the diabetic placenta (374).
Thus, supplementation with some antioxidants could be
beneficial in the treatment of diabetes. Certainly, in type 1
diabetes, vitamins E and C have been shown to improve oxidative stress in children and improves fetal outcome in experimental diabetic pregnancy (88, 149). However, in GDM,
blood glucose levels rise following prenatal vitamins (332),
which has been linked to the development of the components
of metabolic syndrome in adulthood for the male offspring
(339). The DAPIT study has shown no benefits of vitamins E
and C supplementation in preventing preeclampsia in type I
diabetic pregnant women, although the work suggests that a
subgroup of diabetic women with lower antioxidant plasma
concentrations could be a group that may be benefited with
these treatments (240). A very recently published study has
found that women who had taken probiotics in pregnancy
had a reduced frequency of GDM (226). Clearly, more studies
are required to fully understand the short- and long-term
health benefit of these dietary supplements.
Therefore, despite the potential benefit of treatments capable of reducing oxidative stress in GDM (77, 159, 258), there
are a few clinical studies evaluating its potential beneficial
effects in GDM. Thus, whether or not increased antioxidant
intake can reduce the complications of GDM in both mother
and fetus needs to be explored. However, studies examining
the efficacy of antioxidants in the treatment of diabetic complications such as micro- and macro-angiopathy have been
disappointing (334). After intensive investigations for decades, the current consensus is that the evidence obtained
so far is not strong enough to recommend supplementation with antioxidants in the prevention or amelioration of
diabetic complications, and tight glucose control remains the
best, most efficacious measure to prevent diabetes induced
damage.
Collectively, the above data show clear beneficial effects of
antioxidants on diabetes and pregnancy animal models, indicating the relevance of oxidative stress in diabetes-induced
pregnancy complications. There are difficulties in studying
these issues in human diabetic pregnancies, and no safe and
efficacious dose of antioxidants has been found so far to be
helpful in GDM. Future understanding of human maternalto-fetal transport of antioxidants may help addressing this
important issue.
B. Flavonoids as potential antioxidant supplements
to reduce oxidative stress in GDM
There is some evidence to suggest that dietary phytochemicals, including flavonoids, may be of potential benefit in
the management of GDM. Epidemiological studies have
suggested beneficial health effects of the chronic consumption
of flavonoid-rich foods (8, 247). These health effects have been
mostly attributed to their antioxidant properties (343).
Resveratrol is a polyphenol phytochemical that has been
identified in almost 70 species of plants, including red grapes,
LAPPAS ET AL.
peanuts, vegetables, berries, beverages, and herbal medicines
(36, 85, 309). It is known to have a wide range of biological
activities, including antioxidant, antiviral, anti-inflammatory,
cardioprotective, and chemopreventive properties (318). Resveratrol modulates the expression of a series of intracellular
signaling proteins, cellular proliferation, inflammation, and
apoptosis in different cell lines (318).
Resveratrol contains two aromatic groups that enable it to
function as an antioxidant by forming stable radicals via resonance structures, thereby preventing continued oxidation
(326). In vitro studies show that resveratrol protects LDLs
against peroxynitrite-mediated oxidation (94). Resveratrol
has been shown to protect against oxidative stress-induced
endothelial dysfunction in type 2 diabetes (396). It inhibits
vascular NADH/NADPH oxidase, thus decreasing both basal cellular superoxide generation and NO removal. It also
increases eNOS and iNOS, which are likely to play a role in
resveratrol-mediated cardioprotection (reviewed in Refs. 29,
318). Although there are no data on the beneficial effect of
flavonoids in GDM, studies from our own laboratory have
demonstrated that resveratrol has potent anti-inflammatory
(203) and antioxidant (Lappas, personal communications)
properties in human placenta. Further, in these studies, we
showed that resveratrol was able to alleviate inflammation via
activation of sirtuin (SIRT)-1.
C. PPARs as targets to reduce oxidative
and nitrative stress in GDM
PPARs (isoforms a, d, and c) are ligand-activated transcription factors that heterodimerise with retinoid X receptor
(RXR). It has been shown that agonists of PPAR possess antidiabetogenic, anti-inflammatory, and antioxidant effects
(244). Indeed, adipose tissue from obese GDM women has
shown reduced PPARc expression compared to uncomplicated pregnant obese patients (47). Likewise, our previous
studies have shown lower placental PPARc, PPARa, and
RXRa expression in women with GDM (142, 156). In keeping
with this, there is increasing evidence for a role of the PPAR
system in regulating the metabolic and pathways involved in
the pathophysiology of GDM (376). PPAR ligands, including
the natural ligand 15d-PGJ2 and the synthetic anti-diabetic
drug troglitazone, are potent anti-inflammatory and/or antioxidative agents that repress the expression of a number of
inflammatory genes, oxidative stress, and regulating factors,
including the transcription factor NF-jB in human placenta
(205, 209). The prostaglandin 15d-PGJ2 is an endogenous agonist of the nuclear receptor PPARc with relevant anti-inflammatory properties, capable of reducing NO production in
the placenta from healthy patients (156). Placentas from GDM
patients show reduced 15d-PGJ2, diminished PPARc concentrations, and impaired capacity to downregulate NO
production in the presence of 15d-PGJ2, possibly contributing
to the observed increases in placental NO production (156).
PPARc agonists have also been shown to be a negative regulator of NO production in the diabetic rat placenta, also capable of regulating the diabetes-induced dysbalance in MMPs
and their endogenous inhibitors named tissue inhibitors of
metalloproteinases (40, 289).
Sulfonylurea agents, including glimepiride and glibenclamide, exhibit PPARc activity (103). A randomized, controlled trial showed that both the insulin- and glyburide-
GESTATIONAL DIABETES AND OXIDATIVE STRESS
treated women were able to achieve satisfactory glucose
control and had similar perinatal outcome (199). Although the
effect on oxidative stress was not determined, previous
studies have demonstrated the effectiveness of these drugs in
reducing diabetes-induced oxidative stress (272).
Diets enriched in n-3 polyunsaturated fatty acids (PUFAs)
prevent the high plasma levels of lipoperoxides observed in
the offspring from diabetic rats (385). PUFAs are activators of
PPARd, and recent studies have shown that PPARd agonists
are able to reduce lipoperoxidation in the placenta from diabetic rats (195). Interestingly, a recent study demonstrated
that diets enriched in PPAR ligands prevent diabetes-induced
embryonic NO overproduction, congenital malformations,
and resorptions (140).
Overall, these data suggest that overproduction of reactive
oxygen and nitrogen species can be regulated by PPAR ligands in different gestational tissues in experimental models
of diabetes, as well as in the GDM placenta.
X. Future Directions
The involvement of oxidative stress in GDM is well documented and has been discussed above. However, there are
very few studies available on the impact of oxidative stress on
placental development and function and thus fetal development and subsequent adult diseases.
Cell adhesion molecules are important mediators of cellular contacts, proliferation, differentiation, and invasion. Dysregulation of these processes is associated with many
complication of pregnancy, including GDM. There is, however, a paucity of data on the relationship between oxidative
stress and adhesion molecules in placenta. Our preliminary
data demonstrate that HX/XO regulates the expression of
adhesion molecules (selectins, cadherins, and catenins) in
human placenta (Lappas, personal communications). Clearly,
more studies are required to determine the effect of ROS, RNS,
and antioxidants on these molecules.
To compensate for the increasing needs of the embryo,
there is an increase in the capacity of the mitochondria in the
placenta. Mitochondrial dysfunction causes cell damage
and death by compromising ATP production and calcium
homoeostasis and increasing oxidative stress. Certainly, in
pre-eclampsia, the mitochondria are an important source of
oxidative stress and lipid peroxidation (258). The role and
function of mitochondria in GDM placentas and their role in
the generation of ROS also needs to be further evaluated.
Nutrient transport from the mother to the fetus occurs via
the placenta; however, there is a paucity of data on the impact
of oxidative stress on these processes. Certainly, our preliminary data suggest that ROS may play an important role in the
regulation of maternal to fetal transport (Lappas, personal
communications). Using placental BeWo cells as a model, we
have shown that HX/XO increases transcellular fatty acid
transport using transwell system. Specifically, there is an increase in glucose transport from the maternal circulation
(upper chamber) to the fetal circulation (lower chamber). This
would favor fetal fat accretion as well as stimulating oxidative
stress in the fetus. However, further studies are required to
fully elucidate the effect of ROS, RNS, and antioxidants on
nutrient transport in the placenta.
Animal models have been particularly useful in delineating
the effects of oxidative stress on the fetus. Although antioxi-
3087
dant therapies have been useful in the treatment of these fetal
abnormalities, there is a paucity of data for their effectiveness in
GDM women and their offspring. Thus, whether or not increased antioxidant intake can reduce the short- and long-term
complications of GDM in both mother and fetus needs to be
explored. Of potential benefit may be flavonoids as these are
found naturally in many plants. Diets enriched in unsaturated
fatty acids capable of activating PPARs to regulate both oxidative and nitrative stress may also be of benefit in GDM.
The appropriate development of the placenta is crucial to
normal fetal programming. It is feasible that oxidative stress
may disrupt normal intrauterine programming, thus leading
to metabolic diseases later in life. Thus, future studies addressing the role of oxidative stress in GDM-induced intrauterine malprogramming are encouraged.
XI. Conclusions
Pregnancy is a state of oxidative stress as a consequence of
high metabolic activity in the feto-placental compartment.
During normal pregnancies, oxidants have many physiological functions, promoting and controlling cellular fate and
playing a crucial role in normal development through cellular
signaling. In absence of a parallel increase in antioxidative
activity, oxidative stress will result. The elevated ROS levels in
a normal pregnancy are exceeded in GDM. The level of oxidative stress might change the course and the severity of the
side effects of the disease. Overproduction of ROS can lead to
massive cellular damage by acting on proteins, lipids, and
DNA. In the case of a systemic oxidative stress such as in
maternal diabetes, it can also entail biochemical disturbances
of the fetus (77, 259, 307). It is possible, that the management
of oxidative stress, along with tight glycemic control, could be
beneficial both preconceptionally and during pregnancy in
women at risk of GDM. However, whether or not antioxidant
supplementation or eating a diet rich in antioxidants can
improve the consequences of oxidative stress in the offspring
is yet to be elucidated. Clearly, more studies are required to
fully understand the short- and long-term health benefit of
reducing oxidative stress during diabetic pregnancies.
Acknowledgments
Dr. Martha Lappas is a recipient of a National Health and
Medical Research Council (NHMRC) RD Wright Fellowship
(grant no. 454777). The work from M. Lappas’s laboratory
was funded by project grants from NHMRC (grant no.
454310), Diabetes Australia Research Trust (DART), Melbourne Research Grant Scheme (MRGS), ANZ Charitable
Trust (Medical Research and Technology Grant), and the
Medical Research Foundation for Women and Babies. Work
from A. Jawerbaum’s laboratory was supported by ANPCYT
(PICT 2006 00084 and PICT 2005 32268).
References
1. Afkhami-Ardekani M and Rashidi M. Iron status in women
with and without gestational diabetes mellitus. J Diabetes
Complications 23: 194–198, 2009.
2. Agarwal A, Gupta S, and Sharma RK. Role of oxidative stress
in female reproduction. Reprod Biol Endocrinol 3: 28, 2005.
3. Aguirre V, Uchida T, Yenush L, Davis R, and White MF. The cJun NH(2)-terminal kinase promotes insulin resistance during
3088
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047–9054, 2000.
Aisemberg J, Vercelli C, Wolfson M, Salazar AI, OsyckaSalut C, Billi S, Ribeiro ML, Farina M, and Franchi AM.
Inflammatory agents involved in septic miscarriage. Neuroimmunomodulation 17: 150–152, 2010.
Al Ghafli MH, Padmanabhan R, Kataya HH, and Berg B.
Effects of alpha-lipoic acid supplementation on maternal
diabetes-induced growth retardation and congenital anomalies in rat fetuses. Mol Cell Biochem 261: 123–135, 2004.
Allen VM, Armson BA, Wilson RD, Blight C, Gagnon A,
Johnson JA, Langlois S, Summers A, Wyatt P, Farine D, Crane
J, Delisle MF, Keenan-Lindsay L, Morin V, Schneider CE, and
Van Aerde J; Society of Obstetricians and Gynecologists of
Canada. Teratogenicity associated with pre-existing and
gestational diabetes. J Obstet Gynaecol Can 29: 927–944, 2007.
Anastasiou E, Lekakis JP, Alevizaki M, Papamichael CM,
Megas J, Souvatzoglou A, and Stamatelopoulos SF. Impaired endothelium-dependent vasodilatation in women
with previous gestational diabetes. Diabetes Care 21: 2111–
2115, 1998.
Arts IC and Hollman PC. Polyphenols and disease risk in
epidemiologic studies. Am J Clin Nutr 81: 317S–325S, 2005.
Augustin R. The protein family of glucose transport facilitators: it’s not only about glucose after all. IUBMB Life 62:
315–333, 2010.
Avignon A and Sultan A. PKC-B inhibition: a new therapeutic approach for diabetic complications? Diabetes Metab
32: 205–213, 2006.
Babawale MO, Lovat S, Mayhew TM, Lammiman MJ,
James DK, and Leach L. Effects of gestational diabetes on
junctional adhesion molecules in human term placental
vasculature. Diabetologia 43: 1185–1196, 2000.
Ban CR and Twigg SM. Fibrosis in diabetes complications:
pathogenic mechanisms and circulating and urinary
markers. Vasc Health Risk Manage 4: 575–596, 2008.
Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP,
Catalano PM, and Friedman JE. Cellular mechanisms for
insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 30 Suppl 2: S112–S119, 2007.
Barter PJ and Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 121: 1–12, 1996.
Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli
P, Fu C, Kislinger T, Stern DM, Schmidt AM, and De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a
mechanism for amplification of inflammatory responses.
Circulation 105: 816–822, 2002.
Basta G, Schmidt AM, and De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc
Res 63: 582–592, 2004.
Basu S, Haghiac M, Surace P, Challier JC, Guerre-Millo M,
Singh K, Waters T, Minium J, Presley L, Catalano PM, and
Hauguel-de Mouzon S. Pregravid obesity associates with
increased maternal endotoxemia and metabolic inflammation. Obesity (Silver Spring) 19: 476–482, 2011.
Basuroy S, Bhattacharya S, Leffler CW, and Parfenova H.
Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol 296: C422–C432, 2009.
Bellamy L, Casas JP, Hingorani AD, and Williams D. Type
2 diabetes mellitus after gestational diabetes: a systematic
review and meta-analysis. Lancet 373: 1773–1779, 2009.
LAPPAS ET AL.
20. Biri A, Onan A, Devrim E, Babacan F, Kavutcu M, and Durak
I. Oxidant status in maternal and cord plasma and placental
tissue in gestational diabetes. Placenta 27: 327–332, 2006.
21. Bitsanis D, Ghebremeskel K, Moodley T, Crawford MA,
and Djahanbakhch O. Gestational diabetes mellitus enhances arachidonic and docosahexaenoic acids in placental
phospholipids. Lipids 41: 341–346, 2006.
22. Bloch W, Fleischmann BK, Lorke DE, Andressen C, Hops B,
Hescheler J, and Addicks K. Nitric oxide synthase expression and role during cardiomyogenesis. Cardiovasc Res 43:
675–684, 1999.
23. Bo S, Lezo A, Menato G, Gallo ML, Bardelli C, Signorile A,
Berutti C, Massobrio M, and Pagano GF. Gestational hyperglycemia, zinc, selenium, and antioxidant vitamins.
Nutrition 21: 186–191, 2005.
24. Bo S, Menato G, Villois P, Gambino R, Cassader M, Cotrino
I, and Cavallo-Perin P. Iron supplementation and gestational diabetes in midpregnancy. Am J Obstet Gynecol 201,
158.e1–6, 2009.
25. Bogdan C. Nitric oxide and the immune response. Nat
Immunol 2: 907–916, 2001.
26. Bohlender JM, Franke S, Stein G, and Wolf G. Advanced
glycation end products and the kidney. Am J Physiol Renal
Physiol 289: F645–F659, 2005.
27. Boisvert MR, Koski KG, and Skinner CD. Increased oxidative modifications of amniotic fluid albumin in pregnancies associated with gestational diabetes mellitus. Anal
Chem 82: 1133–1137, 2010.
28. Borrego-Diaz E, Rosales JC, Proverbio T, Teppa-Garran A,
Andaluz R, Abad C, Marin R, and Proverbio F. Effect of placental hypoxia on the plasma membrane Ca-ATPase (PMCA)
activity and the level of lipid peroxidation of syncytiotrophoblast and red blood cell ghosts. Placenta 29: 44–50, 2008.
29. Borriello A, Cucciolla V, Della Ragione F, and Galletti P.
Dietary polyphenols: focus on resveratrol, a promising
agent in the prevention of cardiovascular diseases and
control of glucose homeostasis. Nutr Metab Cardiovasc Dis
20: 618–625, 2010.
30. Bouche C, Serdy S, Kahn CR, and Goldfine AB. The cellular
fate of glucose and its relevance in type 2 diabetes. Endocr
Rev 25: 807–830, 2004.
31. Brownlee M. Biochemistry and molecular cell biology of
diabetic complications. Nature 414: 813–820, 2001.
32. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of
type 2 diabetes. J Clin Endocrinol Metab 86: 989–993, 2001.
33. Buchanan TA and Xiang AH. Gestational diabetes mellitus.
J Clin Invest 115: 485–491, 2005.
34. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K,
Marroquin A, Goico J, Ochoa C, and Azen SP. Response of
pancreatic beta-cells to improved insulin sensitivity in
women at high risk for type 2 diabetes. Diabetes 49: 782–
788, 2000.
35. Buhimschi IA, Zhao G, Pettker CM, Bahtiyar MO, Magloire
LK, Thung S, Fairchild T, and Buhimschi CS. The receptor
for advanced glycation end products (RAGE) system in
women with intraamniotic infection and inflammation. Am
J Obstet Gynecol 196: 181.e1–13, 2007.
36. Burns J, Yokota T, Ashihara H, Lean ME, and Crozier A.
Plant foods and herbal sources of resveratrol. J Agric Food
Chem 50: 3337–3340, 2002.
37. Butte NF, Hsu HW, Thotathuchery M, Wong WW, Khoury
J, and Reeds P. Protein metabolism in insulin-treated gestational diabetes. Diabetes Care 22: 806–811, 1999.
GESTATIONAL DIABETES AND OXIDATIVE STRESS
38. Camuzcuoglu H, Toy H, Cakir H, Celik H, and Erel O.
Decreased paraoxonase and arylesterase activities in the
pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus. J Womens Health 18:
1435–1439, 2009.
39. Cani PD. Gut microbiota and pregnancy, a matter of inner
life. Br J Nutr 101: 1579–1580, 2009.
40. Capobianco E, Jawerbaum A, Romanini MC, White V,
Pustovrh C, Higa R, Martinez N, Mugnaini MT, Sonez C,
and Gonzalez E. 15-Deoxy-Delta(12,14)-prostaglandin J2
and peroxisome proliferator-activated receptor gamma
(PPARgamma) levels in term placental tissues from control
and diabetic rats: modulatory effects of a PPARgamma
agonist on nitridergic and lipid placental metabolism. Reprod Fertil Dev 17: 423–433, 2005.
41. Carew TE. Role of biologically modified low-density lipoprotein in atherosclerosis. Am J Cardiol 64: 18G–22G, 1989.
42. Carr DB, Utzschneider KM, Hull RL, Tong J, Wallace TM,
Kodama K, Shofer JB, Heckbert SR, Boyko EJ, Fujimoto
WY, and Kahn SE. Gestational diabetes mellitus increases
the risk of cardiovascular disease in women with a family
history of type 2 diabetes. Diabetes Care 29: 2078–2083, 2006.
43. Casanello P, Escudero C, and Sobrevia L. Equilibrative
nucleoside (ENTs) and cationic amino acid (CATs) transporters: implications in foetal endothelial dysfunction in
human pregnancy diseases. Curr Vasc Pharmacol 5: 69–84,
2007.
44. Casanueva E and Viteri FE. Iron and oxidative stress in
pregnancy. J Nutr 133: 1700S–1708S, 2003.
45. Catalano PM, Drago NM, and Amini SB. Maternal carbohydrate metabolism and its relationship to fetal growth and
body composition. Am J Obstet Gynecol 172: 1464–1470, 1995.
46. Catalano PM, Farrell K, Thomas A, Huston-Presley L,
Mencin P, de Mouzon SH, and Amini SB. Perinatal risk
factors for childhood obesity and metabolic dysregulation.
Am J Clin Nutr 90: 1303–1313, 2009.
47. Catalano PM, Nizielski SE, Shao J, Preston L, Qiao L, and
Friedman JE. Downregulated IRS-1 and PPARgamma in
obese women with gestational diabetes: relationship to FFA
during pregnancy. Am J Physiol Endocrinol Metab 282: E522–
E533, 2002.
48. Catalano PM, Tyzbir ED, Wolfe RR, Roman NM, Amini SB,
and Sims EA. Longitudinal changes in basal hepatic glucose production and suppression during insulin infusion
in normal pregnant women. Am J Obstet Gynecol 167: 913–
919, 1992.
49. Caughey AB, Cheng YW, Stotland NE, Washington AE,
and Escobar GJ. Maternal and paternal race/ethnicity are
both associated with gestational diabetes. Am J Obstet Gynecol 202: 616.e1–5, 2010.
50. Cavanal Mde F, Gomes GN, Forti AL, Rocha SO, Franco
Mdo C, Fortes ZB, and Gil FZ. The influence of L-arginine
on blood pressure, vascular nitric oxide and renal morphometry in the offspring from diabetic mothers. Pediatr
Res 62: 145–150, 2007.
51. Cederberg J, Basu S, and Eriksson UJ. Increased rate of lipid
peroxidation and protein carbonylation in experimental
diabetic pregnancy. Diabetologia 44: 766–774, 2001.
52. Cederberg J and Eriksson UJ. Antioxidative treatment
of pregnant diabetic rats diminishes embryonic dysmorphogenesis. Birth Defects Res A Clin Mol Teratol 73: 498–
505, 2005.
53. Cederberg J, Galli J, Luthman H, and Eriksson UJ. Increased mRNA levels of Mn-SOD and catalase in embryos
3089
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
of diabetic rats from a malformation-resistant strain. Diabetes 49: 101–107, 2000.
Chang TI, Horal M, Jain SK, Wang F, Patel R, and Loeken
MR. Oxidant regulation of gene expression and neural tube
development: insights gained from diabetic pregnancy on
molecular causes of neural tube defects. Diabetologia 46:
538–545, 2003.
Chappell JH Jr., Wang XD, and Loeken MR. Diabetes and
apoptosis: neural crest cells and neural tube. Apoptosis 14:
1472–1483, 2009.
Chaudhari L, Tandon OP, Vaney N, and Agarwal N. Lipid
peroxidation and antioxidant enzymes in gestational diabetics. Indian J Physiol Pharmacol 47: 441–446, 2003.
Chekir C, Nakatsuka M, Noguchi S, Konishi H, Kamada Y,
Sasaki A, Hao L, and Hiramatsu Y. Accumulation of advanced glycation end products in women with preeclampsia: possible involvement of placental oxidative and
nitrative stress. Placenta 27: 225–233, 2006.
Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J,
England LJ, and Dietz PM. Maternal obesity and risk
of gestational diabetes mellitus. Diabetes Care 30: 2070–
2076, 2007.
Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, Charnock-Jones DS, and Burton GJ. Nuclear factor-kappa B, p38,
and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory
cytokines and apoptosis in human placental explants in
response to oxidative stress: effects of antioxidant vitamins.
Am J Pathol 170: 1511–1520, 2007.
Cindrova-Davies T, Yung HW, Johns J, Spasic-Boskovic O,
Korolchuk S, Jauniaux E, Burton GJ, and Charnock-Jones
DS. Oxidative stress, gene expression, and protein changes
induced in the human placenta during labor. Am J Pathol
171: 1168–1179, 2007.
Closs EI, Basha FZ, Habermeier A, and Forstermann U.
Interference of L-arginine analogues with L-arginine
transport mediated by the y + carrier hCAT-2B. Nitric Oxide
1: 65–73, 1997.
Colomiere M, Permezel M, and Lappas M. Diabetes and
obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle
and subcutaneous adipose tissue. J Mol Endocrinol 44: 213–
223, 2010.
Colomiere M, Permezel M, Riley C, Desoye G, and Lappas
M. Defective insulin signaling in placenta from pregnancies
complicated by gestational diabetes mellitus. Eur J Endocrinol 160: 567–578, 2009.
This reference has been deleted.
Conrad KP and Vernier KA. Plasma level, urinary excretion, and metabolic production of cGMP during gestation
in rats. Am J Physiol 257: R847–R853, 1989.
Cooke CLM, Brockelsby JC, Baker PN, and Davidge ST.
The receptor for advanced glycation end products (RAGE)
is elevated in women with preeclampsia. Hypertens Pregnancy 22: 173–184, 2003.
Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA,
Hobbs CA, Cleves MA, Riehle-Colarusso TJ, Waller DK,
and Reece EA. Diabetes mellitus and birth defects. Am J
Obstet Gynecol 199: 237.e1–9, 2008.
Coughlan MT, Oliva K, Georgiou HM, Permezel JM, and
Rice GE. Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in
gestational diabetes mellitus. Diabet Med 18: 921–927, 2001.
This reference has been deleted.
3090
70. Coughlan MT, Permezel M, Georgiou HM, and Rice GE.
Repression of oxidant-induced nuclear factor-kappaB activity mediates placental cytokine responses in gestational
diabetes. J Clin Endocrinol Metab 89: 3585–3594, 2004.
71. Coughlan MT, Vervaart PP, Permezel M, Georgiou HM,
and Rice GE. Altered placental oxidative stress status in
gestational diabetes mellitus. Placenta 25: 78–84, 2004.
72. Coustan DR, Lowe LP, and Metzger BE. The hyperglycemia and adverse pregnancy outcome (HAPO) study: can
we use the results as a basis for change? J Matern Fetal
Neonatal Med 23: 204–209, 2010.
73. Cui XL, Brockman D, Campos B, and Myatt L. Expression
of NADPH oxidase isoform 1 (Nox1) in human placenta:
involvement in preeclampsia. Placenta 27: 422–431, 2006.
74. Damasceno DC, Volpato GT, de Mattos Paranhos Calderon
I, and Cunha Rudge MV. Oxidative stress and diabetes in
pregnant rats. Anim Reprod Sci 72: 235–244, 2002.
75. Davari-Tanha F, Khan-Mohamadi F, Kaveh M, and Shariat
M. Homocysteine in gestational diabetes and normal
pregnancy plus effects of folic acid. Iran J Public Health 37:
118–126, 2008.
76. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, and
Witteman JC. High serum uric acid as a novel risk factor for
type 2 diabetes. Diabetes Care 31: 361–362, 2008.
77. Dennery PA. Effects of oxidative stress on embryonic
development. Birth Defects Res C Embryo Today 81: 155–
162, 2007.
78. Desoye G and Hauguel-de Mouzon S. The human placenta
in gestational diabetes mellitus. The insulin and cytokine
network. Diabetes Care 30 Suppl 2: S120–S126, 2007.
79. Desoye G, Hofmann HH, and Weiss PA. Insulin binding to
trophoblast plasma membranes and placental glycogen
content in well-controlled gestational diabetic women
treated with diet or insulin, in well-controlled overt diabetic patients and in healthy control subjects. Diabetologia
35: 45–55, 1992.
80. Desoye G and Shafrir E. Placental metabolism and its
regulation in health and diabetes. Mol Aspects Med 15: 505–
682, 1994.
81. Desoye G and Shafrir E. The human placenta in diabetic
pregnancy. Diabetes Rev 4: 70–89, 1996.
82. Dey P, Gupta P, Acharya NK, Rao SN, Ray S, Chakrabarty
S, Ramprasad S, Kurian TA, Mawroh A, Kundu A, Bhaktha
G, Joseph CP, Kumar P, Rai L, and Rao A. Antioxidants
and lipid peroxidation in gestational diabetes—a preliminary study. Indian J Physiol Pharmacol 52: 149–156, 2008.
83. Di Iulio JL, Gude NM, King RG, Li CG, Rand MJ, and
Brennecke SP. Human placental nitric oxide synthase
activity is not altered in diabetes. Clin Sci (Lond) 97: 123–
128, 1999.
84. Diderholm B, Stridsberg M, Ewald U, Lindeberg-Norden S,
and Gustafsson J. Increased lipolysis in non-obese pregnant women studied in the third trimester. BJOG 112: 713–
718, 2005.
85. Ector BJ, Magee JB, Hegwood CP, and Coign MJ. Resveratrol concentration in muscadine berries, juice, pomace,
purees, seeds, and wines. Am J Enol Vitic 47: 57–62, 1996.
86. El-Remessy AB, Al-Shabrawey M, Platt DH, Bartoli M,
Behzadian MA, Ghaly N, Tsai N, Motamed K, and Caldwell RB. Peroxynitrite mediates VEGF’s angiogenic signal
and function via a nitration-independent mechanism in
endothelial cells. FASEB J 21: 2528–2539, 2007.
87. Ericsson A, Hamark B, Powell TL, and Jansson T. Glucose
transporter isoform 4 is expressed in the syncytiotropho-
LAPPAS ET AL.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
blast of first trimester human placenta. Hum Reprod 20: 521–
530, 2005.
Eriksson UJ. Congenital anomalies in diabetic pregnancy.
Semin Fetal Neonatal Med 14: 85–93, 2009.
Eriksson UJ, Cederberg J, and Wentzel P. Congenital malformations in offspring of diabetic mothers—animal and
human studies. Rev Endocr Metab Disord 4: 79–93, 2003.
Eriksson UJ and Siman CM. Pregnant diabetic rats fed
the antioxidant butylated hydroxytoluene show decreased
occurrence of malformations in offspring. Diabetes 45: 1497–
1502, 1996.
Escudero C and Sobrevia L. A hypothesis for preeclampsia:
adenosine and inducible nitric oxide synthase in human placental microvascular endothelium. Placenta 29: 469–483, 2008.
Ethier-Chiasson M, Forest JC, Giguere Y, Masse A, Marseille-Tremblay C, Levy E, and Lafond J. Modulation of
placental protein expression of OLR1: implication in pregnancy-related disorders or pathologies. Reproduction 136:
491–502, 2008.
Evans JL, Goldfine ID, Maddux BA, and Grodsky GM.
Oxidative stress and stress-activated signaling pathways: a
unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599–
622, 2002.
Fan E, Zhang L, Jiang S, and Bai Y. Beneficial effects of
resveratrol on atherosclerosis. J Med Food 11: 610–614, 2008.
Farias M, Puebla C, Westermeier F, Jo MJ, Pastor-Anglada
M, Casanello P, and Sobrevia L. Nitric oxide reduces
SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPalpha
in human umbilical vein endothelial cells from gestational
diabetes. Cardiovasc Res 86: 45–54, 2010.
Fasshauer M, Seeger J, Waldeyer T, Schrey S, Ebert T,
Lossner U, Bluher M, Stumvoll M, Faber R, and Stepan H.
Endogenous soluble receptor for advanced glycation endproducts is increased in preeclampsia. J Hypertens 26: 1824–
1828, 2008.
Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, and
Yee SP. Development of heart failure and congenital septal
defects in mice lacking endothelial nitric oxide synthase.
Circulation 106: 873–879, 2002.
Fetita LS, Sobngwi E, Serradas P, Calvo F, and Gautier JF.
Consequences of fetal exposure to maternal diabetes in
offspring. J Clin Endocrinol Metab 91: 3718–3724, 2006.
Figueroa R, Martinez E, Fayngersh RP, Tejani N, Mohazzab
HK, and Wolin MS. Alterations in relaxation to lactate and
H(2)O(2) in human placental vessels from gestational diabetic pregnancies. Am J Physiol Heart Circ Physiol 278:
H706–H713, 2000.
Forbes JM, Coughlan MT, and Cooper ME. Oxidative stress
as a major culprit in kidney disease in diabetes. Diabetes 57:
1446–1454, 2008.
Friedman JE, Ishizuka T, Shao J, Huston L, Highman T, and
Catalano P. Impaired glucose transport and insulin receptor
tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Diabetes 48: 1807–1814, 1999.
Friedman JE, Kirwan JP, Jing M, Presley L, and Catalano
PM. Increased skeletal muscle tumor necrosis factor-alpha
and impaired insulin signaling persist in obese women
with gestational diabetes mellitus 1 year postpartum. Diabetes 57: 606–613, 2008.
Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M,
and Shimomura I. Sulfonylurea agents exhibit peroxisome
proliferator-activated receptor gamma agonistic activity. J
Biol Chem 280: 23653–23659, 2005.
GESTATIONAL DIABETES AND OXIDATIVE STRESS
104. Furchgott RF and Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by
acetylcholine. Nature 288: 373–376, 1980.
105. Gao L, Liu WH, Luan NN, Feng C, and Shang T. Correlation between the expression of high mobility group box 1
and receptor for advanced glycation end products and the
onset of pre-eclampsia. Zhonghua Fu Chan Ke Za Zhi 43:
746–750, 2008.
106. Gao L and Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling.
Cardiovasc Res 82: 9–20, 2009.
107. Gao X, Zhang H, Schmidt AM, and Zhang C. AGE/RAGE
produces endothelial dysfunction in coronary arterioles in
type 2 diabetic mice. Am J Physiol 295: H491–H498, 2008.
108. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ,
and Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem
277: 48115–48121, 2002.
109. Gareskog M, Eriksson UJ, and Wentzel P. Combined supplementation of folic acid and vitamin E diminishes diabetes-induced embryotoxicity in rats. Birth Defects Res A
Clin Mol Teratol 76: 483–490, 2006.
110. Garris DR. Effects of diabetes on uterine condition, decidualization, vascularization, and corpus luteum function in
the pseudopregnant rat. Endocrinology 122: 665–672, 1988.
111. Garvey WT, Maianu L, Hancock JA, Golichowski AM, and
Baron A. Gene expression of GLUT4 in skeletal muscle
from insulin-resistant patients with obesity, IGT, GDM,
and NIDDM. Diabetes 41: 465–475, 1992.
112. Ge X, Yu Q, Qi W, Shi X, and Zhai Q. Chronic insulin
treatment causes insulin resistance in 3T3-L1 adipocytes
through oxidative stress. Free Radic Res 42: 582–591, 2008.
113. Georgiou HM, Lappas M, Georgiou GM, Marita A, Bryant
VJ, Hiscock R, Permezel M, Khalil Z, and Rice GE.
Screening for biomarkers predictive of gestational diabetes
mellitus. Acta Diabetol 45: 157–165, 2008.
114. Gerber RT, Holemans K, O’Brien-Coker I, Mallet AI, van
Bree R, Van Assche FA, and Poston L. Increase of the isoprostane 8-isoprostaglandin f2alpha in maternal and fetal
blood of rats with streptozotocin-induced diabetes: evidence of lipid peroxidation. Am J Obstet Gynecol 183: 1035–
1040, 2000.
115. Getahun D, Nath C, Ananth CV, Chavez MR, and Smulian
JC. Gestational diabetes in the United States: temporal
trends 1989 through 2004. Am J Obstet Gynecol 198: 525.e1–
5, 2008.
116. Gloire G, Legrand-Poels S, and Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493–1505, 2006.
117. Goh SY and Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93: 1143–1152,
2008.
118. Gonzalez E, Jawerbaum A, Novaro V, Sinner D, and Gimeno M. Nitric oxide modulates placental prostanoid
production from late pregnant non-insulin-dependent diabetic rat. Prostaglandins Leukot Essent Fatty Acids 59: 299–
304, 1998.
119. Gonzalez M, Gallardo V, Rodriguez N, Salomon C, Westermeier F, Guzman-Gutierrez E, Abarzua F, Leiva A, Casanello P, and Sobrevia L. Insulin-stimulated L-arginine
transport requires SLC7A1 gene expression and is associated with human umbilical vein relaxation. J Cell Physiol
2011 [Epub ahead of print]; DOI: 10.1002/jcp.22635.
3091
120. Gorovits N, Cui L, Busik JV, Ranalletta M, Hauguel deMouzon S, and Charron MJ. Regulation of hepatic GLUT8
expression in normal and diabetic models. Endocrinology
144: 1703–1711, 2003.
121. Grissa O, Ategbo JM, Yessoufou A, Tabka Z, Miled A, Jerbi
M, Dramane KL, Moutairou K, Prost J, Hichami A, and
Khan NA. Antioxidant status and circulating lipids are
altered in human gestational diabetes and macrosomia.
Transl Res 150: 164–171, 2007.
122. Grossin N, Wautier MP, and Wautier JL. Red blood cell
adhesion in diabetes mellitus is mediated by advanced
glycation end product receptor and is modulated by nitric
oxide. Biorheology 46: 63–72, 2009.
123. Gude NM, Stevenson JL, Rogers S, Best JD, Kalionis B,
Huisman MA, Erwich JJ, Timmer A, and King RG. GLUT12
expression in human placenta in first trimester and term.
Placenta 24: 566–570, 2003.
124. Guilloteau P, Zabielski R, Hammon HM, and Metges CC.
Adverse effects of nutritional programming during prenatal and early postnatal life, some aspects of regulation and
potential prevention and treatments. J Physiol Pharmacol 60
Suppl 3: 17–35, 2009.
125. Gupte S, Labinskyy N, Gupte R, Csiszar A, Ungvari Z, and
Edwards JG. Role of NAD(P)H oxidase in superoxide
generation and endothelial dysfunction in Goto-Kakizaki
(GK) rats as a model of nonobese NIDDM. PLoS One 5:
e11800, 2010.
126. Hagay ZJ, Weiss Y, Zusman I, Peled-Kamar M, Reece EA,
Eriksson UJ, and Groner Y. Prevention of diabetes-associated
embryopathy by overexpression of the free radical scavenger
copper zinc superoxide dismutase in transgenic mouse embryos. Am J Obstet Gynecol 173: 1036–1041, 1995.
127. Haggarty P. Effect of placental function on fatty acid requirements during pregnancy. Eur J Clin Nutr 58: 1559–
1570, 2004.
128. Halliwell B and Gutteridge JMC. (Eds). Free Radicals in
Biology and Medicine, 4th edition. Oxford, NY: Oxford
University Press, 2007.
129. Hannemann MM, Liddell WG, Shore AC, Clark PM, and
Tooke JE. Vascular function in women with previous gestational diabetes mellitus. J Vasc Res 39: 311–319, 2002.
130. Harris LK, McCormick J, Cartwright JE, Whitley GS, and Dash
PR. S-nitrosylation of proteins at the leading edge of migrating
trophoblasts by inducible nitric oxide synthase promotes trophoblast invasion. Exp Cell Res 314: 1765–1776, 2008.
131. Harris MI. Gestational diabetes may represent discovery of
preexisting glucose intolerance. Diabetes Care 11: 402–411, 1988.
132. Hauguel-de Mouzon S, Challier JC, Kacemi A, Cauzac M,
Malek A, and Girard J. The GLUT3 glucose transporter
isoform is differentially expressed within human placental
cell types. J Clin Endocrinol Metab 82: 2689–2694, 1997.
133. Hay WW, Jr. Glucose metabolism in the fetal-placental
unit. In: Principles of Perinatal-Neonatal Metabolism, edited by
Cowett R. New York: Springer, 1998, pp. 337–367.
134. Herman JB and Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet 2: 240–243, 1982.
135. Herrera E. Implications of dietary fatty acids during pregnancy on placental, fetal and postnatal development—a
review. Placenta 23 Suppl A: S9–S19, 2002.
136. Herrera E. Lipid metabolism in pregnancy and its consequences in the fetus and newborn. Endocrine 19: 43–55, 2002.
137. Herring SJ and Oken E. Obesity and diabetes in mothers
and their children: can we stop the intergenerational cycle?
Curr Diab Rep 11: 20–27, 2011.
3092
138. Hiden U, Glitzner E, Ivanisevic M, Djelmis J, Wadsack C,
Lang U, and Desoye G. MT1-MMP expression in first-trimester placental tissue is upregulated in type 1 diabetes as
a result of elevated insulin and tumor necrosis factor-a
levels. Diabetes 57: 150–157, 2008.
139. Higa R, Gonzalez E, Pustovrh MC, White V, Capobianco E,
Martinez N, and Jawerbaum A. PPARdelta and its activator PGI2 are reduced in diabetic embryopathy: involvement
of PPARdelta activation in lipid metabolic and signalling
pathways in rat embryo early organogenesis. Mol Hum
Reprod 13: 103–110, 2007.
140. Higa R, White V, Martinez N, Kurtz M, Capobianco E, and
Jawerbaum A. Safflower and olive oil dietary treatments
rescue aberrant embryonic arachidonic acid and nitric oxide metabolism and prevent diabetic embryopathy in rats.
Mol Hum Reprod 16: 286–295, 2010.
141. Hockett PK, Emery SC, Hansen L, and Masliah E. Evidence
of oxidative stress in the brains of fetuses with CNS
anomalies and islet cell hyperplasia. Pediatr Dev Pathol 7:
370–379, 2004.
142. Holdsworth-Carson SJ, Lim R, Mitton A, Whitehead C, Rice
GE, Permezel M, and Lappas M. Peroxisome proliferatoractivated receptors are altered in pathologies of the human
placenta: gestational diabetes mellitus, intrauterine growth
restriction and preeclampsia. Placenta 31: 222–229, 2010.
143. Holemans K, Gerber RT, Meurrens K, De Clerck F, Poston
L, and Van Assche FA. Streptozotocin diabetes in the
pregnant rat induces cardiovascular dysfunction in adult
offspring. Diabetologia 42: 81–89, 1999.
144. Horvath EM, Magenheim R, Kugler E, Vacz G, Szigethy A,
Levardi F, Kollai M, Szabo C, and Lacza Z. Nitrative stress
and poly(ADP-ribose) polymerase activation in healthy
and gestational diabetic pregnancies. Diabetologia 52: 1935–
1943, 2009.
145. Hotamisligil GS. Inflammation and metabolic disorders.
Nature 444: 860–867, 2006.
146. Ignarro LJ, Buga GM, Wood KS, Byrns RE, and Chaudhuri
G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad
Sci USA 84: 9265–9269, 1987.
147. Innis SM. Essential fatty acid transfer and fetal development. Placenta 26 Suppl A: S70–S75, 2005.
148. Jain M, Brenner DA, Cui L, Lim CC, Wang B, Pimentel DR,
Koh S, Sawyer DB, Leopold JA, Handy DE, Loscalzo J,
Apstein CS, and Liao R. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res 93: e9–e16, 2003.
149. Jain SK, McVie R, and Smith T. Vitamin E supplementation
restores glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic children.
Diabetes Care 23: 1389–1394, 2000.
150. Jaiswal M, LaRusso NF, and Gores GJ. Nitric oxide in
gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver
Physiol 281: G626–G634, 2001.
151. Jansson T, Cetin I, Powell TL, Desoye G, Radaelli T,
Ericsson A, and Sibley CP. Placental transport and metabolism in fetal overgrowth—a workshop report. Placenta 27
Suppl A: S109–S113, 2006.
152. Jansson T, Ekstrand Y, Bjorn C, Wennergren M, and Powell
TL. Alterations in the activity of placental amino acid
transporters in pregnancies complicated by diabetes. Diabetes 51: 2214–2219, 2002.
153. This reference has been deleted.
LAPPAS ET AL.
154. Jansson T and Powell TL. Role of the placenta in fetal
programming: underlying mechanisms and potential interventional approaches. Clin Sci (Lond) 113: 1–13, 2007.
155. Jarvie E, Hauguel-de-Mouzon S, Nelson SM, Sattar N,
Catalano PM, and Freeman DJ. Lipotoxicity in obese
pregnancy and its potential role in adverse pregnancy
outcome and obesity in the offspring. Clin Sci (Lond) 119:
123–129, 2010.
156. Jawerbaum A, Capobianco E, Pustovrh C, White V, Baier
M, Salzberg S, Pesaresi M, and Gonzalez E. Influence of
peroxisome proliferator-activated receptor c activation by
its endogenous ligand 15-deoxy D12,14 prostaglandin J2 on
nitric oxide production in term placental tissues from diabetic women. Mol Hum Reprod 10: 671–676, 2004.
157. This reference has been deleted.
158. Jawerbaum A and Gonzalez E. The role of alterations in
arachidonic acid metabolism and nitric oxide homeostasis
in rat models of diabetes during early pregnancy. Curr
Pharm Des 11: 1327–1342, 2005.
159. Jawerbaum A and Gonzalez E. Diabetic pregnancies: the
challenge of developing in a pro-inflammatory environment. Curr Med Chem 13: 2127–2138, 2006.
160. Jawerbaum A, Higa R, White V, Capobianco E, Pustovrh C,
Sinner D, Martinez N, and Gonzalez E. Peroxynitrites and
impaired modulation of nitric oxide concentrations in embryos from diabetic rats during early organogenesis. Reproduction 130: 695–703, 2005.
161. Jawerbaum A, Sinner D, White V, Pustovrh C, Capobianco
E, and Gonzalez E. Modulation of nitric oxide concentration and lipid metabolism by 15-deoxy Delta12,14prostaglandin J2 in embryos from control and diabetic rats
during early organogenesis. Reproduction 124: 625–631,
2002.
162. Jawerbaum A and White V. Animal models in diabetes and
pregnancy. Endocr Rev 31: 680–701, 2010.
163. Jirkovska M, Kubinova L, Janacek J, Moravcova M, Krejci
V, and Karen P. Topological properties and spatial organization of villous capillaries in normal and diabetic placentas. J Vasc Res 39: 268–278, 2002.
164. Jones CJ and Desoye G. Glycogen distribution in the
capillaries of the placental villus in normal, overt and
gestational diabetic pregnancy. Placenta 14: 505–517, 1993.
165. Jones KL, de Kretser DM, Patella S, and Phillips DJ. Activin
A and follistatin in systemic inflammation. Mol Cell Endocrinol 225: 119–125, 2004.
166. Jones RH and Ozanne SE. Intra-uterine origins of type 2
diabetes. Arch Physiol Biochem 113: 25–29, 2007.
167. Kamath U, Rao G, Raghothama C, Rai L, and Rao P. Erythrocyte indicators of oxidative stress in gestational diabetes. Acta Paediatr 87: 676–679, 1998.
168. Kasapinovic S, McCallum GP, Wiley MJ, and Wells PG. The
peroxynitrite pathway in development: phenytoin and
benzo[a]pyrene embryopathies in inducible nitric oxide
synthase knockout mice. Free Radic Biol Med 37: 1703–
1711, 2004.
169. Katsuyama K, Shichiri M, Marumo F, and Hirata Y. NO
inhibits cytokine-induced iNOS expression and NF-kappaB
activation by interfering with phosphorylation and degradation of IkappaB-alpha. Arterioscler Thromb Vasc Biol 18:
1796–1802, 1998.
170. Kaufmann P, Black S, and Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol
Reprod 69: 1–7, 2003.
GESTATIONAL DIABETES AND OXIDATIVE STRESS
171. Kautzky-Willer A, Fasching P, Jilma B, Waldhausl W, and
Wagner OF. Persistent elevation and metabolic dependence
of circulating E-selectin after delivery in women with gestational diabetes mellitus. J Clin Endocrinol Metab 82: 4117–
4121, 1997.
172. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C,
Schneider B, Ludvik B, Prager R, and Waldhausl W. Increased plasma leptin in gestational diabetes. Diabetologia
44: 164–172, 2001.
173. Khaliq A, Dunk C, Jiang J, Shams M, Li XF, Acevedo C,
Weich H, Whittle M, and Ahmed A. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression:
molecular evidence for ‘placental hyperoxia’ in intrauterine
growth restriction. Lab Invest 79: 151–170, 1999.
174. Kharb S. Lipid peroxidation in pregnancy with preeclampsia
and diabetes. Gynecol Obstet Invest 50: 113–116, 2000.
175. Kharb S. Ascorbic acid and uric acid levels in gestational
diabetes mellitus. J Obstet Gynecol India 27: 401–402, 2007.
176. Khullar S, Greenwood SL, McCord N, Glazier JD, and
Ayuk PT. Nitric oxide and superoxide impair human placental amino acid uptake and increase Na + permeability:
implications for fetal growth. Free Radic Biol Med 36: 271–
277, 2004.
177. Kilinc M, Guven M, Ezer M, Ertas I, and Coskun A. Evaluation of serum selenium levels in Turkish women with
gestational diabetes mellitus, glucose intolerants, and normal controls. Biol Trace Elem Res 123: 35–40, 2008.
178. This reference has been deleted.
179. Kim YM, Bombeck CA, and Billiar TR. Nitric oxide as
a bifunctional regulator of apoptosis. Circ Res 84: 253–
256, 1999.
180. Kinalski M, Sledziewski A, Telejko B, Kowalska I, Kretowski A, and Kinalska I. Evaluation of lipid peroxidation
and acid-base status in cord blood of newborns after diabetes in pregnancy. Przegl Lek 58: 120–123, 2001.
181. Kinalski M, Sledziewski A, Telejko B, Kowalska I, Kretowski A, Zarzycki W, and Kinalska I. Lipid peroxidation,
antioxidant defence and acid-base status in cord blood
at birth: the influence of diabetes. Horm Metab Res 33: 227–
231, 2001.
182. Kinalski M, Sledziewski A, Telejko B, Zarzycki W, and
Kinalska I. Lipid peroxidation and scavenging enzyme
activity in streptozotocin-induced diabetes. Acta Diabetol
37: 179–183, 2000.
183. King GL and Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 122:
333–338, 2004.
184. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC,
Huston-Presley L, Friedman JE, Kalhan SC, and Catalano
PM. TNF-alpha is a predictor of insulin resistance in human
pregnancy. Diabetes 51: 2207–2213, 2002.
185. Klein K, Satler M, Elhenicky M, Brix J, Krzyzanowska K,
Schernthaner G, Husslein PW, and Schernthaner G-H.
Circulating levels of MCP-1 are increased in women with
gestational diabetes. Prenat Diagn 28: 845–851, 2008.
186. Knopp RH, Montes A, Childs M, Li JR, and Mabuchi H.
Metabolic adjustments in normal and diabetic pregnancy.
Clin Obstet Gynecol 24: 21–49, 1981.
187. Konishi H, Nakatsuka M, Chekir C, Noguchi S, Kamada Y,
Sasaki A, and Hiramatsu Y. Advanced glycation end
products induce secretion of chemokines and apoptosis in
human first trimester trophoblasts. Hum Reprod 19: 2156–
2162, 2004.
3093
188. Kossenjans W, Eis A, Sahay R, Brockman D, and Myatt L.
Role of peroxynitrite in altered fetal-placental vascular reactivity in diabetes or preeclampsia. Am J Physiol Heart Circ
Physiol 278: H1311–H1319, 2000.
189. Kourie JI. Interaction of reactive oxygen species with ion
transport mechanisms. Am J Physiol 275: C1–C24, 1998.
190. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52: 818–823, 2003.
191. Krishnaveni GV, Hill JC, Veena SR, Bhat DS, Wills AK,
Karat CL, Yajnik CS, and Fall CH. Low plasma vitamin B12
in pregnancy is associated with gestational ‘diabesity’ and
later diabetes. Diabetologia 52: 2350–2358, 2009.
192. Kroncke KD, Fehsel K, and Kolb-Bachofen V. Inducible
nitric oxide synthase in human diseases. Clin Exp Immunol
113: 147–156, 1998.
193. Kukor Z, Valent S, and Toth M. Regulation of nitric oxide
synthase activity by tetrahydrobiopterin in human placentae from normal and pre-eclamptic pregnancies. Placenta 21: 763–772, 2000.
194. Kumar SD, Dheen ST, and Tay SS. Maternal diabetes induces congenital heart defects in mice by altering the expression of genes involved in cardiovascular development.
Cardiovasc Diabetol 6: 34, 2007.
195. Kurtz M, Capobianco E, Martinez N, Fernandez J, Higa R,
White V, and Jawerbaum A. Carbaprostacyclin, a PPARdelta agonist, ameliorates excess lipid accumulation in diabetic rat placentas. Life Sci 86: 781–790, 2010.
196. Lachili B, Hininger I, Faure H, Arnaud J, Richard MJ, Favier
A, and Roussel AM. Increased lipid peroxidation in pregnant women after iron and vitamin C supplementation. Biol
Trace Elem Res 83: 103–110, 2001.
197. Lager S, Jansson N, Olsson AL, Wennergren M, Jansson T,
and Powell TL. Effect of IL-6 and TNF-alpha on fatty acid
uptake in cultured human primary trophoblast cells. Placenta 32: 121–127, 2011.
198. Langer O. Changing the diagnosis criteria of type 2 diabetes in pregnancy: do the ends justify the means? J Matern
Fetal Neonatal Med 23: 234–238, 2010.
199. Langer O, Conway DL, Berkus MD, Xenakis EM, and
Gonzales O. A comparison of glyburide and insulin in
women with gestational diabetes mellitus. N Engl J Med
343: 1134–1138, 2000.
200. Lao TT, Chan LY, Tam KF, and Ho LF. Maternal hemoglobin and risk of gestational diabetes mellitus in Chinese
women. Obstet Gynecol 99: 807–812, 2002.
201. Lao TT, Chan PL, and Tam KF. Gestational diabetes mellitus in the last trimester—a feature of maternal iron excess?
Diabet Med 18: 218–223, 2001.
202. Lao TT and Tam KF. Maternal serum ferritin and gestational
impaired glucose tolerance. Diabetes Care 20: 1368–1369, 1997.
203. Lappas M, Mitton A, Lim R, Barker G, Riley C, and Permezel M. SIRT1 is a novel regulator of key pathways of
human labor. Biol Reprod 84: 167–178, 2011.
204. Lappas M, Mitton A, and Permezel M. In response to oxidative stress, the expression of inflammatory cytokines and
antioxidant enzymes are impaired in placenta, but not
adipose tissue, of women with gestational diabetes. J Endocrinol 204: 75–84, 2010.
205. Lappas M, Permezel M, Georgiou HM, and Rice GE. Regulation of proinflammatory cytokines in human gestational
tissues by peroxisome proliferator-activated receptor-gamma: effect of 15-deoxy-Delta(12,14)-PGJ(2) and troglitazone.
J Clin Endocrinol Metab 87: 4667–4672, 2002.
3094
206. Lappas M, Permezel M, Ho PW, Moseley JM, Wlodek ME,
and Rice GE. Effect of nuclear factor-kappa B inhibitors and
peroxisome proliferator-activated receptor-gamma ligands
on PTHrP release from human fetal membranes. Placenta
25: 699–704, 2004.
207. Lappas M, Permezel M, and Rice GE. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine
release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol Metab 88: 1723–1729, 2003.
208. Lappas M, Permezel M, and Rice GE. Release of proinflammatory cytokines and 8-isoprostane from placenta,
adipose tissue, and skeletal muscle from normal pregnant
women and women with gestational diabetes mellitus. J
Clin Endocrinol Metab 89: 5627–5633, 2004.
209. Lappas M, Permezel M, and Rice GE. 15-Deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone regulation of
the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues.
Placenta 27: 1060–1072, 2006.
210. Lappas M, Permezel M, and Rice GE. Advanced glycation
endproducts mediate pro-inflammatory actions in human
gestational tissues via nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Endocrinol 193: 269–277,
2007.
211. This reference has been deleted.
212. Lappas M, Riley C, Rice GE, and Permezel M. Increased
expression of ac-FoxO1 protein in prelabor fetal membranes overlying the cervix: possible role in human fetal
membrane rupture. Reprod Sci 16: 635–641, 2009.
213. Lappas M, Yee K, Permezel M, and Rice GE. Lipopolysaccharide and TNF-alpha activate the nuclear factor kappa
B pathway in the human placental JEG-3 cells. Placenta 27:
568–575, 2006.
214. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS,
Andreasen AS, Pedersen BK, Al-Soud WA, Sorensen SJ,
Hansen LH, and Jakobsen M. Gut microbiota in human
adults with type 2 diabetes differs from non-diabetic
adults. PLoS One 5: e9085, 2010.
215. Lauenborg J, Grarup N, Damm P, Borch-Johnsen K, Jorgensen T, Pedersen O, and Hansen T. Common type 2 diabetes risk gene variants associate with gestational
diabetes. J Clin Endocrinol Metab 94: 145–150, 2009.
216. Lee QP and Juchau MR. Dysmorphogenic effects of nitric
oxide (NO) and NO-synthase inhibition: studies with intraamniotic injections of sodium nitroprusside and NGmonomethyl-L-arginine. Teratology 49: 452–464, 1994.
217. Leitch I, Osmond D, Falconer J, Clifton V, Walters W, and
Read M. Vasoactive effects of 8-epi-prostaglandin-F2alpha
in the human placenta in vitro. J Soc Gynecol Invest 6: 195A,
1999.
218. Lesser KB and Carpenter MW. Metabolic changes associated with normal pregnancy and pregnancy complicated
by diabetes mellitus. Semin Perinatol 18: 399–406, 1994.
219. Li H, Gu B, Zhang Y, Lewis DF, and Wang Y. Hypoxiainduced increase in soluble Flt-1 production correlates with
enhanced oxidative stress in trophoblast cells from the
human placenta. Placenta 26: 210–217, 2005.
220. Loeken MR. Advances in understanding the molecular
causes of diabetes-induced birth defects. J Soc Gynecol Investig 13: 2–10, 2006.
221. Loh TT, Higuchi DA, van Bockxmeer FM, Smith CH, and
Brown EB. Transferrin receptors on the human placental
microvillous membrane. J Clin Invest 65: 1182–1191, 1980.
LAPPAS ET AL.
222. Loukovaara MJ, Loukovaara S, Leinonen PJ, Teramo KA,
and Andersson SH. Endothelium-derived nitric oxide
metabolites and soluble intercellular adhesion molecule-1
in diabetic and normal pregnancies. Eur J Obstet Gynecol
Reprod Biol 118: 160–165, 2005.
223. Loven A, Romem Y, Pelly IZ, Holcberg G, and Agam G.
Copper metabolism—a factor in gestational diabetes? Clin
Chim Acta 213: 51–59, 1992.
224. Lunghi L, Ferretti ME, Medici S, Biondi C, and Vesce F.
Control of human trophoblast function. Reprod Biol Endocrinol 5: 6, 2007.
225. Luo ZC, Fraser WD, Julien P, Deal CL, Audibert F, Smith
GN, Xiong X, and Walker M. Tracing the origins of ‘‘fetal
origins’’ of adult diseases: programming by oxidative
stress? Med Hypotheses 66: 38–44, 2006.
226. Luoto R, Laitinen K, Nermes M, and Isolauri E. Impact of
maternal probiotic-supplemented dietary counselling on
pregnancy outcome and prenatal and postnatal growth: a
double-blind, placebo-controlled study. Br J Nutr 103:
1792–1799, 2010.
227. Lurie S, Matas Z, Boaz M, Fux A, Golan A, and Sadan O.
Different degrees of fetal oxidative stress in elective and
emergent cesarean section. Neonatology 92: 111–115, 2007.
228. Lyall F, Gibson JL, Greer IA, Brockman DE, Eis AL, and
Myatt L. Increased nitrotyrosine in the diabetic placenta: evidence for oxidative stress. Diabetes Care 21: 1753–1758, 1998.
229. MacMicking J, Xie QW, and Nathan C. Nitric oxide and
macrophage function. Annu Rev Immunol 15: 323–350, 1997.
230. Madazli R, Tuten A, Calay Z, Uzun H, Uludag S, and Ocak
V. The incidence of placental abnormalities, maternal and
cord plasma malondialdehyde and vascular endothelial
growth factor levels in women with gestational diabetes
mellitus and nondiabetic controls. Gynecol Obstet Invest 65:
227–232, 2008.
231. Maeda H, Okamoto T, and Akaike T. Human matrix
metalloprotease activation by insults of bacterial infection
involving proteases and free radicals. Biol Chem 379: 193–
200, 1998.
232. Maggirwar SB, Dhanraj DN, Somani SM, and Ramkumar
V. Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res
Commun 201: 508–515, 1994.
233. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS,
Cheng G, Lambeth JD, and Goldstein BJ. The NAD(P)H
oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal
transduction. Mol Cell Biol 24: 1844–1854, 2004.
234. Mandang S, Manuelpillai U, and Wallace EM. Oxidative
stress increases placental and endothelial cell activin A secretion. J Endocrinol 192: 485–493, 2007.
235. Manea A, Tanase LI, Raicu M, and Simionescu M. Transcriptional regulation of NADPH oxidase isoforms, Nox1
and Nox4, by nuclear factor-kappaB in human aortic
smooth muscle cells. Biochem Biophys Res Commun 396: 901–
907, 2010.
236. Mann GE, Rowlands DJ, Li FY, de Winter P, and Siow RC.
Activation of endothelial nitric oxide synthase by dietary
isoflavones: role of NO in Nrf2-mediated antioxidant gene
expression. Cardiovasc Res 75: 261–274, 2007.
237. Maritim AC, Sanders RA, and Watkins JB, 3rd. Diabetes,
oxidative stress, and antioxidants: a review. J Biochem Mol
Toxicol 17: 24–38, 2003.
238. Matsubara S, Takizawa T, Suzuki T, Minakami H, and Sato
I. Glucose-6-phosphate dehydrogenase is present in normal
GESTATIONAL DIABETES AND OXIDATIVE STRESS
239.
240.
241.
242.
243.
244.
245.
246.
247.
248.
249.
250.
251.
252.
253.
and pre-eclamptic placental trophoblasts: ultrastructural
enzyme-histochemical evidence. Placenta 22: 90–95, 2001.
Mazzanti L, Nanetti L, Vignini A, Rabini RA, Grechi G,
Cester N, Curzi CM, and Tranquilli AL. Gestational diabetes affects platelet behaviour through modified oxidative
radical metabolism. Diabet Med 21: 68–72, 2004.
McCance DR, Holmes VA, Maresh MJ, Patterson CC,
Walker JD, Pearson DW, and Young IS. Vitamins C and E
for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial.
Lancet 376: 259–266, 2010.
Medalie JH, Papier CM, Goldbourt U, and Herman JB.
Major factors in the development of diabetes mellitus in
10,000 men. Arch Intern Med 135: 811–817, 1975.
Melamed N, Chen R, Soiberman U, Ben-Haroush A, Hod
M, and Yogev Y. Spontaneous and indicated preterm delivery in pregestational diabetes mellitus: etiology and risk
factors. Arch Gynecol Obstet 278: 129–134, 2008.
Metzger BE, Phelps RL, Freinkel N, and Navickas IA. Effects of gestational diabetes on diurnal profiles of plasma
glucose, lipids, and individual amino acids. Diabetes Care 3:
402–409, 1980.
Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK,
Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’Rahilly S, Palmer CNA, Plutzky J, Reddy JK, Spiegelman BM,
Staels B, and Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Pharmacol Rev 58: 726–741, 2006.
Milczarek R, Klimek J, and Zelewski L. The effects of
ascorbate and alpha-tocopherol on the NADPH-dependent
lipid peroxidation in human placental mitochondria. Mol
Cell Biochem 210: 65–73, 2000.
Milner RD and Hill DJ. Fetal growth control: the role of
insulin and related peptides. Clin Endocrinol (Oxf) 21: 415–
433, 1984.
Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP,
Nettleton JA, and Jacobs DR, Jr. Flavonoid intake and
cardiovascular disease mortality: a prospective study in
postmenopausal women. Am J Clin Nutr 85: 895–909, 2007.
Mitanchez D. Foetal and neonatal complications in gestational diabetes: perinatal mortality, congenital malformations, macrosomia, shoulder dystocia, birth injuries,
neonatal complications. Diabetes Metab 36: 617–627, 2010.
Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G,
Wagner OF, Wolzt M, and Kautzky-Willer A. Circulating
concentrations of asymmetrical dimethyl-L-arginine are
increased in women with previous gestational diabetes.
Diabetologia 45: 1372–1378, 2002.
Moellering D, Mc Andrew J, Patel RP, Forman HJ, Mulcahy
RT, Jo H, and Darley-Usmar VM. The induction of GSH
synthesis by nanomolar concentrations of NO in endothelial cells: a role for gamma-glutamylcysteine synthetase and
gamma-glutamyl transpeptidase. FEBS Lett 448: 292–296,
1999.
Moley KH. Hyperglycemia and apoptosis: mechanisms for
congenital malformations and pregnancy loss in diabetic
women. Trends Endocrinol Metab 12: 78–82, 2001.
Moncada S, Palmer RM, and Higgs EA. Nitric oxide:
physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109–142, 1991.
Montalbetti N, Cantero MR, Dalghi MG, and Cantiello HF.
Reactive oxygen species inhibit polycystin-2 (TRPP2) cation
channel activity in term human syncytiotrophoblast. Placenta 29: 510–518, 2008.
3095
254. Morgan SC, Relaix F, Sandell LL, and Loeken MR. Oxidative stress during diabetic pregnancy disrupts cardiac
neural crest migration and causes outflow tract defects.
Birth Defects Res A Clin Mol Teratol 82: 453–463, 2008.
255. Murad F, Mittal CK, Arnold WP, Katsuki S, and Kimura H.
Guanylate cyclase: activation by azide, nitro compounds,
nitric oxide, and hydroxyl radical and inhibition by
hemoglobin and myoglobin. Adv Cyclic Nucleotide Res 9:
145–158, 1978.
256. Mustafa S, Vukovich T, Prikoszovich T, Winzer C,
Schneider B, Esterbauer H, Wagner O, and Kautzky-Willer
A. Haptoglobin phenotype and gestational diabetes. Diabetes Care 27: 2103–2107, 2004.
257. Myatt L. Placental adaptive responses and fetal programming. J Physiol 572: 25–30, 2006.
258. Myatt L. Review: reactive oxygen and nitrogen species and
functional adaptation of the placenta. Placenta 31 Suppl:
S66–S69, 2010.
259. Myatt L and Cui X. Oxidative stress in the placenta. Histochem Cell Biol 122: 369–382, 2004.
260. Nagareddy PR, Soliman H, Lin G, Rajput PS, Kumar U,
McNeill JH, and MacLeod KM. Selective inhibition of protein
kinase C beta(2) attenuates inducible nitric oxide synthasemediated cardiovascular abnormalities in streptozotocininduced diabetic rats. Diabetes 58: 2355–2364, 2009.
261. Navarro A, Alonso A, Garrido P, Gonzalez C, del Rey CG,
Ordonez C, and Tolivia J. Increase in placental apolipoprotein D as an adaptation to human gestational diabetes.
Placenta 31: 25–31, 2010.
262. Neerhof MG, Synowiec S, Khan S, and Thaete LG. Pathophysiology of chronic nitric oxide synthase inhibitioninduced fetal growth restriction in the rat. Hypertens
Pregnancy 30: 28–36, 2011.
263. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura
T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP,
Giardino I, and Brownlee M. Normalizing mitochondrial
superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787–790, 2000.
264. Nolan CJ and Proietto J. The feto-placental glucose steal
phenomenon is a major cause of maternal metabolic adaptation during late pregnancy in the rat. Diabetologia 37:
976–984, 1994.
265. Norwitz ER, Schust DJ, and Fisher SJ. Implantation and
the survival of early pregnancy. N Engl J Med 345: 1400–
1408, 2001.
266. Novaro V, Gonzalez E, Jawerbaum A, Rettori V, Canteros
G, and Gimeno MF. Nitric oxide synthase regulation during embryonic implantation. Reprod Fertil Dev 9: 557–
564, 1997.
267. Novaro V, Jawerbaum A, Faletti A, Gimeno MA, and
Gonzalez ET. Uterine nitric oxide and prostaglandin E
during embryonic implantation in non-insulin-dependent
diabetic rats. Reprod Fertil Dev 10: 217–223, 1998.
268. Novaro V, Pustovrh C, Colman-Lerner A, Radisky D, Lo
Nostro F, Paz D, Jawerbaum A, and Gonzalez E. Nitric
oxide induces gelatinase A (matrix metalloproteinase 2)
during rat embryo implantation. Fertil Steril 78: 1278–
1287, 2002.
269. Oettl K and Stauber RE. Physiological and pathological
changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 151:
580–590, 2007.
270. Okazaki T, Otani H, Shimazu T, Yoshioka K, Fujita M,
Katano T, Ito S, and Iwasaka T. Reversal of inducible nitric
3096
271.
272.
273.
274.
275.
276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.
287.
oxide synthase uncoupling unmasks tolerance to ischemia/
reperfusion injury in the diabetic rat heart. J Mol Cell Cardiol
50: 534–544, 2011.
Okuno S, Akazawa S, Yasuhi I, Kawasaki E, Matsumoto K,
Yamasaki H, Matsuo H, Yamaguchi Y, and Nagataki S.
Decreased expression of the GLUT4 glucose transporter
protein in adipose tissue during pregnancy. Horm Metab
Res 27: 231–234, 1995.
Onozato ML, Tojo A, Goto A, and Fujita T. Radical scavenging effect of gliclazide in diabetic rats fed with a high
cholesterol diet. Kidney Int 65: 951–960, 2004.
Orhan H, Onderoglu L, Yucel A, and Sahin G. Circulating
biomarkers of oxidative stress in complicated pregnancies.
Arch Gynecol Obstet 267: 189–195, 2003.
Ornoy A. Embryonic oxidative stress as a mechanism of
teratogenesis with special emphasis on diabetic embryopathy. Reprod Toxicol 24: 31–41, 2007.
Ornoy A, Tsadok MA, Yaffe P, and Zangen SW. The Cohen
diabetic rat as a model for fetal growth restriction: vitamins
C and E reduce fetal oxidative stress but do not restore
normal growth. Reprod Toxicol 28: 521–529, 2009.
Pacher P, Beckman JS, and Liaudet L. Nitric oxide and
peroxynitrite in health and disease. Physiol Rev 87: 315–
424, 2007.
Pacher P, Obrosova IG, Mabley JG, and Szabo C. Role of
nitrosative stress and peroxynitrite in the pathogenesis of
diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 12: 267–275, 2005.
Pavan L, Hermouet A, Tsatsaris V, Therond P, Sawamura
T, Evain-Brion D, and Fournier T. Lipids from oxidized
low-density lipoprotein modulate human trophoblast invasion: involvement of nuclear liver X receptors. Endocrinology 145: 4583–4591, 2004.
Pertynska-Marczewska M, Glowacka E, Sobczak M, Cypryk K, and Wilczynski J. Glycation endproducts, soluble
receptor for advanced glycation endproducts and cytokines
in diabetic and non-diabetic pregnancies. Am J Reprod Immunol 61: 175–182, 2009.
Pessler D, Rudich A, and Bashan N. Oxidative stress impairs
nuclear proteins binding to the insulin responsive element
in the GLUT4 promoter. Diabetologia 44: 2156–2164, 2001.
Petraglia F, Devita D, Gallinelli A, Aguzzoli L, Genazzani
AR, Romero R, and Woodruff TK. Abnormal concentration
of maternal serum activin-A in gestational diseases. J Clin
Endocrinol Metab 80: 558–561, 1995.
Peuchant E, Brun JL, Rigalleau V, Dubourg L, Thomas MJ,
Daniel JY, Leng JJ, and Gin H. Oxidative and antioxidative
status in pregnant women with either gestational or type 1
diabetes. Clin Biochem 37: 293–298, 2004.
Peunova N and Enikolopov G. Nitric oxide triggers a
switch to growth arrest during differentiation of neuronal
cells. Nature 375: 68–73, 1995.
Pinkney JH, Stehouwer CD, Coppack SW, and Yudkin JS.
Endothelial dysfunction: cause of the insulin resistance
syndrome. Diabetes 46 Suppl 2: S9–S13, 1997.
Plachta N, Traister A, and Weil M. Nitric oxide is involved
in establishing the balance between cell cycle progression
and cell death in the developing neural tube. Exp Cell Res
288: 354–362, 2003.
Poston L and Raijmakers MT. Trophoblast oxidative stress,
antioxidants and pregnancy outcome—a review. Placenta
25 Suppl A: S72–S78, 2004.
Puntarulo S. Iron, oxidative stress and human health. Mol
Aspects Med 26: 299–312, 2005.
LAPPAS ET AL.
288. Pustovrh C, Jawerbaum A, Sinner D, Pesaresi M, Baier M,
Micone P, Gimeno M, and Gonzalez ET. Membrane-type
matrix metalloproteinase-9 activity in placental tissue from
patients with pre-existing and gestational diabetes mellitus.
Reprod Fertil Dev 12: 269–275, 2000.
289. Pustovrh MC, Capobianco E, Martinez N, Higa R, White V,
and Jawerbaum A. MMP/TIMP balance is modulated
in vitro by 15dPGJ(2) in fetuses and placentas from diabetic
rats. Eur J Clin Invest 39: 1082–1090, 2009.
290. Pustovrh MC, Jawerbaum A, Capobianco E, White V, Lopez-Costa JJ, and Gonzalez E. Increased matrix metalloproteinases 2 and 9 in placenta of diabetic rats at
midgestation. Placenta 26: 339–348, 2005.
291. Pustovrh MC, Jawerbaum A, Capobianco E, White V,
Martinez N, Lopez-Costa JJ, and Gonzalez E. Oxidative
stress promotes the increase of matrix metalloproteinases-2
and - 9 activities in the feto-placental unit of diabetic rats.
Free Radic Res 39: 1285–1293, 2005.
292. Pustovrh MC, Jawerbaum A, White V, Capobianco E, Higa
R, Martinez N, Lopez-Costa JJ, and Gonzalez E. The role of
nitric oxide on matrix metalloproteinase 2 (MMP2) and
MMP9 in placenta and fetus from diabetic rats. Reproduction 134: 605–613, 2007.
293. Radaelli T, Varastehpour A, Catalano P, and Hauguel-de
Mouzon S. Gestational diabetes induces placental genes for
chronic stress and inflammatory pathways. Diabetes 52:
2951–3958, 2003.
294. Rahman A, Kefer J, Bando M, Niles WD, and Malik AB. Eselectin expression in human endothelial cells by TNF-alphainduced oxidant generation and NF-kappa B activation. Am J
Physiol Lung Cell Mol Physiol 275: L533–L544, 1998.
295. Rajapakse AG, Ming XF, Carvas JM, and Yang Z. The
hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. Am J Physiol
Heart Circ Physiol 296: H815–H822, 2009.
296. Rajdl D, Racek J, Steinerova A, Novotny Z, Stozicky F,
Trefil L, and Siala K. Markers of oxidative stress in diabetic
mothers and their infants during delivery. Physiol Res 54:
429–436, 2005.
297. Rajesh M, Mukhopadhyay P, Batkai S, Mukhopadhyay B,
Patel V, Hasko G, Szabo C, Mabley JG, Liaudet L, and
Pacher P. Xanthine oxidase inhibitor allopurinol attenuates
the development of diabetic cardiomyopathy. J Cell Mol
Med 13: 2330–2341, 2009.
298. Raza H and John A. Glutathione metabolism and oxidative
stress in neonatal rat tissues from streptozotocin-induced
diabetic mothers. Diabetes Metab Res Rev 20: 72–78, 2004.
299. Read MA, Boura AL, and Walters WA. Vascular actions of
purines in the foetal circulation of the human placenta. Br J
Pharmacol 110: 454–460, 1993.
300. Reti NG, Lappas M, Riley C, Wlodek ME, Permezel M,
Walker S, and Rice GE. Why do membranes rupture at
term? Evidence of increased cellular apoptosis in the supracervical fetal membranes. Am J Obstet Gynecol 196:
484.e1–10, 2007.
301. Roberts VHJ, Smith J, Mclea SA, Heizer AB, Richardson JL,
and Myatt L (Eds). Effect of Increasing Maternal Body Mass
Index on Oxidative and Nitrative Stress in the Human Placenta.
Oxford, ROYAUME-UNI: Elsevier, 2009, p. 7.
302. Rocha SO, Gomes GN, Forti AL, do Carmo Pinho Franco
M, Fortes ZB, de Fatima Cavanal M, and Gil FZ. Long-term
effects of maternal diabetes on vascular reactivity and renal
function in rat male offspring. Pediatr Res 58: 1274–1279, 2005.
GESTATIONAL DIABETES AND OXIDATIVE STRESS
303. Rolo AP and Palmeira CM. Diabetes and mitochondrial
function: role of hyperglycemia and oxidative stress. Toxicol
Appl Pharmacol 212: 167–178, 2006.
304. Rosenfeld CR, Cox BE, Roy T, and Magness RR. Nitric
oxide contributes to estrogen-induced vasodilation of the
ovine uterine circulation. J Clin Invest 98: 2158–2166, 1996.
305. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B,
Barnes S, Kirk M, and Freeman BA. Nitric oxide regulation
of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized
lipid derivatives. J Biol Chem 269: 26066–26075, 1994.
306. Ryan EA, Imes S, Liu D, McManus R, Finegood DT, Polonsky KS, and Sturis J. Defects in insulin secretion and
action in women with a history of gestational diabetes.
Diabetes 44: 506–512, 1995.
307. Ryu S, Kohen R, Samuni A, and Ornoy A. Nitroxide radicals protect cultured rat embryos and yolk sacs from diabetic-induced damage. Birth Defects Res A Clin Mol Teratol
79: 604–611, 2007.
308. San Martin R and Sobrevia L. Gestational diabetes and the
adenosine/L-arginine/nitric oxide (ALANO) pathway in
human umbilical vein endothelium. Placenta 27: 1–10, 2006.
309. Sanders TH, McMichael RW, Jr., and Hendrix KW. Occurrence of resveratrol in edible peanuts. J Agric Food Chem
48: 1243–1246, 2000.
310. Sankaralingam S, Xu Y, Sawamura T, and Davidge ST.
Increased lectin-like oxidized low-density lipoprotein receptor-1 expression in the maternal vasculature of women
with preeclampsia: role for peroxynitrite. Hypertension 53:
270–277, 2009.
311. Santra D, Sawhney H, Aggarwal N, Majumdar S, and
Vasishta K. Lipid peroxidation and vitamin E status in
gestational diabetes mellitus. J Obstet Gynaecol Res 29: 300–
304, 2003.
312. Schaefer-Graf UM, Graf K, Kulbacka I, Kjos SL, Dudenhausen J, Vetter K, and Herrera E. Maternal lipids as
strong determinants of fetal environment and growth in
pregnancies with gestational diabetes mellitus. Diabetes
Care 31: 1858–1863, 2008.
313. Schmid E, Hotz-Wagenblatt A, Hacj V, and Droge W.
Phosphorylation of the insulin receptor kinase by phosphocreatine in combination with hydrogen peroxide: the structural basis of redox priming. FASEB J 13: 1491–1500, 1999.
314. Schonfelder G, John M, Hopp H, Fuhr N, van Der Giet M,
and Paul M. Expression of inducible nitric oxide synthase
in placenta of women with gestational diabetes. FASEB J
10: 777–784, 1996.
315. Sengupta J, Dhawan L, Lalitkumar PG, and Ghosh D. Nitric oxide in blastocyst implantation in the rhesus monkey.
Reproduction 130: 321–332, 2005.
316. Sgarbosa F, Barbisan LF, Brasil MA, Costa E, Calderon IM,
Goncalves CR, Bevilacqua E, and Rudge MV. Changes in
apoptosis and Bcl-2 expression in human hyperglycemic,
term placental trophoblast. Diabetes Res Clin Pract 73: 143–
149, 2006.
317. Shaat N, Karlsson E, Lernmark A, Ivarsson S, Lynch K,
Parikh H, Almgren P, Berntorp K, and Groop L. Common
variants in MODY genes increase the risk of gestational
diabetes mellitus. Diabetologia 49: 1545–1551, 2006.
318. Shakibaei M, Harikumar KB, and Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53:
115–128, 2009.
319. Shao J, Catalano PM, Yamashita H, Ruyter I, Smith S,
Youngren J, and Friedman JE. Decreased insulin receptor
3097
320.
321.
322.
323.
324.
325.
326.
327.
328.
329.
330.
331.
332.
333.
334.
tyrosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese
women with gestational diabetes mellitus (GDM): evidence
for increased serine/threonine phosphorylation in pregnancy and GDM. Diabetes 49: 603–610, 2000.
Sidorkina O, Espey MG, Miranda KM, Wink DA, and Laval
J. Inhibition of poly(ADP-RIBOSE) polymerase (PARP) by
nitric oxide and reactive nitrogen oxide species. Free Radic
Biol Med 35: 1431–1438, 2003.
Siman CM and Eriksson UJ. Vitamin E decreases the occurrence of malformations in the offspring of diabetic rats.
Diabetes 46: 1054–1061, 1997.
Simpson JL, Elias S, Martin AO, Palmer MS, Ogata ES, and
Radvany RA. Diabetes in pregnancy, Northwestern University series (1977–1981). I. Prospective study of anomalies
in offspring of mothers with diabetes mellitus. Am J Obstet
Gynecol 146: 263–270, 1983.
Sivan E, Homko CJ, Whittaker PG, Reece EA, Chen X, and
Boden G. Free fatty acids and insulin resistance during
pregnancy. J Clin Endocrinol Metab 83: 2338–2342, 1998.
Sivan E, Lee YC, Wu YK, and Reece EA. Free radical
scavenging enzymes in fetal dysmorphogenesis among
offspring of diabetic rats. Teratology 56: 343–349, 1997.
Sivan E, Reece EA, Wu YK, Homko CJ, Polansky M, and
Borenstein M. Dietary vitamin E prophylaxis and diabetic
embryopathy: morphologic and biochemical analysis. Am J
Obstet Gynecol 175: 793–799, 1996.
Soares DG, Andreazza AC, and Salvador M. Sequestering
ability of butylated hydroxytoluene, propyl gallate, resveratrol, and vitamins C and E against ABTS, DPPH, and
hydroxyl free radicals in chemical and biological systems. J
Agric Food Chem 51: 1077–1080, 2003.
Sobki SH, Al-Senaidy AM, Al-Shammari TA, Inam SS, AlGwiser AA, and Bukhari SA. Impact of gestational diabetes
on lipid profiling and indices of oxidative stress in maternal
and cord plasma. Saudi Med J 25: 876–880, 2004.
Sobrevia L, Abarzua F, Nien JK, Salomon C, Westermeier F,
Puebla C, Cifuentes F, Guzman-Gutierrez E, Leiva A, and
Casanello P. Review: differential placental macrovascular
and microvascular endothelial dysfunction in gestational
diabetes. Placenta 32 Suppl 2: S159–S164, 2011.
Sobrevia L, Cesare P, Yudilevich DL, and Mann GE. Diabetes-induced activation of system y + and nitric oxide
synthase in human endothelial cells: association with
membrane hyperpolarization. J Physiol 489 (Pt 1): 183–
192, 1995.
Sobrevia L, Yudilevich DL, and Mann GE. Elevated Dglucose induces insulin insensitivity in human umbilical
endothelial cells isolated from gestational diabetic pregnancies. J Physiol 506 (Pt 1): 219–230, 1998.
Soubasi V, Petridou S, Sarafidis K, Tsantali C, Diamanti E,
Buonocore G, and Drossou-Agakidou V. Association of
increased maternal ferritin levels with gestational diabetes
and intra-uterine growth retardation. Diabetes Metab 36:
58–63, 2010.
Sparks SP, Jovanovic-Peterson L, and Peterson CM. Blood
glucose rise following prenatal vitamins in gestational diabetes. J Am Coll Nutr 12: 543–546, 1993.
Stanley JL, Sankaralingam S, Baker PN, and Davidge ST.
Previous gestational diabetes impairs long-term endothelial
function in a mouse model of complicated pregnancy. Am J
Physiol Regul Integr Comp Physiol 299: R862–R870, 2010.
Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol 101: 14D–19D, 2008.
3098
335. Sugimura Y, Murase T, Oyama K, Uchida A, Sato N,
Hayasaka S, Kano Y, Takagishi Y, Hayashi Y, Oiso Y, and
Murata Y. Prevention of neural tube defects by loss of
function of inducible nitric oxide synthase in fetuses of a
mouse model of streptozotocin-induced diabetes. Diabetologia 52: 962–971, 2009.
336. Surapaneni KM and Vishnu Priya V. Antioxidant enzymes
and vitamins in gestational diabetes. J Clin Diagn Res 2:
1081–1085, 2008.
337. This reference has been deleted.
338. Suzuki T, Nagamatsu C, Kushima T, Miyakoshi R, Tanaka
K, Morita H, Sakaue M, and Takizawa T. Apoptosis caused
by an inhibitor of NO production in the decidua of rat from
mid-gestation. Exp Biol Med (Maywood) 235: 455–462, 2010.
339. Szeto IMY, Aziz A, Das PJ, Taha AY, Okubo N, Reza-Lopez
S, Giacca A, and Anderson GH. High multivitamin intake
by Wistar rats during pregnancy results in increased food
intake and components of the metabolic syndrome in male
offspring. Am J Physiol Regul Integr Comp Physiol 295: R575–
R582, 2008.
340. Tain YL, Hsieh CS, Lin IC, Chen CC, Sheen JM, and Huang
LT. Effects of maternal L-citrulline supplementation on
renal function and blood pressure in offspring exposed to
maternal caloric restriction: the impact of nitric oxide
pathway. Nitric Oxide 23: 34–41, 2010.
341. Tan M, Sheng L, Qian Y, Ge Y, Wang Y, Zhang H, Jiang M,
and Zhang G. Changes of serum selenium in pregnant
women with gestational diabetes mellitus. Biol Trace Elem
Res 83: 231–237, 2001.
342. Tarim E, Yigit F, Kilicdag E, Bagis T, Demircan S, Simsek E,
Haydardedeoglu B, and Yanik F. Early onset of subclinical
atherosclerosis in women with gestational diabetes mellitus. Ultrasound Obstet Gynecol 27: 177–182, 2006.
343. Terao J. Dietary flavonoids as antioxidants. Forum Nutr 61:
87–94, 2009.
344. Thadhani R, Powe CE, Tjoa ML, Khankin E, Ye J, Ecker J,
Schneyer A, and Karumanchi SA. First-trimester follistatinlike-3 levels in pregnancies complicated by subsequent
gestational diabetes mellitus. Diabetes Care 33: 664–669,
2010.
345. Thaler CD and Epel D. Nitric oxide in oocyte maturation,
ovulation, fertilization, cleavage and implantation: a little
dab’ll do ya. Curr Pharm Des 9: 399–409, 2003.
346. Thomas SR, Chen K, and Keaney JF, Jr. Oxidative stress
and endothelial nitric oxide bioactivity. Antioxid Redox
Signal 5: 181–194, 2003.
347. Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P,
Widder JD, Tsikas D, Ertl G, and Bauersachs J. Endothelial
nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes
56: 666–674, 2007.
348. Toescu V, Nuttall SL, Martin U, Nightingale P, Kendall MJ,
Brydon P, and Dunne F. Changes in plasma lipids and
markers of oxidative stress in normal pregnancy and
pregnancies complicated by diabetes. Clin Sci (Lond) 106:
93–98, 2004.
349. Topel I, Stanarius A, and Wolf G. Distribution of the endothelial constitutive nitric oxide synthase in the developing rat brain: an immunohistochemical study. Brain Res
788: 43–48, 1998.
350. Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah
AN, Moron AF, and Valente O. Prepregnancy BMI and the
risk of gestational diabetes: a systematic review of the literature with meta-analysis. Obes Rev 10: 194–203, 2009.
LAPPAS ET AL.
351. Umekawa T, Sugiyama T, Kihira T, Murabayashi N, Zhang
L, Nagao K, Kamimoto Y, Ma N, Yodoi J, and Sagawa N.
Overexpression of thioredoxin-1 reduces oxidative stress
in the placenta of transgenic mice and promotes fetal
growth via glucose metabolism. Endocrinology 149: 3980–
3988, 2008.
352. Vaisanen-Tommiska MR. Nitric oxide in the human uterine
cervix: endogenous ripening factor. Ann Med 40: 45–55, 2008.
353. Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB,
and Joyner-Grantham J. Vasodilator factors in the systemic
and local adaptations to pregnancy. Reprod Biol Endocrinol
7: 79, 2009.
354. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M,
and Telser J. Free radicals and antioxidants in normal
physiological functions and human disease. Int J Biochem
Cell Biol 39: 44–84, 2007.
355. Van Assche FA, De Prins F, Aerts L, and Verjans M. The
endocrine pancreas in small-for-dates infants. Br J Obstet
Gynaecol 84: 751–753, 1977.
356. Vasquez G, Sanhueza F, Vasquez R, Gonzalez M, San
Martin R, Casanello P, and Sobrevia L. Role of adenosine
transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein
endothelium. J Physiol 560: 111–122, 2004.
357. Viana M, Aruoma OI, Herrera E, and Bonet B. Oxidative
damage in pregnant diabetic rats and their embryos. Free
Radic Biol Med 29: 1115–1121, 2000.
358. Viana M, Castro M, Barbas C, Herrera E, and Bonet B.
Effect of different doses of vitamin E on the incidence of
malformations in pregnant diabetic rats. Ann Nutr Metab
47: 6–10, 2003.
359. von Mandach U, Lauth D, and Huch R. Maternal and fetal
nitric oxide production in normal and abnormal pregnancy.
J Matern Fetal Neonatal Med 13: 22–27, 2003.
360. Vonnahme KA, Wilson ME, Li Y, Rupnow HL, Phernetton
TM, Ford SP, and Magness RR. Circulating levels of nitric
oxide and vascular endothelial growth factor throughout
ovine pregnancy. J Physiol 565: 101–109, 2005.
361. Wang Y, Tan M, Huang Z, Sheng L, Ge Y, Zhang H, Jiang
M, and Zhang G. Elemental contents in serum of pregnant
women with gestational diabetes mellitus. Biol Trace Elem
Res 88: 113–118, 2002.
362. Wang Y and Walsh SW. Increased superoxide generation is
associated with decreased superoxide dismutase activity
and mRNA expression in placental trophoblast cells in preeclampsia. Placenta 22: 206–212, 2001.
363. Weiss U, Cervar M, Puerstner P, Schmut O, Haas J, Mauschitz R, Arikan G, and Desoye G. Hyperglycaemia in vitro
alters the proliferation and mitochondrial activity of the
choriocarcinoma cell lines BeWo, JAR and JEG-3 as models
for human first-trimester trophoblast. Diabetologia 44: 209–
219, 2001.
364. Weksler-Zangen S, Yaffe P, and Ornoy A. Reduced SOD
activity and increased neural tube defects in embryos of the
sensitive but not of the resistant Cohen diabetic rats cultured under diabetic conditions. Birth Defects Res A Clin Mol
Teratol 67: 429–437, 2003.
365. Wentzel P, Ejdesjö A, and Eriksson UJ. Maternal diabetes
in vivo and high glucose in vitro diminish GAPDH activity
in rat embryos. Diabetes 52: 1222–1228, 2003.
366. Wentzel P and Eriksson UJ. 8-Iso-PGF(2alpha) administration generates dysmorphogenesis and increased lipid
peroxidation in rat embryos in vitro. Teratology 66: 164–
168, 2002.
GESTATIONAL DIABETES AND OXIDATIVE STRESS
367. Wentzel P, Gareskog M, and Eriksson UJ. Decreased cardiac glutathione peroxidase levels and enhanced mandibular apoptosis in malformed embryos of diabetic rats.
Diabetes 57: 3344–3352, 2008.
368. Wentzel P, Welsh N, and Eriksson UJ. Developmental
damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic
environment. Diabetes 48: 813–820, 1999.
369. Westermeier F, Puebla C, Vega JL, Farias M, Escudero C,
Casanello P, and Sobrevia L. Equilibrative nucleoside
transporters in fetal endothelial dysfunction in diabetes
mellitus and hyperglycaemia. Curr Vasc Pharmacol 7: 435–
449, 2009.
370. Westermeier F, Salomon C, Gonzalez M, Puebla C, Guzman-Gutierrez E, Cifuentes F, Leiva A, Casanello P, and
Sobrevia L. Insulin restores gestational diabetes mellitusreduced adenosine transport involving differential expression of insulin receptor isoforms in human umbilical vein
endothelium. Diabetes 60: 1677–1687, 2011.
371. White V, Capobianco E, Higa R, Martinez N, Sosa M,
Pustovrh MC, and Jawerbaum A. Increased nitration and
diminished activity of copper/zinc superoxide dismutase
in placentas from diabetic rats. Free Radic Res 44: 1407–1415,
2010.
372. White V, Gonzalez E, Capobianco E, Pustovrh C, Martinez
N, Higa R, Baier M, and Jawerbaum A. Leptin modulates
nitric oxide production and lipid metabolism in human
placenta. Reprod Fertil Dev 18: 425–432, 2006.
373. White V, Gonzalez E, Pustovrh C, Capobianco E, Martinez
N, Do Porto DF, Higa R, and Jawerbaum A. Leptin in
embryos from control and diabetic rats during organogenesis: a modulator of nitric oxide production and lipid
homeostasis. Diabetes Metab Res Rev 23: 580–588, 2007.
374. White V, Jawerbaum A, Sinner D, Pustovrh C, Capobianco
E, and Gonzalez E. Oxidative stress and altered prostanoid
production in the placenta of streptozotocin-induced diabetic rats. Reprod Fertil Dev 14: 117–123, 2002.
375. Whitley GS and Cartwright JE. Cellular and molecular
regulation of spiral artery remodelling: lessons from the
cardiovascular field. Placenta 31: 465–474, 2010.
376. Wieser F, Waite L, Depoix C, and Taylor RN. PPAR action
in human placental development and pregnancy and its
complications. PPAR Res 2008: 527048, 2008.
377. Wink DA, Miranda KM, Espey MG, Pluta RM, Hewett SJ,
Colton C, Vitek M, Feelisch M, and Grisham MB. Mechanisms of the antioxidant effects of nitric oxide. Antioxid
Redox Signal 3: 203–213, 2001.
378. Wiznitzer A, Ayalon N, Hershkovitz R, Khamaisi M, Reece
EA, Trischler H, and Bashan N. Lipoic acid prevention of
neural tube defects in offspring of rats with streptozocininduced diabetes. Am J Obstet Gynecol 180: 188–193, 1999.
379. Xia L, Wang H, Munk S, Kwan J, Goldberg HJ, Fantus IG,
and Whiteside CI. High glucose activates PKC-zeta and
NADPH oxidase through autocrine TGF-beta1 signaling in
mesangial cells. Am J Physiol Renal Physiol 295: F1705–
F1714, 2008.
380. Xia Y. Superoxide generation from nitric oxide synthases.
Antioxid Redox Signal 9: 1773–1778, 2007.
381. Xing AY, Challier JC, Lepercq J, Cauzac M, Charron MJ,
Girard J, and Hauguel-de Mouzon S. Unexpected expression of glucose transporter 4 in villous stromal cells of
human placenta. J Clin Endocrinol Metab 83: 4097–4101,
1998.
3099
382. Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, BabaeiJadidi R, and Thornalley PJ. Activation of NF-E2-related
factor-2 reverses biochemical dysfunction of endothelial
cells induced by hyperglycemia linked to vascular disease.
Diabetes 57: 2809–2817, 2008.
383. Yallampalli C and Garfield RE. Inhibition of nitric oxide
synthesis in rats during pregnancy produces signs similar
to those of preeclampsia. Am J Obstet Gynecol 169: 1316–
1320, 1993.
384. Yang P, Cao Y, and Li H. Hyperglycemia induces inducible
nitric oxide synthase gene expression and consequent nitrosative stress via c-Jun N-terminal kinase activation. Am J
Obstet Gynecol 203: 185.e5–11, 2010.
385. Yessoufou A, Soulaimann N, Merzouk SA, Moutairou K,
Ahissou H, Prost J, Simonin AM, Merzouk H, Hichami A,
and Khan NA. N-3 Fatty acids modulate antioxidant status
in diabetic rats and their macrosomic offspring. Int J Obes
(Lond) 30: 739–750, 2006.
386. This reference has been deleted.
387. Young SL, Evans K, and Eu JP. Nitric oxide modulates
branching morphogenesis in fetal rat lung explants. Am J
Physiol Lung Cell Mol Physiol 282: L379–L385, 2002.
388. Yu T, Robotham JL, and Yoon Y. Increased production of
reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc
Natl Acad Sci USA 103: 2653–2658, 2006.
389. Yu Y, Singh U, Shi W, Konno T, Soares MJ, Geyer R, and
Fundele R. Influence of murine maternal diabetes on placental morphology, gene expression, and function. Arch
Physiol Biochem 114: 99–110, 2008.
390. Yuan B, Ohyama K, Takeichi M, and Toyoda H. Direct
contribution of inducible nitric oxide synthase expression
to apoptosis induction in primary smooth chorion trophoblast cells of human fetal membrane tissues. Int J Biochem
Cell Biol 41: 1062–1069, 2009.
391. Zabihi S, Eriksson UJ, and Wentzel P. Folic acid supplementation affects ROS scavenging enzymes, enhances
Vegf-A, and diminishes apoptotic state in yolk sacs of
embryos of diabetic rats. Reprod Toxicol 23: 486–498, 2007.
392. Zabihi S, Wentzel P, and Eriksson UJ. Altered uterine
perfusion is involved in fetal outcome of diabetic rats.
Placenta 29: 413–421, 2008.
393. Zangen SW, Yaffe P, Shechtman S, Zangen DH, and Ornoy
A. The role of reactive oxygen species in diabetes-induced
anomalies in embryos of Cohen diabetic rats. Int J Exp
Diabetes Res 3: 247–255, 2002.
394. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T,
de Bakker PI, Abecasis GR, Almgren P, Andersen G, Ardlie
K, Bostrom KB, Bergman RN, Bonnycastle LL, BorchJohnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar
P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR,
Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup
N, Groves CJ, Guiducci C, Hansen T, Herder C, Hitman
GA, Hughes TE, Isomaa B, Jackson AU, Jorgensen T, Kong
A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C,
Lango H, Lauritzen T, Li Y, Lindgren CM, Lyssenko V,
Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou C,
Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ,
Sandbaek A, Shields B, Sjogren M, Steinthorsdottir V,
Stringham HM, Swift AJ, Thorleifsson G, Thorsteinsdottir
U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ, Illig T, Hveem K, Hu FB,
3100
LAPPAS ET AL.
Laakso M, Stefansson K, Pedersen O, Wareham NJ, Barroso
I, Hattersley AT, Collins FS, Groop L, McCarthy MI,
Boehnke M, and Altshuler D. Meta-analysis of genomewide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nat Genet
40: 638–645, 2008.
395. Zhang DX and Gutterman DD. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J
Physiol Heart Circ Physiol 292: H2023–H2031, 2007.
396. Zhang H, Zhang J, Ungvari Z, and Zhang C. Resveratrol
improves endothelial function: role of TNF{alpha} and
vascular oxidative stress. Arterioscler Thromb Vasc Biol 29:
1164–1171, 2009.
Address correspondence to:
Dr. Martha Lappas
Department of Obstetrics and Gynaecology
University of Melbourne
Mercy Hospital for Women
Level 4/163 Studley Road
Heidelberg VIC 3084
Australia
E-mail: mlappas@unimelb.edu.au
Date of first submission to ARS Central, November 21, 2010;
date of final revised submission, June 14, 2011; date of acceptance, June 15, 2011.
Abbreviations Used
4-HNE ¼ 4-hydroxynonenal or trans-4-hydroxy2-nonenal
8-isoprostane ¼ 8-epi prostaglandin F2a
15d-PGJ2 ¼ 15-deoxy-D12;14 -prostaglandin J2
AGE ¼ advanced glycation endproducts
Apo D ¼ apolipoprotein D
ARE ¼ antioxidant response elements
BH4 ¼ 6(R)-5,6,7,8 tetrahydrobiopterin
BM ¼ basal membranes
CML ¼ Ne -carboxymethyl-lysine
CuZnSOD ¼ copper/zinc superoxide dismutase
EC ¼ endothelial cell
ECM ¼ extracellular matrix
ECSOD ¼ extracellular superoxide dismutase
eNOS ¼ endothelial nitric oxide synthase
esRAGE ¼ endogenous secretory receptor for
advanced glycation endproducts
FABP ¼ fatty acid binding protein
FACL ¼ fatty acyl-CoA ligases
FADH+ ¼ flavin adenine dinucleotide
Flt-1 ¼ fms-like tyrosine kinase
FMNH+ ¼ flavin mononucleotide
G6PD ¼ glucose-6-phosphate dehydrogenase
GAPDH ¼ glyceraldehyde-3-phosphate
dehydrogenase
GDM ¼ gestational diabetes mellitus
GLUT ¼ glucose transporter
GPx ¼ glutathione peroxidase
GSH ¼ reduced glutathione
GSR ¼ glutathione reductase
GSSG ¼ oxidized glutathione
GST ¼ glutathione s-transferases
H2 O2 ¼ hydrogen peroxide
HAPO ¼ hyperglycemia and adverse pregnancy
outcome
HAS ¼ human serum albumin
HDL ¼ high density lipoprotein
Hp ¼ haptoglobin
HX ¼ hypoxanthine
ICAM ¼ intercellular cell adhesion molecule
IKKb ¼ inhibitor kappa b kinase
IL ¼ interleukin
iNOS ¼ inducible nitric oxide synthase
IRS ¼ insulin receptor substrate
JNK ¼ c-Jun N-terminal kinase
LDL ¼ low density lipoprotein
LOOH ¼ lipid hydroperoxide
LPL ¼ lipoprotein lipase
MDA ¼ malondialdehyde
MIP ¼ macrophage inflammatory protein
MMP ¼ matrix metalloproteinase
MnSOD ¼ manganese superoxide dismutase
MVM ¼ microvillous membrane
NAC ¼ N-acetyl-cysteine
NADPH ¼ nicotinamide adenine dinucleotide
phosphate
NEFA ¼ nonesterified fatty acid
NF-jB ¼ nuclear factor-kappa B
NGT ¼ normal glucose tolerant
nNOS ¼ neuronal nitric oxide synthase
NO ¼ nitric oxide
NOS ¼ nitric oxide synthase
O2 E ¼ superoxide anion
OD ¼ oxygenase domain
OH ¼ hydroxyl radical
OLR ¼ oxidized LDL receptor
PARP ¼ poly(ADP-ribose) polymerase
PAX ¼ paired box
PGE2 ¼ prostaglandin E2
PI3K ¼ phosphatidylinositol 3-kinases
PKC ¼ protein kinase C
PPAR ¼ peroxisome proliferator-activated
receptor
PUFAs ¼ polyunsaturated fatty acids
RAGE ¼ receptor for advanced glycation
endproducts
RD ¼ reductase domain
RNS ¼ reactive nitrogen species
ROS ¼ reactive oxygen species
SOD ¼ superoxide dismutase
sRAGE ¼ soluble receptor for advanced glycation
endproducts
ST ¼ syncytiotrophoblast
TAC ¼ total antioxidant capacity
TAG ¼ triacylglycerol
TBARS ¼ thiobarbituric acid reactive substances
TCA ¼ tricarboxylic acid
VCAM ¼ vascular cell adhesion molecule
VEGF ¼ vascular endothelial growth factor
XDH ¼ xanthine dehydrogenase
XO ¼ xanthine oxidase
XOR ¼ xanthine oxidoreductase